Document:

Office Lease (California Street)

 Exhibit 10.11 

OFFICE LEASE 
 THIS LEASE (this
“Lease”) is made as of September 21, 2015 (the “Delivery Date”), by and between 
  

			
	“Landlord”	  	MEPT 600 CALIFORNIA STREET LLC, a Delaware limited liability company
		
		  	 and

		
	“Tenant”	  	AUDENTES THERAPEUTICS, INC., a Delaware corporation

 TABLE OF CONTENTS 
  

					
	 SECTION 1: DEFINITIONS
	  	 	1	  
	 Access Laws
	  	 	1	  
	 Base Rent
	  	 	1	  
	 Broker
	  	 	1	  
	 Building
	  	 	1	  
	 Business Day
	  	 	1	  
	 Building Standard Hours
	  	 	1	  
	 Claims
	  	 	1	  
	 Commencement Date
	  	 	1	  
	 Construction Management Fee
	  	 	1	  
	 Delivery Date
	  	 	1	  
	 Extension Period
	  	 	1	  
	 Green Agency Ratings
	  	 	2	  
	 Hazardous Substance(s):
	  	 	2	  
	 Insurance Base Amount
	  	 	2	  
	 Initial Lease Term
	  	 	2	  
	 Landlord’s Agents
	  	 	2	  
	 Landlord’s Work
	  	 	2	  
	 Lease Security Deposit
	  	 	2	  
	 Lease Term
	  	 	2	  
	 Lease Year
	  	 	2	  
	 Manager
	  	 	2	  
	 Operating Costs
	  	 	2	  
	 Operating Costs Allocable to the Premises
	  	 	2	  
	 Operating Costs Base Amount
	  	 	2	  
	 Qualified Expenses
	  	 	2	  
	 Permitted Use
	  	 	2	  
	 Plans and Specifications
	  	 	3	  
	 Premises
	  	 	3	  
	 Prepaid Rent
	  	 	3	  
	 Property Tax Base Amount
	  	 	3	  
	 Property Taxes
	  	 	3	  
	 Punch List Work
	  	 	3	  
	 Rentable Area of Building
	  	 	3	  
	 Rentable Area of Premises
	  	 	3	  
	 Restrictions
	  	 	3	  
	 Space Planning Allowance
	  	 	3	  
	 Substantial Completion
	  	 	3	  
	 Telecommunication Facilities
	  	 	3	  
	 Telecommunication Services
	  	 	3	  
	 Tenant Alterations
	  	 	4	  
	 Tenant Improvement Allowance
	  	 	4	  
	 Tenant Improvements
	  	 	4	  
	 Tenant’s Agents
	  	 	4	  
	 Tenant’s Pro Rata Share
	  	 	4	  

							
	 SECTION 2: PREMISES AND TERM
	  	 	4	  
	 2.1
	 	 Lease of Premises
	  	 	4	  
	 2.2
	 	 Rentable Areas
	  	 	4	  
	 2.3
	 	 Lease Term
	  	 	4	  
	 2.4
	 	 Physical Condition of Premises
	  	 	4	  
	 2.5
	 	 Tenant Improvements
	  	 	4	  
	 2.6
	 	 Tenant Improvement Allowance
	  	 	5	  
	 2.7
	 	 Removal of Specialty Improvements and Telecommunication Facilities
	  	 	7	  
	 2.8
	 	 Lease Memorandum
	  	 	7	  
	 2.9
	 	 Use and Conduct of Business
	  	 	7	  
	 2.10
	 	 Compliance with Governmental Requirements and Rules and Regulations
	  	 	8	  
	 2.11
	 	 Sustainable Building Operations
	  	 	8	  
	 2.12
	 	 Recycling and Waste Management
	  	 	8	  
	 2.13
	 	 Right of First Offer
	  	 	9	  
	 2.14
	 	 Holdover
	  	 	9	  
	 2.15
	 	 Parking
	  	 	10	  
	 SECTION 3: BASE RENT, ADDITIONAL RENT AND OTHER SUMS PAYABLE UNDER LEASE
	  	 	10	  
	 3.1
	 	 Payment of Rental
	  	 	10	  
	 3.2
	 	 Base Rent
	  	 	10	  
	 3.3
	 	 Lease Security Provisions
	  	 	10	  
	 3.4
	 	 Additional Rent
	  	 	12	  
	 3.5
	 	 Intentionally Omitted
	  	 	14	  
	 3.6
	 	 Late Charge
	  	 	14	  
	 3.7
	 	 Default Rate
	  	 	14	  
	 SECTION 4: SERVICES AND REPAIR
	  	 	15	  
	 4.1
	 	 Utilities and Services
	  	 	15	  
	 4.2
	 	 Maintenance and Repair by Landlord
	  	 	16	  
	 4.3
	 	 Maintenance and Repair by Tenant
	  	 	17	  
	 4.4
	 	 Common Areas/Security
	  	 	17	  
	 SECTION 5: OCCUPANCY PROVISIONS
	  	 	18	  
	 5.1
	 	 Tenant Alterations
	  	 	18	  
	 5.2
	 	 Signage
	  	 	19	  
	 5.3
	 	 Surrender of Possession
	  	 	19	  
	 5.4
	 	 Removal of Property
	  	 	19	  
	 5.5
	 	 Reasonable Access
	  	 	19	  
	 5.6
	 	 Damage or Destruction
	  	 	20	  
	 5.7
	 	 Condemnation
	  	 	21	  
	 5.8
	 	 Estoppel Certificates and Financial Statements
	  	 	21	  
	 5.9
	 	 Utility Bills
	  	 	21	  
	 5.10
	 	 Intentionally Omitted
	  	 	21	  
	 5.11
	 	 Hazardous Substances
	  	 	22	  
	 5.12
	 	 Access Laws
	  	 	22	  
	 5.13
	 	 Quiet Enjoyment
	  	 	23	  
	 5.14
	 	 Subordination
	  	 	23	  
	 5.15
	 	 Liens and Tenant’s Personal Property Taxes
	  	 	24	  
	 5.16
	 	 Work Performance and Responsible Contracting
	  	 	24	  
	 SECTION 6: INSURANCE AND INDEMNIFICATION
	  	 	24	  
	 6.1
	 	 Indemnification
	  	 	24	  
	 6.2
	 	 Tenant Insurance
	  	 	25	  
	 6.3
	 	 Landlord’s Insurance
	  	 	26	  
	 6.4
	 	 Waiver of Subrogation
	  	 	26	  
	 SECTION 7: ASSIGNMENT AND SUBLETTING
	  	 	26	  
	 7.1
	 	 Assignment and Subletting by Tenant
	  	 	26	  
	 7.2
	 	 Assignment by Landlord
	  	 	28	  

  
 ii 

							
	 SECTION 8: DEFAULT AND REMEDIES
	  	 	28	  
	 8.1
	 	 Events of Default
	  	 	28	  
	 8.2
	 	 Remedies
	  	 	29	  
	 8.3
	 	 Right to Perform
	  	 	31	  
	 8.4
	 	 Landlord’s Default
	  	 	31	  
	 8.5
	 	 Limitation on Recourse
	  	 	31	  
	 SECTION 9: MISCELLANEOUS PROVISIONS
	  	 	31	  
	 9.1
	 	 Notices
	  	 	31	  
	 9.2
	 	 Attorney’s Fees and Expenses
	  	 	32	  
	 9.3
	 	 No Accord and Satisfaction
	  	 	32	  
	 9.4
	 	 Successors; Joint and Several Liability
	  	 	32	  
	 9.5
	 	 Choice of Law
	  	 	32	  
	 9.6
	 	 No Waiver of Remedies
	  	 	32	  
	 9.7
	 	 Offer to Lease
	  	 	32	  
	 9.8
	 	 Force Majeure
	  	 	32	  
	 9.9
	 	 Severability; Captions
	  	 	33	  
	 9.10
	 	 Interpretation
	  	 	33	  
	 9.11
	 	 Incorporation of Prior Agreement; Amendments
	  	 	33	  
	 9.12
	 	 Authority
	  	 	33	  
	 9.13
	 	 Time of Essence
	  	 	33	  
	 9.14
	 	 Survival of Obligations
	  	 	33	  
	 9.15
	 	 Consent to Service
	  	 	33	  
	 9.16
	 	 Landlord’s Authorized Agents
	  	 	33	  
	 9.17
	 	 Waiver of Jury Trial
	  	 	33	  
	 9.18
	 	 Tenant Certification
	  	 	33	  
	 9.19
	 	 Broker
	  	 	33	  

  

			
	LISTING OF EXHIBITS
		
	Exhibit A	  	Legal Description of the Land
	Exhibit B	  	Drawing Showing Location and Configuration of the Premises
	Exhibit C	  	Determination of Fair Market Value in Extension Period
	Exhibit D	  	Form of Lease Memorandum
	Exhibit E	  	Rules and Regulations
	Exhibit F	  	Schedule of Cleaning Services
	
	RIDERS
		
	Rider 1	  	Letter of Credit Criteria
	Rider 2	  	Description of Landlord’s Work
	Rider 3	  	HVAC Specifications
	Rider 4	  	Asbestos Notification

  
 iii 

 SECTION 1: DEFINITIONS 

Access Laws: The Americans With Disabilities Act of 1990 (including the Americans with Disabilities Act
Accessibility Guidelines for Building and Facilities) and all other Governmental Requirements relating to the foregoing. 

Base Rent: The monthly amount of Base Rent and the portion of the Initial Lease Term during which such monthly
amount of Base Rent is payable shall be determined from the following table. For convenience and ease of reference, the annual rental rate for the computation of Base Rent and the annual Base Rent are also set forth in tabular form with the annual
Base Rent equaling the monthly Base Rent installment multiplied by twelve. In the case of any conflict or inconsistency between the Monthly Base Rent installment and the other illustrative figures set forth in tabular form or in any computations
utilizing such figures, the monthly Base Rent installment so specified shall be controlling and conclusive. 
  

													
	 Applicable Portion of Lease Term
	  	Total Rent
Sq. Ft./ Annum	 	  	Annual Base Rent	 	  	Monthly Base
Rent Installment
(Annual ÷ 12)	 
	 2/18/16 - 2/17/17*
	  	$	72.09	  	  	$	1,556,832.81	  	  	$	129,736.07	  
	 2/18/17 - 2/17/18
	  	$	74.19	  	  	$	1,602,184.41	  	  	$	133,515.37	  
	 2/18/18 - 2/17/19
	  	$	76.35	  	  	$	1,648,896.57	  	  	$	137,408.05	  
	 2/18/19 - 2/17/20
	  	$	78.58	  	  	$	1,697,010.09	  	  	$	141,417.51	  
	 2/18/20 - 2/17/21
	  	$	80.87	  	  	$	1,746,566.97	  	  	$	145,547.25	  
	 2/18/21 - 2/17/22
	  	$	83.24	  	  	$	1,797,610.53	  	  	$	149,800.88	  
	 2/18/22 - 6/7/22
	  	$	85.67	  	  	$	1,850,185.53	  	  	$	154,182.13	  

  

	*	The Base Rent for the first three (3) months of the Initial Lease Term following the Commencement Date (February 18, 2016 through May 17, 2016) shall be abated but shall become immediately due and payable if
at any time during the Initial Lease Term, there is an Event of Default by Tenant as described below. 

Broker: Collectively, Evolution Real Estate Inc., dba Faller Real Estate, as Tenant’s broker, and Jones
Lang LaSalle Brokerage, Inc., a Texas corporation, as Landlord’s broker. 
 Building: The building
located at 600 California Street, San Francisco, California, and located on the real estate legally described on Exhibit A (the “Land”). 

Business Day: Calendar days, except for Saturdays and Sundays and holidays when banks are closed in Washington,
D.C. 
 Building Standard Hours: Except for the holidays specified in this definition, the following
specified hours: Monday through Friday from 8:00 a.m. to 6:00 p.m. and Saturdays from 9:00 a.m. to 12:00 p.m. The holidays excepted from the foregoing are New Years’ Day, Presidents Day, Memorial Day, July 4, Labor Day, Thanksgiving Day,
Christmas Day and any other regionally or city-wide recognized holidays. 
 Claims: An individual and
collective reference to any and all claims, demands, damages, injuries, losses, liens, liabilities, penalties, fines, lawsuits, actions, other proceedings and expenses (including attorneys’ fees and expenses incurred in connection with the
proceeding whether at trial or on appeal). 
 Commencement Date: February 18, 2016. 

Construction Management Fee: An amount equal to three percent (3%) of the total actual, third party hard
costs paid by Tenant for the Tenant Improvements. 
 Delivery Date: The date set forth on the first page of
this Lease. 
 Extension Period: One (1) option for a period of five (5) years. 

  
 1 

 Green Agency Ratings: Any one or more of the following ratings, as
same may be in effect or amended or supplemented from time to time: The U.S. EPA’s Energy Star® rating and/or Design to Earn Energy Star, the Green Building Initiative’s Green GlobesTM for Continual Improvement of Existing
Buildings (Green GlobesTM-CIEB), the U.S. Green Building Council’s Leadership in Energy and Environmental Design (LEED) rating system, LEED EBOM (existing buildings operations and maintenance) and any applicable substitute third party or
government mandated rating systems. 
 Hazardous Substance(s): Asbestos, PCBs, petroleum or petroleum-based
chemicals or substances, urea formaldehyde or any chemical, material, element, compound, solution, mixture, sub-stance or other matter of any kind whatsoever which is now or later defined, classified, listed, designated or regulated as hazardous,
toxic or radioactive by any Governmental Agency. 
 Insurance Base Amount: The actual insurance costs
applicable to the Building for calendar year 2016 (the “Insurance Base Amount Year”). 
 Initial
Lease Term: Commencing on the Commencement Date and ending on June 7, 2022. 
 Landlord’s
Agents: The manager, members, investment advisors, agents of and consultants to Landlord and employees of the foregoing. 

Landlord’s Work: The work to be performed by Landlord, including the improvements to the 16th floor common area corridor of the Building, as more fully described on Rider 2, attached hereto. 

Lease Security Deposit: The sum of One Million Nine Hundred Thirty Thousand and No/100 Dollars ($1,930,000.00)
in the form of a standby Letter of Credit and subject to the reduction under Section 3.3 below. 
 Lease
Term: The Initial Lease Term, together with the Extension Period, if any, provided that Tenant properly exercises its Extension Period in accordance with this Lease. 

Lease Year: A period of twelve (12) full and consecutive calendar months. The initial Lease Year shall
begin on the Commencement Date and end on the last day of the month preceding the first anniversary of the Commencement Date; provided, however, if the Commencement Date does not occur on the first day of a calendar month, then the initial Lease
Year shall begin on the Commencement Date and end on the last day of the month which contains the first anniversary thereof. Each succeeding Lease Year shall begin upon the termination of the preceding Lease Year. 

Manager: Jones Lang LaSalle Americas, Inc., or its replacement as specified by written notice from Landlord to
Tenant. 
 Operating Costs: Defined in paragraph captioned “Additional Rent”. 

Operating Costs Allocable to the Premises: The product of Tenant’s Pro Rata Share times Operating Cost
less the Operating Costs Base Amount. 
 Operating Costs Base Amount. The actual Operating Costs applicable
to the Building for calendar year 2016 (the “Operating Costs Base Amount Year”), based on One Hundred Percent (100%) occupancy at the Building. 

Qualified Expenses: shall mean costs and expenses paid by Tenant (without duplication) for the design,
permitting and construction of the Tenant Improvements, including (a) Soft Costs, (b) plan check, permit and license fees relating to construction; (c) the cost of construction, including, without limitation, testing and inspection
costs, freight elevator usage, hoisting and trash removal costs, and contractors’ fees and general conditions; (d) the cost of any changes in the base, shell and core of the Premises, when such changes are required by the construction
drawings (including if such changes are due to the fact that such work is prepared on an unoccupied basis), such cost to include all direct architectural and/or engineering fees and expenses incurred in connection therewith; and (e) the cost of
any changes to the construction drawings required by applicable laws and building codes. 
 Permitted Use:
General business office uses. 

  
 2 

 Plans and Specifications: Those certain plans for the Tenant
Improvements, and any modifications to them, approved in writing by Landlord and Tenant, and the specifications to be approved in writing by Landlord and Tenant following the Delivery Date as provided herein. 

Premises: 14,642 rentable square feet consisting of the entire seventeenth (17th) floor of the Building and 6,954 rentable square feet on a portion of the sixteenth (16th) floor of the Building, for a total of 21,596
rentable square feet, as depicted on the plan attached as Exhibit B. 
 Prepaid Rent: One Hundred
Twenty-Nine Thousand Seven Hundred Thirty-Six and 07/100 Dollars ($129,736.07), to be applied toward Base Rent for the first full calendar month which commences on the three (3) month anniversary of the Commencement Date. 

Property Tax Base Amount: The actual Property Taxes applicable to the Building for calendar year 2016 (the
“Property Taxes Base Amount Year”). 
 Property Taxes: (a) Any form of ad valorem real
or personal property tax or assessment imposed by any Governmental Agency on the Land, Building, related improvements or any personal property owned by Landlord associated with such Land, Building or Improvements; (b) any other form of tax or
assessment, license fee, license tax, tax or excise on rent or any other levy, charge, expense or imposition made or required by any Governmental Agency on any interest of Landlord in such Land, Building, related improvements or personal property;
(c) any fee for services charged by any Governmental Agency for any services such as fire protection, street, sidewalk and road maintenance, refuse collection, school systems or other services provided or formerly provided to property owners
and residents within the general area of the Land; (d) any governmental impositions allocable to or measured by the area of any or all of such Land, Building, related improvements or personal property or the amount of any base rent, additional
rent or other sums payable under any lease for any or all of such Land, Building, related improvements or personal property; (e) any gross receipts or other excise tax allocable to, measured by or a function of any one or more of the matters
referred to in clause (d); (f) any impositions by any Governmental Agency on any transaction evidenced by a lease of any or all of such Land, Building, related improvements or personal property; and (g) any increase in any of the foregoing
based upon construction of improvements or change of ownership of any or all of such Land, Building, related improvements or personal property. Property Taxes shall not include taxes on Landlord’s net income, inheritance taxes, estate taxes or
franchise taxes. 
 Punch List Work: Minor items of repair, correction, adjustment or completion as such
phrase is commonly understood in the construction industry in the metropolitan area in which the Land is located. 

Rentable Area of Building: 346,127 rentable square feet of office space and 12,463 rentable square feet of
retail space for a total of 358,590 rentable square feet. 
 Rentable Area of Premises: 21,596 rentable
square feet as measured and computed by Landlord or its agents in general accordance with the American National Standard Method of Measuring Area in Office Buildings of the Building Owners Association International’s Standard Method of
Measuring Floor Area in Office Buildings (ANSI/BOMA Z65.1-1996). 
 Restrictions: Any covenants, conditions
and restrictions applicable to the Land. 
 Space Planning Allowance: A maximum amount, if any, to be
expended by Landlord for space planning which shall not exceed $0.15 per rentable square foot for a total of Three Thousand Two Hundred Thirty-Nine and 40/100 Dollars ($3,239.40). 

Substantial Completion: The date that the Tenant Improvements have been completed substantially in accordance
with the Plans and Specifications, subject to Punch List Work. 
 Telecommunication Facilities: Equipment,
facilities, apparatus and other materials utilized for the purpose of electronic telecommunication, including cable, switches, wires, conduit and sleeves. 

Telecommunication Services: Services associated with electronic telecommunications, whether in a wired or
wireless mode. Basic voice telephone services are included within this definition. 

  
 3 

 Tenant Alterations: Defined in paragraph captioned “Tenant
Alterations”. 
 Tenant Improvement Allowance: The maximum amount, if any, to be expended by
Landlord for the cost of Tenant Improvements (including amounts payable towards the Space Planning Allowance and the Construction Management Fee), which maximum shall not exceed $75.00 per rentable square foot for a total of One Million Six Hundred
Nineteen Thousand Seven Hundred and 00/100 Dollars ($1,619,700.00). 
 Tenant Improvements: Those alterations
or improvements to the Premises which will be performed by Tenant and which will appear and be depicted in the Plans and Specifications. 

Tenant’s Agents: Any and all officers, partners, contractors, subcontractors, consultants, licensees,
agents, concessionaires, subtenants, servants, employees, customers, guests, Invitees or visitors of Tenant. 

Tenant’s Pro Rata Share: 6.24%, which is the Rentable Area of Premises divided by 346,127 rentable square
feet. 
 SECTION 2: PREMISES AND TERM 

2.1 Lease of Premises. Landlord leases the Premises to Tenant, and Tenant leases the Premises from Landlord, upon the terms and conditions set
forth in this Lease. 
 2.2 Rentable Areas. The Rentable Areas of the Premises and the Building as specified in Section 1 are final,
conclusive and controlling for all purposes. A portion of the Building common areas is included in the Rentable Area of the Premises. 
 2.3 Lease
Term. The Initial Lease Term shall be for the period stated in the definition of that term, unless earlier terminated as provided in this Lease. Tenant shall have the option to renew the Lease for the entire Premises for the Extension
Period. The option to extend the term for the Extension Period shall be exercised by written notice from Tenant to Landlord no earlier than fifteen (15) months prior to the expiration of the Initial Lease Term, but no later than twelve
(12) months prior to the expiration of the Initial Lease Term; provided that, (a) as of the date of such notice and as of such commencement date for the Extension Period Tenant is not in default under the Lease beyond the expiration of any
applicable notice and cure periods; and (b) Tenant is leasing and occupying all of the Premises as of the date of such notice and as of such commencement date for the Extension Term. The Base Rent for the Extension Period shall be the amount
specified in Exhibit C, attached hereto. All other terms and conditions of this Lease shall remain in full force and effect during the Extension Period. Failure of the Tenant to provide such written notice to Landlord by the date that is
twelve (12) months prior to the expiration of the Initial Lease Term shall constitute a waiver of Tenant’s option to renew the Lease for the Extension Period. In the event that the Tenant exercises its option to extend the Lease Term for
the Extension Period, the term “Lease Term” as used in this Lease shall include the Extension Period, except as expressly stated otherwise in this Lease. 

2.4 Physical Condition of Premises. Subject to the completion of the Landlord’s Work and the delivery by Landlord of the Premises
demolished, vacant and In broom-clean condition, and otherwise in compliance with this Lease and except as otherwise set forth herein, Tenant (a) accepts the Premises, the Building and all Building systems in their current AS IS condition, and
(b) acknowledges that Tenant is not relying on any representations or warranties by any person regarding the Premises or the Building. Landlord shall, at Landlord’s sole cost and expense, perform the Landlord’s Work in a good and
workman-like manner and in compliance with any applicable Governmental Requirements, which Landlord’s Work shall be performed by Landlord concurrently with Tenant’s construction of the Tenant Improvements. 

2.5 Tenant Improvements. 
 2.5.1
Tenant Improvements. Tenant shall be responsible for the design, permitting and construction of the Tenant Improvements. 

  
 4 

 (a) Plans and Specifications. Tenant’s Plans and Specifications shall be in
compliance with all applicable Governmental Requirements. At the conclusion of construction pursuant to Section 2.5.1(b) below, Tenant shall cause its architect to provide to Landlord’s designated construction representative a “record
set” of as-built electronic CAD files within thirty (30) days following completion of the Tenant Improvements. Tenant shall rely solely on the advice and experience of Tenant’s architect in assuring the accuracy and sufficiency of the
Plans and Specifications for Tenant’s purposes. 
 (b) Construction of the Tenant Improvements. Promptly following the
Delivery Date, Tenant shall commence permitting and construction of the Tenant Improvements and diligently prosecute the same to completion in a good and workmanlike manner. The Tenant Improvements shall be constructed in accordance with the Plans
and Specifications. Tenant shall complete the construction of the Tenant Improvements in accordance with all Governmental Requirements and Tenant shall promptly notify Landlord if it discovers aspects of the Plans and Specifications that, if
constructed, would result in violation of any applicable Governmental Requirements. The Tenant Improvements shall be subject to, and in compliance with the Union Requirement (defined below), and pursuant to all other terms and conditions of the
Lease. Landlord shall cooperate with Tenant (including, without limitation, signing applications for Building Department permits and path of travel drawings, if and to the extent available) in Tenant’s efforts to obtain any permits and
certificates of occupancy necessary in connection with the construction of the Tenant Improvements; provided that, Tenant shall reimburse Landlord on demand for any reasonable out-of-pocket costs incurred by Landlord, including reasonable
attorneys’ fees, in connection therewith. Tenant shall be permitted to use the freight elevators on a non-exclusive, first-come, first-served basis during Building Standard Hours at no charge to Tenant during the construction of the Tenant
Improvements. The “Union Requirement” shall mean the obligation that the contractors and each subcontractor of every tier used by Tenant shall for the duration of its contract (a) be a party to or bound by a collective
bargaining agreement applicable to the geographic area in which the Building is located, applicable to the trade or trades in which the work under the contract is to be performed, and entered into with one or more labor organizations affiliated with
the Building and Construction Trades Department of the AFL-CIO or with an independent, nationally recognized labor organization or one of its affiliated locals, and (b) solely employ members of such labor organizations to perform work within
their respective traditional jurisdictions. 
 (c) Early Access. 

(i) Notwithstanding anything contained in this Lease to the contrary, Landlord shall allow Tenant access to the Premises prior to the
Commencement Date for the purpose of performing the Tenant Improvements. Tenant’s entry to the Premises for any purpose prior to the Commencement Date shall be scheduled in advance with Landlord. Such access shall be governed by the terms and
conditions of this Lease; however, in no event shall any Base Rent or Additional Rent be payable during such early access period. Any Tenant Improvements performed by Tenant during such early access period shall be completed in compliance with the
provisions of this Lease. Tenant shall coordinate its work reasonably with Landlord to ensure that Tenant’s access does not interfere with Landlord’s Work. 

(ii) Prior to any early occupancy by Tenant, Tenant shall have delivered to Landlord certificates of Insurance confirming that Tenant has in
force the insurance required by this Lease. Prior to commencement of any Tenant Improvements by Tenant, Tenant shall have delivered to Landlord evidence of insurance as required by Section 5.1.1 and identifying Landlord, Manager, Bentall
Kennedy (U.S.) Limited Partnership, NewTower Trust Company, and each of their agents, affiliates, members, directors, officers and employees as additional named insureds. Tenant’s entry into the Premises prior to the Commencement Date shall be
at Tenant’s risk and Landlord shall not be liable in any way for any injury, loss or damage which may occur to any of the Tenant Improvements in the Premises or to properties placed therein, except for the gross negligence or willful misconduct
of Landlord, and subject to all of the terms of this Lease (other than the obligation to pay Base Rent and Additional Rent). 
 (iii) Upon
substantial completion of all of the Tenant Improvements, Tenant shall be entitled to occupy the Premises for business prior to the Commencement Date subject to all of the terms of this Lease (other than the obligation to pay Base Rent and
Additional Rent). 
 2.6 Tenant Improvement Allowance. Tenant shall be entitled to the Tenant Improvement Allowance, which amount shall
include Space Planning Allowance and Construction Management Fee for 

  
 5 

 
the design, permitting and construction of the Tenant Improvements to be constructed at the Premises; provided, however, that Landlord shall have no obligation to disburse all or any portion of
the Tenant Improvement Allowance to Tenant unless Tenant makes a request for disbursement pursuant to the terms and conditions set forth below. Landlord shall have no obligation to disburse all or any portion of the Tenant Improvement Allowance if
Tenant makes a request for a disbursement of the Tenant Improvement Allowance on or after December 31, 2016. Without limiting the foregoing, the portion of the Tenant Improvement Allowance to be expended by Landlord for space planning, shall
not exceed the Space Planning Allowance. Subject to the provisions of the Lease, the Tenant Improvement Allowance shall be used to pay for any actual, out-of-pocket costs and expenses incurred in connection with the design and engineering work
performed by Tenant under Section 2.5.1(a) above and for the permitting and construction of the Tenant Improvements pursuant to the Plans and Specifications performed by Tenant pursuant to Section 2.5.1(b) above, provided that such costs
and expenses are deemed Qualified Expenses. For the avoidance of doubt, no portion of the Tenant Improvement Allowance shall be used to pay for the costs and expenses of any work at the Premises not included in the Plans and Specifications, and
Tenant shall be responsible, at its sole cost and expense, for all costs and expenses incurred in connection with such work. Landlord shall reimburse Tenant for any actual, out-of-pocket costs and expenses which constitute Qualified Expenses paid by
Tenant for the Tenant Improvements up to the amount of the Tenant Improvement Allowance. Landlord’s payment of such amount shall not be deemed Landlord’s approval or acceptance of the work furnished or materials supplied in connection with
the Tenant Improvements as set forth in Tenant’s payment request. Tenant shall pay the applicable excess out of its own funds if, when and to the extent that (a) the cost of the Tenant Improvements exceeds the Tenant Improvement Allowance,
or (b) the cost of space planning exceeds the Space Planning Allowance. Tenant shall not be entitled to a credit for any unused portion of the Tenant Improvement Allowance. Landlord shall be entitled to receive the Construction Management Fee
from the Tenant Improvement Allowance and the Supplement Tenant Improvement Allowance, if applicable, in connection with its management of the construction of the Tenant Improvements. 

2.6.1 Disbursement of Tenant Improvement Allowance. During the construction of the Tenant Improvements, Landlord shall make
monthly disbursements of the Tenant Improvement Allowance, and shall authorize the release of monies for the benefit of Tenant as follows: 

(a) On or before the fifth (5th) day of each calendar month during the construction
of the Tenant Improvements (or such other date as Landlord may designate), Tenant shall deliver to Landlord: (i) a request for payment of the contractor, approved by Tenant, in a reasonable form to be provided by Landlord, showing the schedule, by
trade, of percentage of completion of the Tenant Improvements in the Premises, detailing the portion of the work completed and the portion not completed, and demonstrating that the relationship between the cost of the work completed and the cost of
the work to be completed; (ii) invoices for labor rendered and materials delivered to the Premises; (iii) executed mechanic’s lien releases from all of third parties to receive payment pursuant to the request for payment which shall
comply with the appropriate provisions, as reasonably determined by Landlord, of applicable California law; and (iv) all other information reasonably requested by Landlord. Tenant’s request for payment shall be deemed Tenant’s
acceptance and approval of the work furnished and/or the materials supplied as set forth in Tenant’s payment request. On or before the last day of the following calendar month, Landlord shall deliver a check to Tenant made jointly payable to
Tenant and Tenant’s contractor in payment of the lesser of: (A) the amounts so requested by Tenant, less a ten percent (10%) retention (the aggregate amount of such retentions to be known as the “Final Retention”),
and (B) the balance of any remaining available portion of the Tenant Improvement Allowance (not including the Final Retention), provided that Landlord does not dispute any request for payment based on non-compliance of any work with the Plans
and Specifications or due to any substandard work, or for any other reason. Landlord’s payment of such amounts shall not be deemed Landlord’s approval or acceptance of the work furnished or materials supplied as set forth in Tenant’s
payment request. Notwithstanding the foregoing, if Landlord reasonably determines at any time that (a) the cost of the Tenant Improvements will exceed the Tenant Improvement Allowance, or (b) the cost of space planning will exceed the
Space Planning Allowance, then Tenant shall be required to begin funding a share of future monthly disbursements in an amount equal to the proportion of the expected excess costs over the expected total cost amount, and Landlord’s monthly
disbursement shall be reduced by such amount. 

  
 6 

 (b) Subject to the provisions hereof, a check for the Final Retention payable jointly to Tenant
and Tenant’s contractor shall be delivered by Landlord to Tenant following the Substantial Completion of construction of the Premises, provided that (i) Tenant delivers to Landlord properly executed mechanics lien releases in compliance
with applicable California law; and (ii) Landlord has determined that no substandard work exists which adversely affects the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life-safety or other systems of the
Building, the curtain wall of the Building, the structure or exterior appearance of the Building, or any other tenant’s use of such other tenant’s leased premises in the Building. 

2.7 Removal of Specialty Improvements and Telecommunication Facilities. All Tenant Improvements, regardless of which party constructed or paid
for them, shall become the property of Landlord and shall remain upon and be surrendered with the Premises on the expiration or earlier termination of this Lease; provided that, on the expiration or earlier termination of this Lease, Tenant
shall be required to remove any non-standard improvements built, constructed or installed by the Tenant as part of the Tenant Improvements or any Tenant Alterations, including, but not limited to, raised flooring, racking systems, classrooms,
interconnecting stairwells, backup battery systems and multi-tenant corridors (the “Specialty Improvements”), and any Telecommunication Facilities. At the time Landlord approves any structural alteration, improvement, addition,
equipment or fixture installed or brought on the Premises by or for Tenant (the “Structural Improvements”), Landlord shall advise Tenant if such Structural Improvements must be removed at the end of the Lease Term. Tenant shall
repair any damage resulting from any required removal of the Structural Improvements, the Specialty Improvements and Telecommunication Facilities and return the Premises to the same condition as existed prior to such Structural Improvements,
Specialty Improvements and Telecommunication Facilities, normal wear and tear excluded. Notwithstanding anything to the contrary contained herein, in lieu of requiring Tenant to remove any Structural Improvements, Specialty Improvements or
Telecommunication Facilities and repair of the Premises as set forth above, Landlord may, in Landlord’s sole discretion, require Tenant to pay to Landlord, as additional rent hereunder, the cost of such removal and repair in an amount
reasonably estimated by Landlord which amount shall be supported by competitive bids from Landlord-approved contractors that satisfy the Union Requirement. 

2.8 Lease Memorandum. Contemporaneously with Substantial Completion, Landlord shall prepare and submit to the Tenant a Lease Memorandum in the
form of Exhibit D, completed in good faith by Landlord, and executed by Landlord. If Tenant does object in good faith to any information set forth in the Lease Memorandum, it shall execute the Lease Memorandum subject to its
specifically-stated, written objections. Pending resolution of any dispute by agreement or a final determination by a court of competent jurisdiction in accordance with this Lease, Landlord’s information as inserted in the Lease Memorandum
shall be utilized subject to any later adjustment agreed or found to be appropriate. Tenant’s refusal or failure to execute a Lease Memorandum shall neither prevent nor delay the occurrence of the Commencement Date. In no event shall the Lease
Memorandum be recorded. 
 2.9 Use and Conduct of Business. 

2.9.1 The Premises are to be used only for the Permitted Use, and for no other business or purpose without the prior written consent of
Landlord. Landlord makes no representation or warranty as to the suitability of the Premises for Tenant’s intended use. Tenant shall, at its own cost and expense, obtain and maintain any and all licenses, permits, and approvals necessary or
appropriate for its use, occupation and operation of the Premises for the Permitted Use. Tenant’s inability to obtain or maintain any such license, permit or approval necessary or appropriate for its use, occupation or operation of the Premises
shall not relieve it of its obligations under this Lease, including the obligation to pay Base Rent and Additional Rent. 
 2.9.2 No act
shall be done in or about the Premises that is unlawful or that will increase the existing rate of insurance on any or all of the Land or Building. Tenant shall not commit or allow to be committed or exist: (a) any waste upon the Premises,
(b) any public or private nuisance, or (c) any act or condition which disturbs the quiet enjoyment of any other tenant in the Building, violates any of Landlord’s contracts affecting any or all of the Land or Building, creates or
contributes to any work stoppage, strike, picketing, labor disruption or dispute, interferes in any way with the business of Landlord or any other 

  
 7 

 
tenant in the Building or with the rights or privileges of any contractors, subcontractors, licensees, agents, concessionaires, subtenants, servants, employees, customers, guests, invitees or
visitors or any other persons lawfully in and upon the Land or Building. 
 2.9.3 Tenant shall not, without the prior written consent of
Landlord, use any apparatus, machinery, device or equipment in or about the Premises which will cause any substantial noise or vibration or any increase in the normal consumption level of electric power. If any of Tenant’s apparatus, machinery,
devices or equipment should disturb the quiet enjoyment of any other tenant in the Building, then Tenant shall provide, at its sole cost and expense, adequate insulation or take other such action, including removing such apparatus, machinery,
devices or equipment, as may be necessary to eliminate the disturbance. No food or beverage dispensing machines shall be installed by Tenant in the Premises without the prior written consent of Landlord. 

2.9.4 Tenant shall not use or operate the Premises in any manner that will cause the Building or any part thereof not to conform with
Landlord’s sustainability practices or the certification of the Building issued pursuant to any Green Agency Rating; provided that, other than as set forth in this Lease, Landlord has provided Tenant with any written rules or policies with
respect to its sustainability practices, if and to the extent Landlord has created or published any rules or policies. 
 2.10 Compliance with
Governmental Requirements and Rules and Regulations. Tenant shall comply with all Governmental Requirements and Restrictions relating to its use, occupancy and operation of the Premises and shall observe such reasonable, nondiscriminatory
rules and regulations as may be adopted and published by Landlord from time to time for the safety, care and cleanliness of the Premises and the Building, and for the preservation of good order in the Building and for the administration and
management of the Building. Current Rules and Regulations are attached to this Lease as Exhibit E. “Governmental Requirements” are any and all statutes, ordinances, codes, laws, rules, regulations, orders and directives of
any Governmental Agency as now or later amended, promulgated or Issued and all current or future final orders, judgments or decrees of any court with jurisdiction interpreting or enforcing any of the foregoing. A “Governmental
Agency” is the United States of America, the state in which the Land is located, any county, city, district, municipality or other governmental subdivision, court or agency or quasi-governmental agency having jurisdiction over the Land and
any board, agency or authority associated with any such governmental entity. 
 2.11 Sustainable Building Operations. 

2.11.1 This Building is or may become in the future certified under certain Green Agency Ratings or operated pursuant to Landlord’s
sustainable building practices, as same may be in effect or modified from time to time. Landlord’s sustainability practices address, without limitation, whole-building operations and maintenance issues including chemical use; indoor air
quality; energy efficiency; water efficiency; recycling programs; exterior maintenance programs; and systems upgrades to meet green building energy, water, Indoor Air Quality, and lighting performance standards. All of Tenant’s construction and
maintenance methods and procedures, material purchases, and disposal of waste must be in compliance with minimum standards and specifications as outlined by the Green Agency Ratings, in addition to all Governmental Requirements. Landlord shall
provide a copy of such standards and specifications of the Green Agency Ratings to Tenant, if and to the extent such standards and specifications are available. 

2.11.2 Tenant shall use proven energy and carbon reduction measures, including energy efficient bulbs in task lighting; use of lighting
controls; daylighting measures to avoid overlighting interior spaces; closing shades on the south side of the building to avoid over heating the space; turning off lights and equipment at the end of the work day; and purchasing ENERGY STAR®
qualified equipment, including but not limited to lighting, office equipment, commercial and residential quality kitchen equipment, vending and ice machines; and purchasing products certified by the U.S. EPA’s Water Sense® program. 

2.12 Recycling and Waste Management: Tenant covenants and agrees, at its sole cost and expense: (a) to comply with all present and future
Governmental Requirements regarding the collection, sorting, separation, and recycling of garbage, trash, rubbish and other refuse (collectively, “trash”); (b) to comply with Landlord’s recycling policy, as stated in the Rules
and Regulations (as such policy may be 

  
 8 

 
amended or supplemented from time to time), as part of Landlord’s sustainability practices where it may be more stringent than applicable Governmental Requirements, including without
limitation, recycling such categories of items designated by Landlord and transporting such items to any recycling areas designated by Landlord; (c) to sort and separate its trash and recycling into such categories as are provided by
Governmental Requirements or Landlord’s then-current sustainability practices; (d) that each separately sorted category of trash and recycling shall be placed in separate receptacles as directed by Landlord; (e) that Landlord reserves
the right to refuse to collect or accept from Tenant any waste that is not separated and sorted as required by Governmental Requirements, and to require Tenant to arrange for such collection at Tenant’s sole cost and expense, utilizing a
contractor satisfactory to Landlord; and (f) that Tenant shall pay all costs, expenses, fines, penalties or damages that may be imposed on Landlord or Tenant by reason of Tenant’s failure to comply with the provisions of this paragraph
2.11. 
 2.13 Right of First Offer. If the remainder of the 16th Floor of the Building
(the “Offer Space”) becomes vacant after a new-to-be-determined tenant first leases and then vacates the Offer Space, and if Landlord intends to lease the Offer Space, then Landlord shall notify the Tenant of the particulars of the
Offer Space (a “ROFO Trigger Notice”). The ROFO Trigger Notice shall include Landlord’s determination of Fair Market Value for the Offer Space, the base year for Operating Costs, Taxes and Insurance for the Offer Space, a new
calculation of Tenant’s Pro Rata Share, a floor plan of the Offer Space and the date the Offer Space is available for possession by Tenant, and all material economic terms applicable to the leasing of the Offer Space. The right of first offer
provided to Tenant as described in this Section 2.13 (the “ROFO”) shall be a one-time right, subject to any Prior Rights, and may be exercised by Tenant, if and only if: (A) no default has occurred under the Lease (which
remains uncured beyond the expiration of any applicable notice and cure periods) as of the date Landlord is to send the ROFO Trigger Notice for the Offer Space; (B) Tenant is not in default of the Lease (which remains uncured beyond the
expiration of any applicable notice and cure periods) as of the commencement date of the lease of the Offer Space; and (C) Tenant is then-leasing and occupying seventy percent (70%) or more of the Premises. Tenant shall have ten
(10) calendar days after receipt of such ROFO Trigger Notice to notify the Landlord in writing (a “ROFO Acceptance Notice”) that it wishes to exercise the ROFO to lease the Offer Space by incorporation thereof into the Premises
under this Lease, for the remainder of the Lease Term. If Tenant declines to accept the Offer Space or fails to deliver a ROFO Acceptance Notice within the required time period, then the Landlord shall be free to complete a lease transaction by
execution of a binding lease with a bona fide, third-party for all or any portion of the Offer Space. If the Tenant delivers a ROFO Acceptance Notice to Landlord in accordance with the foregoing, then the terms and conditions for the Offer Space
shall be the same terms and conditions as for the Premises, including the expiration date of this Lease, except as set out in the ROFO Trigger Notice (including Tenant’s requirement to accept possession of the Offer Space on the date the ROFO
Trigger Notice states that the Offer Space is available for possession, and except that, in the event the Landlord and Tenant are unable to agree on Fair Market Value for the Offer Space within thirty (30) days after Landlord’s receipt of
the ROFO Acceptance Notice, the Base Rent for the Offer Space shall be the amount determined in accordance with Exhibit C, attached hereto, and the rentable square footage of the Offer Space shall be determined upon the completion of a
mutually agreed upon space plan for the Offer Space). The Base Tax Year for the Offer Space shall be reset to the fiscal year in which the commencement date of lease for the Offer Space occurs and the Base Operating Year for the Offer Space shall be
reset to the calendar year in which the commencement date of the lease for the Offer Space occurs. In such event, Landlord shall prepare an addendum to the Lease in respect of the Offer Space mutually-acceptable to Tenant and Landlord for signature
by the Tenant and the Landlord. For the avoidance of doubt, in the event that the ROFO has been made by Landlord to Tenant, and Tenant (i) declines to accept such Offer Space; (ii) fails to deliver the ROFO Acceptance Notice in the time
period specified above, or (iii) is unable to accept the Offer Space because of a failure of Tenant to meet any of the conditions to exercise such ROFO in this Section 2.13, the ROFO shall be deemed forfeited and Tenant shall no longer
have any rights pursuant to this Section 2.13. “Prior Rights” shall mean the explicit rights under leases with the existing tenants in the Building to lease the Offer Space which rights exist as of the Delivery Date of this
Lease. 
 2.14 Holdover. Tenant is not authorized to hold over beyond the expiration or earlier termination of the Lease Term. If Landlord
consents to a holdover and no other agreement is reached between Tenant and Landlord concerning the duration and terms of the Holdover, Tenant’s holdover shall be a month-to-month tenancy. During such tenancy, Tenant shall pay to Landlord
(a) for the first sixty (60) days of such 

  
 9 

 
holdover tenancy, One Hundred Twenty-Five Percent (125%) of Base Rent in effect on the expiration or termination of the Lease Term plus all Additional Rent and other sums payable under this
Lease; and (b) for the balance of such holdover tenancy, Two Hundred Percent (200%) of Base Rent in effect on the expiration or termination of the Lease Term plus all Additional Rent and other sums payable under this Lease, and shall be
bound by all of the other covenants and conditions specified in this Lease, so far as applicable. If Landlord does not consent to the Tenant’s remaining in possession, Landlord shall have all the rights and remedies provided for by law and this
Lease, including the right to recover consequential damages suffered by Landlord in the event of Tenant’s wrongful refusal to relinquish possession of the Premises. 

2.15 Parking. Landlord has entered into a parking garage lease with Ace Parking (“Operator”) to operate the parking garage
located in the Building (the “Garage”). Landlord shall cause the Operator to lease to Tenant and Tenant shall have the right to lease from Operator up to twelve (12) parking spaces in the Garage at the current rate of $415.00
per parking space or, as such rate may be adjusted from time to time. Tenant’s parking privileges shall be subject to the reasonable, nondiscriminatory rules and regulations for the Building relating to parking adopted by Landlord from time to
time of which Tenant has been given written notice thereof. Landlord shall have the right to grant designated, reserved parking stalls at the Garage to other tenants in the Building; provided that Tenant’s right to its twelve (12) parking
spaces is not affected. In no event shall the number of parking stalls used by Tenant exceed the number of stalls allocated to Tenant in the definition of “Parking” unless Tenant has made arrangements with Landlord or the manager or
the Garage to rent additional parking spaces. Landlord shall have no obligation whatsoever to monitor, secure or police the use of the Garage or other common areas. 

SECTION 3: BASE RENT, ADDITIONAL RENT AND OTHER SUMS PAYABLE UNDER LEASE 

3.1 Payment of Rental. Tenant agrees to pay Base Rent, Additional Rent and any other sum due under this Lease to Landlord without demand,
deduction, credit, adjustment or offset of any kind or nature, in lawful money of the United States when due under this Lease, at the offices of Manager, or to such other party or at such other place as Landlord may from time to time designate in
writing or Tenant may pay such sums to Landlord by ACH transfer. 
 3.2 Base Rent. On the Commencement Date, Tenant shall pay to Landlord the
amount specified in the definition of Prepaid Rent for the month specified in the definition of that term. Tenant agrees to pay the monthly installments of Base Rent to Landlord, without demand and in advance, on or before the first day of each
calendar month of the Lease Term. The monthly Base Rent installment for any partial month at the beginning or end of the Lease Term shall be prorated. 

3.3 Lease Security Provisions. 

3.3.1 On execution of this Lease, Tenant shall deliver in favor of Landlord a letter of credit in the sum specified in the definition of the
term “Lease Security Deposit” (the “Letter of Credit”), as security for the full and faithful payment of all sums due under this Lease and the full and faithful performance of every covenant and condition of this Lease to
be performed by Tenant; provided, however, commencing on the third (3rd) anniversary of the Commencement Date and on each anniversary of the Commencement Date thereafter, the amount of the
Letter of Credit shall be reduced by Three Hundred Fifteen Thousand and No/100 Dollars ($315,000.00); provided that if Tenant is in default under this Lease as of any such anniversary of the Commencement Date (beyond the expiration of any applicable
notice and cure periods), the amount of the Letter of Credit shall not be reduced unless and until such default is cured, and provided further that, if Tenant is entitled to the reduction of the Letter of Credit pursuant to the terms set forth
herein, Landlord shall promptly deliver to the issuing bank a statement signed by an authorized party of Landlord authorizing the reduction of the Letter of Credit as permitted hereunder. Notwithstanding anything to the contrary in this Lease, the
amount of the Letter of Credit shall not be reduced below One Million One Hundred Seventy Four Thousand One Hundred Sixty-Four and 78/100 Dollars ($1,174,164.78), and after the reduction of the Letter of Credit on the fifth (5th) anniversary of the Commencement Date, the Letter of Credit shall not be reduced further and shall remain at such amount for the remainder of the Lease Term. The Letter of Credit initially
delivered pursuant to this paragraph and all substitutions, replacements and renewals of the Letter of Credit, must be consistent with and shall satisfy all the requirements in the letter of credit criteria in Rider 1, attached hereto. 

  
 10 

 3.3.2 If the Letter of Credit is not delivered to and in a form reasonably acceptable to Landlord
within ten (10) Business Days after the execution of this Lease, Landlord may, at its election, exercised in its absolute discretion, (a) void the Lease for failure of a condition subsequent or (b) proceed with its rights and remedies
for an Event(s) of Default (as defined below). 
 3.3.3 Landlord may draw on the Letter of Credit, in whole or in part at Landlord’s
election, without advance notice to Tenant, at any time or from time to time, but only on or after (a) the occurrence of any Event of Default, (b) if Tenant, or anyone in possession of the Premises through Tenant, wrongfully holds over
after the expiration or earlier termination of this Lease, (c) if Landlord is given notice by the issuing bank of the Letter of Credit that it is terminating the Letter of Credit, (d) if the issuing bank gives notice to Landlord that it
will cease to act in that capacity, (e) if the Letter of Credit expires on a specified date by its terms and is not renewed or replaced at least thirty (30) days in advance of its expiration date, (f) to the extent permitted by law,
in the event any bankruptcy, insolvency, reorganization or any other debtor creditor proceeding is instituted by or against Tenant or (g) as otherwise specified in or in connections with the letter of credit. Notwithstanding, any draw(s) on the
Letter of Credit shall not exceed those amounts reasonably necessary to cure any such Event of Default. 
 3.3.4 Landlord may apply any sum
drawn on the Letter of Credit to amounts owing to Landlord under this Lease in such order and priority as Landlord elects in its absolute discretion. If any of the proceeds drawn on the Letter of Credit are not applied immediately to sums owing to
Landlord under this Lease, Landlord shall credit any such excess proceeds to future sums next due and owing to Landlord under this Lease. Tenant shall, within fifteen (15) Business Days after Landlord’s written demand, restore the amount
of the Letter of Credit drawn to its then-current amount (taking into account any reduction(s) pursuant to Section 3.3.1, above). If Tenant does not restore the Letter of Credit to its original amount within the required time period, such
non-restoration shall be considered an Event of Default. 
 3.3.5 Additionally, Landlord’s draw and application of all or any portion
of the proceeds of the Letter of Credit shall not impair any other rights or remedies provided under this Lease or under applicable law and shall not be construed as a payment of liquidated damages. If Tenant shall have fully complied with all of
the covenants and conditions of this Lease, the remaining balance of the Letter of Credit shall be returned to Tenant or, if Landlord has drawn on the Letter of Credit, the remaining proceeds of the Letter of Credit which are in excess of sums due
the Landlord shall be repaid to Tenant, if not previously applied in accordance with Section 3.3.4, without interest, within thirty (30) Business Days after the expiration or termination of the Lease Term and delivery of possession of the
Premises to Landlord in accordance with this Lease. 
 3.3.6 On any request by Landlord made during the Lease Term, Tenant shall cooperate
in accomplishing any reasonable modification of the Letter of Credit requested by Landlord. If the Letter of Credit should be lost, mutilated, stolen or destroyed, Tenant shall cooperate in obtaining the issuance of a replacement. 

3.3.7 Tenant shall not assign or grant any security interest in the Letter of Credit and any attempt to do so shall be void and of no effect.

 3.3.8 In the event of a sale or transfer of Landlord’s estate or interest in the Land and Building, Landlord shall have the right to
transfer the Letter of Credit to the vendee or the transferee, Tenant shall pay any transfer fees charged by the issuing bank and Landlord shall thereafter be considered released by Tenant from all liability for the return of the Letter of Credit,
subject to applicable law. Tenant shall reasonably cooperate in effecting such transfer. 
 3.3.9 No mortgagee or purchaser of any or all of
the Building at any foreclosure proceeding brought under the provisions of any mortgage shall (regardless of whether the Lease is at the time in question subordinated to the lien of any mortgage) be liable to Tenant or any other person for any or
all amounts drawn against the Letter of Credit or any other or additional Lease Security Deposit or other payment made by Tenant under the provisions of this Lease), unless Landlord has actually delivered it in cash to such mortgagee or purchaser,
as the case may be. 
 3.3.10 The parties hereto (1) recite that the Letter of Credit is not intended to serve as a security deposit
and such Section 1950.7 and any and all other laws, rules and regulations applicable to security deposits in the commercial context (“Security Deposit Laws”) shall have no applicability or relevancy thereto and (2) waive
any and all rights, duties and obligations either party may now or, in the future, will have relating to or arising from the Security Deposit Laws. 

  
 11 

 3.4 Additional Rent. Commencing on January 1, 2017, Tenant shall pay to Landlord Additional
Rent as computed in this paragraph. “Additional Rent” is composed of Operating Costs, Property Taxes, and Insurance Costs. 

3.4.1 Operating Costs. “Operating Costs” means all expenses paid or incurred by Landlord for maintaining,
operating, owning and repairing any or all of the Land, Building, Premises, related improvements, and the personal property used in conjunction with such Land, Building, Premises and related improvements. Included are all expenses paid or incurred
by Landlord for: (a) utilities, including electricity, water, gas, sewers, fire sprinkler charges, refuse collection, Telecommunication Services, cable television, steam, heat, cooling or any other similar service and which are not payable
directly by tenants in the Building; (b) supplies; (c) cleaning, painting and janitorial services (including window washing), landscaping and landscaping maintenance (including irrigating, trimming, mowing, fertilizing, seeding and
replacing plants) and other services as typical and customary for other Class A buildings in downtown San Francisco; (d) security services, if any; (e) management fees not to exceed three percent (3%) of gross revenue derived
from the Building and rent associated with the management office; (f) tax consultant fees and expenses, and costs of appeals of any Property Taxes (provided that the tenants of the Building get the benefit of refunds); (g) compensation
(including employment taxes and fringe benefits) of all persons and business organizations who perform duties in connection with any service, repair, maintenance, replacement or improvement or other work included in this subparagraph up to the level
of General Manager, Project Director or Senior Property Manager; (h) license, permit and inspection fees; (i) assessments and special assessments due to deed restrictions, declarations or owners associations or other means of allocating
costs of a larger tract of which the Land is a part; (j) rental of any machinery or equipment; (k) audit fees and accounting services related to the Building, and charges for the computation of the rents and charges payable by tenants in
the Building (but only to the extent the cost of such fees and services are in addition to the cost of the management fee); (l) the cost of any repairs or the cost of any replacements for Permitted Capital Improvements; (m) charges under
maintenance and service contracts; (n) legal fees and other expenses of legal or other dispute resolution proceedings that affect the Land or the Building; (o) maintenance and repair of the roof and roof membranes, (p) costs incurred
by Landlord for compliance with any and all Governmental Requirements, including Access Laws, and to increase the efficiency of any electrical, mechanical or other system servicing the Building or the Land; (q) elevator service and repair, if
any; (r) business taxes and license fees; (s) any other expense or charge which in accordance with generally accepted accounting and management principles would be considered an expense of maintaining, operating, owning or repairing the
Building; and (t) the amortization of costs of Permitted Capital Improvements in accordance with the next sentence. For the avoidance of doubt “Permitted Capital Improvements” are the cost of capital improvements or other costs
incurred in connection with the Building (A) which are intended to effect economies in the operation or maintenance of the Building, or any portion thereof, or to reduce current or future Operating Costs, or to enhance the safety or security of
the Building or its occupants, (B) that are required to comply with present or anticipated conservation programs, (C) which are replacements, modifications or additions of nonstructural items located in the Common Areas required to keep
the Common Areas in good order or condition, or (D) that are required under any Governmental Requirement first enacted or enforced after the Commencement Date; provided, however, that any capital expenditure shall be amortized in accordance
with sound real estate management and accounting practices consistently applied. 
 Operating Costs shall not include any of the following: (1) repair,
replacements and general maintenance paid by proceeds of insurance or by Tenant or other third parties; (2) interest, amortization or other payments on loans to Landlord; (3) depreciation on the Building, the Project or any Common Area;
(4) cost of space planning, tenant improvements, marketing expenses and real estate broker commissions; (5) legal expenses and costs incurred in connection with negotiations or disputes with any other occupant of the Building and costs arising
from the violation by Landlord or any other occupant of the Building of the terms and conditions of any lease or other agreement; (6) the cost of repairs or other work to the extent Landlord is reimbursed by insurance or condemnation proceeds
or by another tenant or other entity; (7) construction costs related to the remodel of the lobby of the Building; (8) costs in connection with preparing for lease any space in the Building, including legal fees, space planners’ fees,
advertising and promotional expenses, brokerage commissions and lease concessions, including rental abatements and construction allowances, granted to specific tenants or costs incurred in renovating or otherwise

  
 12 

 
improving, decorating, painting or redecorating vacant space for tenants or other occupants of the Building; (9) costs incurred in connection with the sale, financing or refinancing of the
Building; (10) any penalties or damages that Landlord pays to Tenant under this Lease or to other tenants in the Building under their respective leases; (11) any bad debt loss, rent loss, or reserves for bad debts or rent loos or fines;
(12) any costs incurred due to Landlord’s violation of Law unless directly related to Tenant’s use of the Building; (13) all items and services for which Tenant or any other tenant in the Building reimburses Landlord or which
Landlord provides selectively to one or more tenants (other than Tenant) without reimbursement; (14) costs arising from the gross negligence or willful misconduct of Landlord or its agents, employees or contractors; (15) repairs or
replacements covered by warranties or guaranties; (16) costs incurred to comply with Governmental Requirements relating to the removal of Hazardous Substances which were located in the Building prior to the Delivery Date; (17) costs
incurred to remove, remedy, contain or treat Hazardous Substances, which Hazardous Substances were brought into the Building after the Delivery Date by Landlord or any other tenant of the Building; provided that Operating Costs may include the
incidental costs attributable to removing Hazardous Substances in the ordinary course of cleaning and maintaining the Building; (18) costs associated with the operation of the business of the limited liability company which constitutes
Landlord, as the same may be distinguished from the costs of operation of the Building (which shall specifically include, but not be limited to, accounting costs associated with the operation of the Building) and costs associated with defending any
lawsuits with any mortgagee (except as the actions of the Tenant may be in issue), costs of selling, syndicating, financing, mortgaging or hypothecating any of Landlord’s interest in the Building, any costs incurred in connection with any
disputes or negotiations between Landlord and its employees, between Landlord and Building management, or between Landlord and other tenants or occupants; (19) Taxes and Insurance which are paid separately pursuant to Sections 3.4.2 and 3.4.3
below; and (20) federal income taxes imposed on or measured by the income of Landlord from the operation of the Building. 
 3.4.2
Property Taxes. Property Taxes are defined in Section 1 above. If any portion of such Property Taxes is charged on an accrual basis, for purposes of this Lease the Property Taxes payable during the calendar year shall be included
in such year’s Operating Costs. 
 3.4.3 Insurance Costs. Insurance costs shall include premiums and applicable insurance
deductible payments by Landlord. 
 3.4.4 Additional Rent Estimate Payments. Landlord shall prepare and furnish to Tenant an
estimate of the Additional Rent computed in accordance with this paragraph (“Additional Rent Estimate”) (a) on January 1, 2017, (b) in advance of the beginning of each calendar year during the Lease Term and
(c) from time to time during the Lease Term. Tenant shall pay one-twelfth (1/12th) of the current Additional Rent Estimate in advance on or before the first day of each calendar month of
the Lease Term. If such written statement is furnished after the commencement of any calendar year, Tenant shall also make a retroactive lump-sum payment to Landlord equal to the monthly payment amount multiplied by the number of months during the
calendar year for which no payment was paid. Notwithstanding the foregoing, Landlord reserves the right, from time to time during each calendar year, but not more than twice per calendar year, to revise the Estimated Operating Costs Allocable to the
Premises and upon notice to Tenant of such revision, Tenant shall adjust its payment to Landlord under this subparagraph accordingly. 

3.4.5 Computation of Additional Rent. The determination and computation of the Additional Rent shall be made by Landlord. The
Additional Rent shall equal the product of (a) Tenant’s Pro Rata Share of Operating Costs multiplied by the difference between Operating Costs minus the Operating Cost Base Amount; (b) Tenant’s Pro Rata Share of Property Taxes
multiplied by the difference between Property Taxes minus the Property Tax Base Amount; and (c) Tenant’s Pro Rata Share of Insurance Costs multiplied by the difference between Insurance Costs minus the Insurance Base Amount. After the
close of each calendar year, Landlord shall deliver to Tenant a written statement setting forth the Additional Rent payable for the preceding calendar year. If the Additional Rent exceeds the Additional Rent Estimate paid by Tenant, Tenant shall pay
the amount of such excess to Landlord within thirty (30) days after delivery of such statement to Tenant. If such statement shows the Additional Rent to be less than the Additional Rent Estimate paid by Tenant, then the amount of such
overpayment shall be paid by Landlord to Tenant within thirty (30) days following the date of such statement or, (unless the Lease has ended) at Landlord’s option, shall be credited toward future installment(s) of Additional Rent Estimate.

 3.4.6 End of Term. If this Lease shall terminate on a day other than the last day of a calendar year, (a) Landlord
shall estimate the Operating Costs Allocable to the Premises for such calendar year 

  
 13 

 
predicated on the most recent reliable information available to Landlord; (b) the amount determined under clause (a) of this sentence shall be prorated by multiplying such amount by a
fraction, the numerator of which is the number of days within the Initial Lease Term, as may be extended, in such calendar year and the denominator of which is 360; (c) if the clause (b) amount exceeds the Estimated Operating Costs
Allocable to the Premises paid by Tenant for the last calendar year in the Initial Lease Term, as may be extended, then Tenant shall pay the excess to Landlord within thirty (30) days after Landlord’s delivery to Tenant of a statement for
such excess; and (d) if the Estimated Operating Costs Allocable to the Premises paid by Tenant for the last calendar year in the Initial Lease Term, as may be extended, exceeds the clause (b) amount, then Landlord shall refund to Tenant
the excess within such thirty (30) day period if Tenant is not then in default of any of its obligations under this Lease. Landlord’s and Tenant’s obligations under this paragraph shall survive the expiration or other termination of
this Lease. 
 3.4.7 Operating Cost Audit. Landlord shall maintain records concerning estimated and actual Operating Costs,
Property Taxes and Insurance Costs Allocable to the Premises for no less than twenty-four (24) months following the period covered by the statement or statements furnished Tenant, after which time Landlord may dispose of such records. Provided
that Tenant is not then in default of its obligation to pay Base Rent, Additional Rent or other payments required to be made by it under this Lease (beyond the expiration of any applicable notice and cure periods) and provided that Tenant is not
otherwise in default under this Lease (beyond the expiration of any applicable notice and cure periods), Tenant may, at Tenant’s sole cost and expense, cause a Qualified Person (defined below) to inspect Landlord’s records for the previous
year of the Lease Term. Such inspection, if any, shall be conducted no more than once each calendar year, during Landlord’s normal business hours within one hundred twenty (120) calendar days after receipt of Landlord’s written
statement of Operating Costs Allocable to the Premises for the previous year (and for the first year of the Initial Lease Term, this right shall include the right to inspect the records for the Operating Costs Base Amount Year and the Property Taxes
Base Amount Year), upon first furnishing Landlord at least twenty (20) calendar days prior written notice. Any errors disclosed by the review shall be promptly corrected by Landlord; provided, however, that if Landlord disagrees with any such
claimed errors, Landlord shall have the right, (at Landlord’s sole cost and expense; provided that, if the actual Operating Costs Allocable to the Premises are overstated by less than 3%, Tenant shall reimburse Landlord for the cost of its
audit), to cause another review to be made by an auditor of Landlord’s choice. In the event the results of the review of records (taking into account, if applicable, the results of any additional review caused by Landlord) reveal that Tenant
has overpaid obligations for a preceding period, the amount of such overpayment shall be credited against Tenant’s subsequent installment of Base Rent, Additional Rent or other payments due to Landlord under the Lease unless provided after the
expiration of the Lease Term, in which case, Landlord shall make the payment directly to Tenant. In the event that such results show that Tenant has underpaid its obligations for a preceding period, the amount of such underpayment shall be paid by
Tenant to Landlord within thirty (30) calendar days thereafter. If the actual Operating Costs Allocable to the Premises for any given calendar year were improperly computed and if the actual Operating Costs Allocable to the Premises are
overstated by more than 5%, Landlord shall reimburse Tenant for the cost of its audit. For purposes of this subparagraph, the term “Qualified Person” means an certificated public accountant who is engaged solely by Tenant on terms which do
not entail any compensation based or measured in any way upon any savings in Additional Rent or reduction in Operating Costs Allocable to the Premises achieved through the inspection process described in this subparagraph. 

3.5 (Intentionally Omitted). 
 3.6 Late
Charge. If Tenant fails to make any payment of Base Rent, Additional Rent or other amount when due under this Lease, a late charge is due and payable by Tenant equal to the greater of Fifty Dollars ($50.00) or five percent (5%) of the
amount of any such payment. Landlord and Tenant agree that this charge compensates Landlord for the administrative costs caused by the delinquency. The parties agree that Landlord’s damage would be difficult to compute and the amount stated in
this paragraph represents a reasonable estimate of such damage. Assessment or payment of the late charge contemplated in this paragraph shall not excuse or cure any Event of Default or breach by Tenant under this Lease or impair any other right or
remedy provided under this Lease or under law. Notwithstanding the foregoing, the late charge referenced above shall not be charged with respect to the first occurrence (but may be charged with respect to any subsequence occurrence) per calendar
year of the Lease Term. 
 3.7 Default Rate. Any Base Rent, Additional Rent or other sum payable under this Lease which is not paid when due
shall bear interest at a rate equal to the lesser of: (a) the published prime or reference 

  
 14 

 
rate then in effect at a national banking institution designated by Landlord (the “Prime Rate”), plus two (2) percentage points, or (b) the maximum rate of interest per
annum permitted by applicable law (the “Default Rate”), but the payment of such interest shall not excuse or cure any Event of Default or breach by Tenant under this Lease or Impair any other right or remedy provided under this
Lease or under law. 
 SECTION 4: SERVICES AND REPAIR 

4.1 Utilities and Services. 

4.1.1 Landlord shall furnish to Tenant, the following utilities or services: (a) electricity as specified in subparagraph 4.1.2;
(b) heating, ventilation and air-conditioning services (“HVAC”) as specified in subparagraph 4.1.4; (c) hot and cold domestic water in the common area restrooms, wastewater and sewage service at the points now existing in
the Premises or as specified for Initial Tenant Improvements (where applicable); (d) cold domestic water in kitchen areas unless supplemental hot water is requested by Tenant; (e) Telecommunication services to the extent specified in
subparagraph 4.1.5; (f) cleaning and janitorial service as specified on Exhibit F; and (g) elevator service specified in subparagraph 4.1.6. Landlord shall select the company or companies providing such utility and other services
described in this subparagraph. 
 4.1.2 Landlord shall have the right from time to time to select the company or companies providing
electricity, gas, fuel, one or more categories of Telecommunication Services and any other utility services to the Building. Landlord reserves the right to change electricity providers for the Building at anytime and to purchase green or renewable
energy. Landlord will provide only a suitable connection for usual and customary voice telephone service at the designated locations in or near the Premises, with all other costs related to installation of Telecommunication Facilities being the
responsibility of Tenant. All connection, installation, usage charges, maintenance and repair charges for such telephone service shall be Tenant’s responsibility. Landlord reserves the right to install and activate separate metering of
electricity, water or other utilities to the Premises, and Tenant agrees to reimburse or pay Landlord within thirty (30) calendar days after invoice from Landlord for all costs of such separate metering, in which case the Operating Costs shall
be adjusted accordingly. Electrical services will be supplied to a panel box designated for each floor of the Building. Landlord shall provide 3 watts per rentable square footage of receptacle capacity and 1.25 watts per rentable square footage of
lighting capacity as required by the applicable Governmental Requirements (“Electrical Allowance”). Tenant shall pay for any such excess electrical consumption above the Electrical Allowance or outside of Building Standard Hours,
calculated using the same energy rates paid by Landlord during the interval of such usage, with a reasonable markup over cost to Landlord. 

4.1.3 Common area hallways and emergency lighting operate 24 hours a day, 7 days a week. 

4.1.4 Landlord shall provide a base building mechanical system to provide HVAC in season during the following days and hours: Mondays through
Fridays from 8:00 a.m. to 6:00 p.m., and Saturdays from 9:00 a.m. to 12:00 p.m., except for Holidays; provided that Tenant shall provide Landlord with no less than two (2) Business Days’ prior notice for activation of HVAC services on
Saturday morning. See Rider 3 attached for more specifics regarding HVAC. If Tenant desires HVAC services other than during such hours (“After-Hours HVAC”), Tenant shall give Landlord a minimum of 24 hours’ notice prior
to the time such After-Hours HVAC is required with respect to service on Business Days and Tenant shall pay for its use of the After-Hours HVAC as additional rent, at a rate of One Hundred Dollars ($100.00) per floor per hour, subject to reasonable
increases. Any HVAC service on Holidays shall be considered After-Hours HVAC. 
 4.1.5 Landlord will provide only a suitable connection for
usual and customary voice telephone service at the designated locations in or near the Premises. All connection, installation, usage charges, maintenance and repair charges for such telephone service shall be Tenant’s responsibility.
Installation of Telecommunication Facilities beyond those specified as Landlord’s responsibility under the first sentence shall be the responsibility of Tenant. 

4.1.6 Elevator service will be provided during the time periods and with a frequency reasonably necessary to Tenant’s authorized
purposes, but in no event beyond the rated capacity of the elevators. 
 4.1.7 Tenant acknowledges that space on the Building rooftop and in
Building risers, equipment rooms and equipment closets is limited. Unless otherwise required by law, neither Tenant nor a provider of Telecommunication Services to Tenant shall be entitled to locate or install

  
 15 

 
Telecommunication Facilities in, on or about the Building without (a) first obtaining Landlord’s advance, written consent, which consent shall not be unreasonably withheld, conditioned
or delayed, and (b) the advance execution by Landlord and Tenant of a satisfactory agreement granting a license to Tenant for such purposes. The agreement referred to in clause (b) of the previous sentence shall be incorporated in and
become part of this Lease. Notwithstanding anything to the contrary herein, Tenant shall have the right to lease in the Building risers located between the sixteenth (16th) and seventeenth
(17th) floors of the Building at no additional charge to Tenant and Tenant shall be required to use Landlord’s riser management company associated therewith; provided that Tenant shall
pay for any costs incurred for the coring and installation of the conduit and any fees payable to Landlord’s riser management company in connection therewith; and provided further that Tenant shall not be permitted install any equipment, other
than the conduit, in such space. 
 4.1.8 Landlord shall in no case be liable or in any way be responsible for damages (including
consequential damages) or the loss to Tenant of utilities or other services arising from the failure of, diminution of or interruption of any kind to the Premises, unless such interruption in, deprivation of or reduction of any such service was
caused by the gross negligence or willful misconduct of Landlord, its employees, agents or contractors. To the extent that Landlord bears any responsibility for the foregoing, Landlord’s responsibility and Tenant’s remedy shall be limited
to an abatement in Base Rent for the period beginning with (a) the day which is two (2) consecutive days after the date on which Tenant delivers notice to Landlord of such interruption, deprivation or reduction and of the fact that Tenant
is unable to conduct its business in the Premises and ending on (b) the date such interruption, deprivation or reduction which is Landlord’s responsibility is no longer causing Tenant to be deprived of its ability to conduct its business,
in the Premises. 
 4.1.9 Landlord shall in no case be liable or in any way be responsible for damages or loss to Tenant arising from the
failure of, diminution of or interruption in electrical power, natural gas, HVAC, fuel, Telecommunication Services, sewer, water, or garbage collection services, other utility service or building service of any kind to the Premises. 

4.1.10 Tenant shall not install any supplemental HVAC, space heaters or other utilities or energy-intensive equipment (“Supplemental
Utilities Equipment”) in the Premises without Landlord’s prior written consent. In the event that Landlord consents in writing to such installation, Tenant shall be responsible, all at its sole cost and expense, for the installation,
maintenance, and repair of any of Supplemental Utilities Equipment, and Landlord will advise Tenant, at the time it gives its consent, as to whether Tenant must remove same from the Premises upon the expiration or termination of the Lease Term. Such
removal will be at Tenant’s sole cost and expense. Tenant agrees that it will maintain and repair any Supplemental Utilities Equipment, and major components thereof, in good working order, and any such equipment will be operated on sensors or
timers that limit the operation of such Supplemental Utilities Equipment to hours of occupancy in the areas immediately adjacent to the occupying personnel. Tenant shall, at its sole cost and expense, enter into a regularly scheduled preventative
maintenance/service contract with a maintenance contractor or the seller of any such Supplemental Utilities Equipment, and upon Landlord’s reasonable request, Tenant will provide Landlord with reasonable evidence of such maintenance and repair.
Upon Landlord’s request, on not less than one (1) Business Day’s prior written notice and during Tenant’s normal business hours (except in the event of an emergency, where no notice is required) Landlord shall have the right to
inspect, on not less than a monthly basis, the aforementioned Supplemental Utilities Equipment and major components provided Landlord shall use commercially reasonable efforts to minimize Landlord’s interference with Tenant’s business.
Tenant shall not permit any Supplemental Utilities Equipment to disturb or interfere with any of the Building’s systems or any other tenant in the Building, and Tenant will remove or modify, at Tenant’s sole cost and expense, any such
Supplemental Utilities Equipment in the event of such disturbance or interference. Landlord reserves the right to separately submeter (or cause Tenant to separately submeter) any Supplemental Utilities Equipment, all at Tenant’s sole cost and
expense. Tenant shall be responsible to Landlord for any damage caused to the Premises or Building in connection with the removal of the Supplemental Utilities Equipment. 

4.1.11 Tenant shall be required to submit to Landlord any electricity consumption data and costs in a format deemed reasonably acceptable by
Landlord. 
 4.2 Maintenance and Repair by Landlord. Subject to the paragraphs captioned “Damage or Destruction” and
“Condemnation”, Landlord shall maintain the public and common areas of the Building in first class condition subject to reasonable wear and tear. Landlord shall make such repairs thereto as

  
 16 

 
become necessary after obtaining actual knowledge of the need for such repairs. In addition, within the Premises, Landlord shall replace light bulbs and ballasts in fixtures; Tenant shall be
billed separately for the replacement of any non-Building-standard bulbs purchased for use in the Premises (which lighting purchases must comply with Landlord’s sustainability practices and shall be reported to Landlord in a format suitable to
Landlord). All repair costs shall be included in Operating Costs, except for damage occasioned by the act or omission of Tenant or Tenant’s Agents which shall be paid for entirely by Tenant within thirty (30) days after written demand by
Landlord, which must be accompanied by reasonably appropriate back-up. In the event any or all of the Building becomes in need of maintenance or repair which Landlord is required to make under this Lease, Tenant shall promptly give written notice to
Landlord, and Landlord shall be obligated to commence such maintenance or repairs within a reasonable time after Landlord’s receipt of such notice. Tenant hereby waives the benefit of Sections 1941 and 1942 of the California Civil Code and any
other statute providing a right to make repairs and deduct the cost thereof from the Rent. Tenant waives any right to terminate this Lease or offset or abate Rent by reason of any failure of Landlord to make repairs to the Premises pursuant to this
Section 4.2. 
 4.3 Maintenance and Repair by Tenant. Except as is expressly set forth as Landlord’s responsibility pursuant to the
paragraph captioned “Maintenance and Repair by Landlord,” Tenant shall at Tenant’s sole cost and expense keep, clean and maintain the Premises in good condition and repair, including interior painting, plumbing and utility
fixtures and installations within the Premises, carpets and floor coverings, all interior wall surfaces and coverings (including tile and paneling), window replacement (only if Tenant or Tenant’s Agent caused the window to crack or shatter),
exterior and interior doors, roof penetrations and membranes in connection with any Tenant installations on the roof, and interior preventative maintenance. All maintenance and repairs made by Tenant must comply with the requirements set forth in
the subparagraph captioned “Work Performance” and with Landlord’s sustainability practices and any applicable Green Agency Rating, as the same may change from time to time. If Tenant fails to maintain or repair the Premises in
accordance with this paragraph, then Landlord may, but shall not be required to, enter the Premises upon two (2) Business Days prior written notice to Tenant (or immediately without any notice in the case of an emergency) to perform such
maintenance or repair at Tenant’s sole cost and expense. Tenant shall pay to Landlord the cost of such maintenance or repair plus a ten percent (10%) administration fee within thirty (30) days after written demand from Landlord,
accompanied by reasonably appropriate back-up. Notwithstanding the foregoing, if at any time during the Lease Term, Landlord determines, in Landlord’s reasonable discretion, that repairs or maintenance need to be performed by Tenant as required
hereunder, Landlord shall provide Tenant with written notice thereof. 
 4.4 Common Areas/Security. 

4.4.1 The common areas of the Building shall be subject to Landlord’s sole management and control; provided that, Landlord shall not
interfere with Tenant’s access to the Premises (except to the extent necessary in an emergency situation). Without limiting the generality of the immediately preceding sentence, Landlord reserves the exclusive right as it deems necessary or
desirable to install, construct, remove, maintain and operate lighting systems, facilities, improvements, equipment, Telecommunication Facilities and signs on, in or to all parts of the common areas; change the number, size, height, layout, or
locations of walks, driveways and truckways or parking areas now or later forming a part of the Land or Building; make alterations or additions to the Building or common area; close temporarily all or any portion of the common areas to make repairs,
changes or to avoid public dedication; grant easements to which the Land will be subject; replat, subdivide, or make other changes to the Land; place or relocate or cause to be placed or located utility lines and Telecommunication Facilities
through, over or under the Land and Building; and use or permit the use of all or any portion of the roof of the Building; provided however, in performing any of these functions, Landlord shall not unreasonably interfere with Tenant’s conduct
of business within the Premises. Landlord reserves the right to relocate parking areas and driveways and to build additional improvements in the common areas. 

4.4.2 The lobby desk of the Building is staffed twenty-four (24) hours a day, seven (7) days a week and 365 days per year. Landlord
has no duty or obligation to provide any security services in, on or around the Premises, Land or Building. Tenant recognizes that any security services at the Building provided by Landlord will be for the sole benefit of Landlord and the protection
of Landlord’s property and under no circumstances shall Landlord be responsible for, and Tenant waives any rights with respect to, Landlord providing security or other protection for Tenant or Tenant’s Agents or property in, on or about
the Premises, Land or Building. Subject to Landlord’s prior approval, Tenant may, at its sole cost and 

  
 17 

 
expense, install, establish and maintain security services within the Premises; provided that, such security services (including any apparatus, facilities, equipment or people utilized in
connection with the provision of such security services) comply with the Governmental Requirements and shall not cause the Building to be out of compliance with the Governmental Requirements. Notwithstanding the foregoing, any such security services
installed, established or maintained by Tenant must not affect or impact any portion of the Building or the Land other than the Premises and shall not in any way limit or interfere with Landlord’s ability to exercise its rights as provided in
the paragraph captioned “Access”. Tenant’s rights under this subparagraph are subject to all the obligations, limitations and requirements as set forth in the paragraphs captioned “Tenant Alterations” and
“Work Performance”. 
 SECTION 5: OCCUPANCY PROVISIONS 

5.1 Tenant Alterations. 
 5.1.1
Tenant shall not make any alterations, additions or improvements in or to the Premises, or make changes to locks on doors, or add, disturb or in any way change any floor covering, wall covering, fixtures, plumbing, wiring or Telecommunication
Facilities (individually and collectively “Tenant Alterations”), without first obtaining the consent of Landlord which shall not be unreasonably withheld, conditioned or delayed. Notwithstanding anything to the contrary herein,
Tenant shall not be required to obtain Landlord’s prior written consent to any cosmetic, non-structural alterations of the Premises (a “Cosmetic Alteration”), so long as (i) the total costs of such Cosmetic Alteration do
not exceed Fifty Thousand and No/100 Dollars ($50,000.00) per floor of the Premises, (ii) such Cosmetic Alteration does not affect the structure of the Building or any operating systems of the Building, (iii) Tenant is not required by
applicable Governmental Requirements to obtain a permit to perform such Cosmetic Alteration, and (iv) such Cosmetic Alteration does not violate or render invalid the certificate of occupancy for the Building or the Premises; provided, however,
Tenant shall be required to provide Landlord with prior written notice thereof, and Landlord shall have the right to reasonably request additional information and documentation to reasonably determine whether such Cosmetic Alteration shall require
Landlord’s prior review and approval under this Section. Tenant shall deliver to Landlord full and complete plans and specifications for any proposed Tenant Alterations and, if consent by Landlord is either required or given, as applicable, all
such work shall be performed by Tenant at Tenant’s sole cost and expense. Tenant shall pay to Landlord all reasonable costs incurred by Landlord for any architecture, engineering, supervisory and/or legal services in connection with any Tenant
Alterations, including, without limitation, Landlord’s review of the Plans and Specifications. Without limiting the generality of the foregoing, Landlord may require Tenant, at Tenant’s sole cost and expense, to obtain and provide Landlord
with proof of insurance coverage and a payment and performance bond for Tenant Alterations where the cost thereof is equal to or greater than One Hundred Thousand and No/100 Dollars ($100,000.00), in forms, amounts and by companies acceptable to
Landlord. Upon completion of any Tenant Alterations, Tenant agrees to cause a Notice of Completion to be recorded in the office of the Recorder of the County of San Francisco in accordance with Section 8182 of the Civil Code of the State of
California or any successor statute. 
 5.1.2 If Tenant makes any alterations without Landlord’s prior written consent, if consent is
required hereunder, or without satisfaction of any conditions established by Landlord, Landlord shall have the right, in addition to and without limitation of any right or remedy Landlord may have under this Lease, at law or in equity, to require
Tenant to remove some or all of Tenant Alterations, or at Landlord’s election, Landlord may remove such Tenant Alterations and restore the Premises at Tenant’s expense. Nothing contained in this paragraph or the paragraph captioned
“Work Performance” shall be deemed a waiver of the provisions of the paragraph captioned “Mechanic’s Liens”. 

5.1.3 Tenant shall be solely responsible for all costs and expenses relating to or incurred in connection with: (a) failure of the
Premises to comply with the Governmental Requirements; and (b) bringing the Building and the common areas of the Building into compliance with Governmental Requirements, including without limitations, requirements for seismic tests, if and to
the extent such non-compliance arises out of or relates to any Tenant Alterations which are not normal and customary business office improvements, or triggered by Tenant’s use of the Premises for non-general office use. Notwithstanding the
foregoing, Tenant obligations under this Section 5.1.3 (and the limitations on Tenant’s responsibility for any non-compliance hereunder) shall not limit Tenant’s obligations with respect to compliance with Access Laws specifically set
forth in Section 5.12.5 of this Lease. 

  
 18 

 5.2 Signage. At Landlord’s expense, Landlord shall provide Building-standard signage on the
Building director in the ground floor lobby on a pro-rata basis. 
 5.3 Surrender of Possession. Tenant shall, at the expiration or earlier
termination of this Lease, surrender and deliver the Premises to Landlord in as good condition as when received by Tenant from Landlord or as later improved, reasonable use, wear and tear and damage by fire or other casualty excepted (except to the
extent Tenant’s insurance, as required to be maintained pursuant to this Lease, covers any damage to the Premises resulting from fire or other casualty), and free from all tenancies or occupancies by any person. 

5.4 Removal of Property. Unless otherwise agreed to in writing by Landlord, Tenant agrees that there are and shall be no trade fixtures in the
Premises owned by Tenant. Upon expiration or earlier termination of this Lease, Tenant may remove its personal property, office supplies and office furniture and equipment if (a) such items are readily moveable and are not attached to the
Premises; (b) such removal is completed prior to the expiration or earlier termination of this Lease; (c) Tenant is not in default of any covenant or condition of this Lease (beyond the expiration of any applicable notice and cure periods)
at the time of such removal; and (d) Tenant promptly repairs all damage caused by or resulting from such removal. All other property in the Premises and any Tenant Alterations (including, wall-to-wall carpeting, paneling, wall covering,
lighting fixtures and apparatus or Telecommunication Facilities or any other article affixed to the floor, walls, ceiling or any other part of the Premises or Building) shall become the property of Landlord and shall remain upon and be surrendered
with the Premises; provided, however, at Landlord’s sole election, upon written notice by Landlord to Tenant at the time of approval of the plans and specifications for the Tenant Alterations, Tenant shall be obligated, at its sole cost and
expense, to remove all (or such portion as Landlord shall have designated at the time of giving consent to such Tenant Alterations) of the Tenant Alterations (including Telecommunication Facilities), repair any damages resulting from such removal
and return the Premises to substantially the same condition as existed prior to such Tenant Alterations. Tenant waives all rights to any payment or compensation for such Tenant Alterations (including Telecommunication Facilities). If Tenant shall
fail to remove any of its property from the Premises, Building or Land at the expiration or earlier termination of this Lease or when Landlord has the right of re-entry, Landlord may, at its option, remove and store such property at Tenant’s
expense without liability for loss of or damage to such property, such storage to be for the account and at the expense of Tenant. Tenant shall pay all costs incurred by Landlord within five (5) Business Days after written demand for such
payment. If Tenant fails to pay the cost of storing any such property, Landlord may, at its option, after it has been stored for a period of twenty (20) Business Days or more, sell or permit to be sold, any or all such property at public or
private sale (and Landlord may become a purchaser at such sale), in such manner and at such times and places as Landlord in its sole discretion may deem proper, without notice to Tenant, and Landlord shall apply the proceeds of such safe:
first, to the cost and expense of such sale, including reasonable attorney’s fees actually incurred; second, to the payment of the costs or charges for storing any such property; third, to the payment
of any other sums of money which may then be or later become due Landlord from Tenant under this Lease; and, fourth, the balance, if any, to Tenant. 

5.5 Reasonable Access. Tenant shall permit Landlord and Landlord’s Agents to enter into the Premises during Tenant’s normal business
hours on at least one (1) Business Day’s prior written notice (except in case of emergency in which case no notice shall be required), for the purpose of inspecting the same or for the purpose of repairing, altering or improving the
Premises or the Building. Nothing contained in this paragraph shall be deemed to impose any obligation upon Landlord not expressly stated elsewhere in this Lease. When reasonably necessary, Landlord may temporarily close Building or Land entrances,
Building doors or other facilities, without liability to Tenant by reason of such closure and without such action by Landlord being construed as an eviction of Tenant or as relieving Tenant from the duty of observing or performing any of the
provisions of this Lease; provided that Landlord shall use good faith efforts to minimize disruption to Tenant’s business and shall provide continued access to the Premises. Landlord shall have the right to enter the Premises during
Tenant’s normal business hours upon one (1) Business Days’ notice during the Lease Term (but no advance notice shall be required during the last twelve (12) months of the Lease Term) for the purpose of showing the Premises to
prospective tenants. Tenant shall give written notice to Landlord at least twenty (20) Business Days prior to vacating the Premises and shall arrange to meet with Landlord for a joint inspection of the Premises prior to vacating. In the event
of Tenant’s failure to give such notice or arrange such joint inspection, Landlord’s inspection at or after Tenant’s vacating the Premises shall be conclusively deemed correct for 

  
 19 

 
purposes of determining Tenant’s responsibility for repairs and restoration. Landlord shall not be liable for the consequences of admitting by passkey, or refusing to admit to the Premises,
Tenant or any of Tenant’s Agents, or other persons claiming the right of admittance. 
 5.6 Damage or Destruction. 

5.6.1 If the Premises are damaged by fire, earthquake or other casualty (the “Casualty”), Tenant shall give prompt written
notice thereof to Landlord. If Landlord estimates (such estimate to be provided within sixty (60) calendar days of Landlord’s receipt of written notice of the damage) that the damage can be repaired to meet Tenant’s business needs
within one hundred-twenty (120) Business Days after Landlord is notified by Tenant of such damage and if there are sufficient insurance proceeds available to repair such damage, then Landlord shall proceed to restore the Premises to
substantially the condition which existed prior to the damage and this Lease shall not terminate. If, in Landlord’s estimation, the damage cannot be repaired within such 120 Business Day period or if there are insufficient insurance proceeds
available to repair such damage, Landlord may elect in its absolute discretion to either: (a) terminate this Lease or (b) restore the Premises to substantially the condition which existed prior to the damage and this Lease will continue.

 5.6.2 If Landlord elects to restore the Premises under subparagraph 5.6.1 above, then Landlord shall, at its sole cost and expense,
restore the Premises with reasonable diligence to substantially the condition existing prior to the Casualty; provided that Landlord shall not be obligated to restore Tenant Improvements and Tenant Alterations installed by Tenant or Tenant’s
furniture, fixtures or equipment. Landlord shall provide Tenant with notice of its election to restore the Premises, which notice shall also specify the expected duration of such restoration. Failure to so elect shall be deemed Landlord’s
decision not to restore. During the restoration period, the Base Rent and Additional Rent shall abate for the period during which the Premises are not suitable for Tenant’s business needs. If only a portion of the Premises is rendered not
suitable for Tenant’s business needs, the Base Rent and Additional Rent shall abate proportionately. When performing such restoration, Landlord will not be obligated to spend more than the net insurance proceeds received by Landlord as a result
of such Casualty plus an amount equal to the applicable deductible under Landlord’s insurance policy. If Landlord fails to complete such restoration within one hundred eighty (180) Business Days, as such time period may be extended by
Force Majeure events described in Section 9.8 of this Lease, then Tenant shall have the right to terminate this Lease upon fifteen (15) Business Days’ written notice to Landlord. If Tenant does not terminate the Lease, then
(1) the Lease Term shall be extended for the time required to complete such restoration, (2) Tenant shall pay to Landlord, upon demand, Tenant’s Pro Rata Share of any applicable deductible amount specified under Landlord’s
insurance and (3) Landlord shall not be required to repair or restore any Tenant Alterations installed by Tenant or Tenant’s furniture, fixtures, or equipment or other property of Tenant. Except for the abatement of Base Rent and
Additional Rent during reconstruction as provided in this subparagraph, Tenant agrees to look to the provider of Tenant’s insurance for coverage for the loss of Tenant’s use of the Premises and any other related losses or damages incurred
by Tenant during any reconstruction period. 
 5.6.3 If the Building is damaged by fire, earthquake or other casualty and more than fifty
percent (50%) of the Building is rendered untenantable, without regard to whether the Premises are affected by such damage, Landlord may in its absolute discretion and without limiting any other options available to Landlord under this Lease or
otherwise, elect to terminate this Lease by notice in writing to Tenant within sixty (60) days after the occurrence of such damage if Landlord is also terminating the leases of other tenants in the Building. Such notice shall be effective
twenty (20) Business Days after receipt by Tenant unless a later date is set forth in Landlord’s notice. 
 5.6.4 Notwithstanding
anything contained in this Lease to the contrary, if there is damage to the Premises or Building and the holder of any indebtedness secured by a mortgage or deed of trust covering any such property requires that the insurance proceeds be applied to
such indebtedness or if the insurance proceeds are otherwise inadequate to complete the repair of the damages to the Premises, the Building or both, then Landlord shall have the right to terminate this Lease by delivering written notice of
termination to Tenant within fifteen (15) Business Days after Landlord is notified of such requirement. 
 5.6.5 Notwithstanding the
foregoing, if the Premises or the Building are wholly or partially damaged or destroyed within the final six (6) months of the Lease Term, either Landlord or Tenant may, at its option, elect to terminate this Lease upon written notice to the
other party within thirty (30) days following such damage or destruction. 

  
 20 

 5.6.6 Tenant waives the provisions of any statutes presently existing or hereafter enacted
(including, without limitation, California Civil Code sections 1932 and 1933) which relate to termination of leases when the thing leased is destroyed and agrees that such event will be governed by the terms of this Lease. 

5.7 Condemnation. If more than fifty percent (50%) of the Premises, or such portions of the Building as may be required for the
Tenant’s reasonable use of the Premises, are taken by eminent domain or by conveyance in lieu thereof, this Lease shall automatically terminate as of the date the physical taking occurs, and all Base Rent, Additional Rent and other sums payable
under this Lease shall be paid to that date. In case of taking of a part of the Premises or a portion of the Building not required for the Tenant’s reasonable use of the Premises, then this Lease shall continue in full force and effect and the
Base Rent shall be equitably reduced based on the proportion by which the floor area of the Premises is reduced, such reduction in Base Rent to be effective as of the date the physical taking occurs. Additional Rent and all other sums payable under
this Lease shall not be abated but Tenant’s Pro Rata Share may be redetermined as equitable under the circumstances. Landlord reserves all rights to damages or awards for any taking by eminent domain relating to the Premises, Building, Land and
the unexpired term of this Lease. Tenant assigns to Landlord any right Tenant may have to such damages or award and Tenant shall make no claim against Landlord for damages for termination of its leasehold interest or interference with Tenant’s
business. Tenant shall have the right, however, to claim and recover from the condemning authority compensation for any loss to which Tenant may be entitled for Tenant’s moving expenses or other relocation costs; provided that, such
expenses or costs may be claimed only if they are awarded separately in the eminent domain proceedings and not as a part of the damages recoverable by Landlord. Tenant waives all rights it may have under California Code of Civil Procedure section
1265.130, or otherwise, to terminate this Lease based on a partial condemnation. 
 5.8 Estoppel Certificates and Financial Statements. Tenant
shall, not more than twice in any twelve (12) month period, upon the written request of Landlord, execute, acknowledge and deliver to Landlord or its designee a written statement stating: (a) the date this Lease was executed and the date
it expires; (b) the date Tenant entered into occupancy of the Premises; (c) the amount of monthly Base Rent and Additional Rent and the date to which such Base Rent and Additional Rent have been paid; and (d) certifying that
(1) this Lease is in full force and effect and has not been assigned, modified, supplemented or amended in any way (or specifying the date of the agreement so affecting this Lease); (2) to the best of Tenant’s knowledge, Landlord is
not in breach of this Lease (or, if so, a description of each such breach) and that no event, omission or condition has occurred which would result, with the giving of notice or the passage of time, in a breach of this Lease by Landlord;
(3) this Lease represents the entire agreement between the parties with respect to the Premises; (4) all required contributions by Landlord to Tenant on account of Tenant Improvements have been received or stating the amount of
contributions outstanding; (5) on the date of execution, to the best of Tenant’s knowledge, there exist no defenses or offsets which the Tenant has against the enforcement of this Lease by the Landlord; (6) no Base Rent, Additional
Rent or other sums payable under this Lease have been paid in advance except for Base Rent and Additional Rent for the then current month; (7) no security has been deposited with Landlord (or, if so, the amount of such security); (8) it is
intended that any Tenant’s statement may be relied upon by a prospective purchaser or mortgagee of Landlord’s interest or an assignee of any such mortgagee; and (9) such other information as may be reasonably requested by Landlord. If
Tenant fails to respond within ten (10) Business Days of its receipt of a written request by Landlord as provided in this paragraph, such shall be a breach of this Lease and Tenant shall be deemed to have admitted the accuracy of any
information supplied by Landlord to a prospective purchaser, mortgagee or assignee. In addition, as long as Tenant is not a publicly traded corporation or company, Tenant shall, from time to time, upon the written request of Landlord, deliver to or
cause to be delivered to Landlord or its designee then current financial statements (including a statement of operations and balance sheet and statement of cash flows) certified as accurate by a certified public accountant and prepared in
conformance with generally accepted accounting principles for (i) Tenant, (ii) any entity which owns a controlling interest in Tenant, (iii) any entity the controlling interest of which is owned by Tenant, and (iv) any successor
entity to Tenant by merger or operation of law. 
 5.9 Utility Bills. In order to assist Landlord in monitoring the energy efficiency of the
Building, on Landlord’s request, Tenant shall timely deliver to Landlord a copy of Tenant’s utility bills for the Premises and such other information related to Tenant’s use of utilities as may reasonably be requested. 

5.10 Intentionally Omitted. 

  
 21 

 5.11 Hazardous Substances. 

5.11.1 Landlord shall make such disclosures to Tenant of Hazardous Substances located on, in, under or around the Land or the Building as are
required by applicable Governmental Requirements. A notice letter to Tenant regarding the presence of any known asbestos-containing construction materials is attached as Rider 4. 

5.11.2 Neither Tenant, any of Tenant’s Agents nor any other person shall store, place, generate, manufacture, refine, handle, or locate
on, in, under or around the Land or Building any Hazardous Substance, except for storage, handling and use of reasonable quantities and types of cleaning fluids and office supplies in the Premises in the ordinary course and the prudent conduct of
Tenant’s business in the Premises. Tenant agrees that (a) the storage, handling and use of such permitted Hazardous Substances must at all times conform to all Governmental Requirements and to applicable fire, safety and insurance
requirements; (b) the types and quantities of permitted Hazardous Substances which are stored in the Premises must be reasonable and appropriate to the nature and size of Tenant’s operation in the Premises and reasonable and appropriate
for a first-class building of the same or similar use and in the same market area as the Building; and (c) no Hazardous Substance shall be spilled or disposed of on, in, under or around the Land or Building or otherwise discharged from the
Premises or any area adjacent to the Land or Building. In no event will Tenant be permitted to store, handle or use on, in, under or around the Premises any Hazardous Substance which will increase the rate of fire or extended coverage insurance on
the Land or Building, unless: (1) such Hazardous Substance and the expected rate increase have been specifically disclosed in writing to Landlord; (2) Tenant has agreed in writing to pay any rate increase related to each such Hazardous
Substance; and (3) Landlord has approved in writing each such Hazardous Substance, which approval shall be subject to Landlord’s discretion. 

5.11.3 Tenant shall indemnify, defend and hold harmless Landlord and Landlord’s Agents from and against any and all Claims arising out of
any breach of any provision of this paragraph, which expenses shall also include laboratory testing fees, personal injury claims, clean-up costs and environmental consultants’ fees. Tenant agrees that Landlord may be irreparably harmed by
Tenant’s breach of this paragraph and that a specific performance action may appropriately be brought by Landlord; provided that, Landlord’s election to bring or not bring any such specific performance action shall in no way limit,
waive, impair or hinder Landlord’s other remedies against Tenant. 
 5.11.4 As of the execution date of this Lease, Tenant represents
and warrants to Landlord that, except as otherwise disclosed by Tenant to Landlord, Tenant has no intent to bring any Hazardous Substances on, in or under the Premises except for the type and quantities authorized in subsection 5.11.2 above. In
addition, as of the Delivery Date, Landlord represents and warrants to Tenant that, except as otherwise disclosed by Landlord to Tenant, to Landlord’s actual knowledge, there are not Hazardous Substances in the Premises or the Building which
are in violation of any applicable Governmental Requirements. 
 5.12 Access Laws. 

5.12.1 Pursuant to California Civil Code Section 1938, Landlord hereby certifies to Tenant that, as of the Lease Date, access to the Premises
from within the Project has undergone inspection by a “Certified Access Specialist” (“Clasp”) and has been determined pursuant to such inspection to meet all applicable construction-related accessibility standards under
California Civil Code Section 55.53. 
 5.12.2 Landlord represents and warrants to Tenant that, as of the Commencement Date, to
Landlord’s actual knowledge, the Building (including the common areas of the Building) and the path of travel to the Premises are in material compliance with Access Laws. 

5.12.3 Tenant agrees to notify Landlord promptly if Tenant receives notification or otherwise becomes aware of: (a) any condition or
situation on, in, under or around the Land or Building which may constitute a violation of any Access Laws or (b) any threatened or actual lien, action or notice that the Land or Building is not in compliance with any Access Laws. If Tenant is
responsible for such condition, situation, lien, action or notice under this paragraph, Tenant’s notice to Landlord shall include a statement as to the actions Tenant proposes to take in response to such condition, situation, lien, action or
notice. 
 5.12.4 Tenant shall not alter or permit any assignee or subtenant or any other person to alter the Premises in any manner which
would violate any Access Laws or increase Landlord’s responsibilities for compliance with Access Laws, without the prior approval of the Landlord. In connection with any such approval, Landlord may require a certificate of compliance with
Access Laws from an architect, engineer or other person acceptable to Landlord. Tenant agrees to pay the reasonable fees incurred by such architect, engineer or other third party in connection with the issuance of such certificate of compliance.

  
 22 

 
Landlord’s consent to any proposed Tenant Alteration shall (a) not relieve Tenant of its obligations or indemnities contained in this paragraph or this Lease or (b) be construed as
a warranty that such proposed alteration complies with any Access Law. 
 5.12.5 Tenant shall be solely responsible for all costs and
expenses relating to or incurred in connection with: (a) failure of the Premises to comply with the Access Laws; and (b) bringing the Building and the common areas of the Building into compliance with Access Laws, if and to the extent such
noncompliance arises out of or relates to: (1) Tenant’s specific use of the Premises for non-general office use; (2) the hiring of employees; (3) any Tenant Alterations to the Premises which are not normal and customary business
office uses; or (4) any Tenant Improvements constructed in the Premises at the request of Tenant which are not consistent with normal and customary business office uses, regardless of whether such improvements are constructed prior to or after
the Commencement Date. For the avoidance of doubt, other than as expressly set forth in the preceding sentence, Tenant shall not be responsible for any other costs or expenses associated with (a) the failure of the Building to comply with the
Governmental Requirements; and (b) bringing the Building and the common areas of the Building outside of the Premises (including the restrooms on the 16th floor of the Building) into
compliance with Governmental Requirements. Tenant shall be responsible, at Tenant’s sole cost and expense, for ensuring that the restrooms located on the 17th floor of the Premises are in
compliance with all applicable Access Laws. 
 5.12.6 Landlord shall be responsible, at Landlord’s sole cost and expense, for
correcting any violations of any Access Laws with respect to the common areas of the Building which are required to be corrected in order for Tenant to obtain a permit for the construction of the Tenant Improvements prior to the Commencement Date;
provided that any such corrections to the common areas of the Building are not necessitated by Tenant’s specific use and occupancy of the Premises, or unless such costs and expenses are Tenant’s responsibility as provided in the preceding
subparagraph. Any cost or expense paid or incurred by Landlord to bring the Premises or common areas of the Building into compliance with Access Laws which is not Tenant’s responsibility under the preceding subparagraphs shall be amortized over
the useful economic life of the improvements (not to exceed ten (10) years) with interest as provided in Section 3.4 of this Lease. 

5.12.7 Tenant agrees to indemnify, defend and hold harmless Landlord and Landlord’s Agents from and against any and all Claims arising
out of or relating to any failure of Tenant or Tenant’s Agents to comply with Tenant’s obligations under this paragraph. 
 5.12.8
Tenant hereby agrees to use reasonable efforts to notify Landlord if Tenant makes any alterations, additions and/or improvements to the Premises that might impact accessibility to the Premises and/or the Building under any Access Laws. Landlord
hereby agrees to use reasonable efforts to notify Tenant if Landlord makes any alterations, additions and/or improvements to the Premises that might impact accessibility to the Premises and/or the Building under any Access Laws. 

5.12.9 The provisions of this paragraph shall supersede any other provisions in this Lease regarding Access Laws, to the extent inconsistent
with the provisions of any other paragraphs. 
 5.13 Quiet Enjoyment. Landlord covenants that Tenant, upon paying Base Rent, Additional Rent
and all other sums payable under this Lease and performing all covenants and conditions required of Tenant under this Lease shall and may peacefully have, hold and enjoy the Premises without hindrance or molestation by Landlord subject to the
provisions of this Lease. 
 5.14 Subordination. Landlord represents and warrants to Tenant that as of the Commencement Date, the Property is
not encumbered by a mortgage or deed of trust. Notwithstanding the foregoing, the holder or beneficiary of such mortgage, deed of trust, ground lease, vendor’s lien or similar instrument shall have the right to subordinate or cause to be
subordinated any such mortgage, deed of trust, ground lease, vendor’s lien or similar instrument to this Lease. Tenant shall have the right to request that any holder or beneficiary of such mortgage, deed of trust, ground lease, vendor’s
lien or similar instrument execute a non-disturbance agreement in favor of Tenant on the commercially reasonable standard form utilized by such lender or ground lessor, and Landlord shall use commercially reasonable efforts to obtain such executed
non-disturbance agreement if so requested by Tenant. At the request of Landlord, the holder of such mortgage or deed of trust or any ground lessor, Tenant shall execute, acknowledge and deliver promptly in recordable form any commercially reasonable
instrument or subordination agreement that Landlord or such holder may request; provided that such agreement provides that Tenant’s occupancy will not be disturbed so long as Tenant is not in default under the Lease beyond the expiration of any
applicable notice and cure periods. Tenant further covenants and agrees that if the lender or 

  
 23 

 
ground lessor acquires the Premises as a purchaser at any foreclosure sale or otherwise, Tenant shall recognize and attorn to such party as landlord under this Lease, and shall make all payments
required hereunder to such new landlord without deduction or set-off and, upon the request of such purchaser or other successor, execute, deliver and acknowledge commercially reasonable documents confirming such attornment. Tenant waives the
provisions of any law or regulation, now or hereafter in effect, which may give or purport to give Tenant any right to terminate or otherwise adversely affect this Lease or the obligations of Tenant hereunder in the event that any such foreclosure
or termination or other proceeding is prosecuted or completed. 
 5.15 Liens and Tenant’s Personal Property Taxes. 

5.15.1 Tenant shall have no authority, express or implied, to create or place any lien or encumbrance of any kind or nature whatsoever upon,
or in any manner to bind, the interest of Landlord or Tenant in the Premises or to charge the rentals payable under this Lease for any Claims in favor of any person dealing with Tenant, including those who may furnish materials or perform labor for
any construction or repairs. Tenant shall promptly pay or cause to be paid all sums legally due and payable by it on account of any labor performed or materials furnished in connection with any work performed on the Premises on which any lien is or
can be validly and legally asserted against its leasehold interest in the Premises and Tenant shall indemnify, defend and hold harmless Landlord from any and all Claims arising out of any such asserted Claims. Tenant agrees to give Landlord prompt
written notice of any such Claim. 
 5.15.2 Tenant shall be liable for all taxes levied or assessed against personal property, furniture or
fixtures placed by Tenant in the Premises. If any such taxes for which Tenant is liable are levied or assessed against Landlord or Landlord’s property and Landlord elects to pay them or if the assessed value of Landlord’s property is
increased by inclusion of such personal property, furniture or fixtures and Landlord elects to pay the taxes based on such increase, Tenant shall reimburse Landlord for the sums so paid by Landlord, within thirty (30) days after written demand
by Landlord, which is accompanied by reasonably appropriate back-up. 
 5.16 Work Performance and Responsible Contracting. 

5.16.1 Tenant acknowledges and agrees that all alterations, additions, improvements, repair and installations made to or on the Premises
(including any Tenant Improvements and any future Tenant Alterations) shall be performed subject to the Union Requirement. 
 5.16.2 In
addition to the requirement the previous subparagraph, Tenant shall use commercially reasonable efforts to contract for services to be performed in or about the Premises with companies which are a “Responsible Contractor”. A
“Responsible Contractor” is defined as a contractor or subcontractor who pays workers a fair wage and Fair Benefits as evidenced by payroll and employee records and who complies with the service-disabled veteran business policy.
“Fair Benefits” are defined as including employer-paid family health care coverage, pension benefits, and apprenticeship programs. 

SECTION 6: INSURANCE AND INDEMNIFICATION 

6.1 Indemnification. 
 6.1.1
Tenant shall indemnify, defend and hold harmless Landlord and Landlord’s Agents from and against any and all Claims, arising in whole or in part out of (a) the possession, use or occupancy of the Premises or the business conducted in the
Premises, (b) any act, omission or negligence of Tenant or Tenant’s Agents, or (c) any breach or default under this Lease by Tenant. 

6.1.2 Landlord shall indemnify, defend and hold harmless Tenant and Tenant’s Agents from and against any and all Claims, arising in whole
or in part out of (a) any act, omission or negligence of Landlord or Landlord’s Agents, or (b) any breach or default under this Lease by Landlord. 

6.1.3 Except as specified in subparagraph 6.1.2 above or in the next sentence or as otherwise provided in this Lease, neither Landlord nor
Landlord’s Agents shall, to the extent permitted by law, have any liability to Tenant, or to Tenant’s Agents, for (1) any Claims arising out of any cause whatsoever, including repair to any portion of the Premises;
(2) interruption in or interference with the use of the Premises or any equipment therein; (3) any accident or damage resulting from any use or operation by Landlord, Tenant or any person or entity of heating, cooling, electrical, sewerage
or plumbing equipment or apparatus or Telecommunication Facilities; (4) termination of this Lease by reason of damage to the Premises or Building; (5) fire, robbery, theft, vandalism, mysterious disappearance or a casualty of any kind or
nature; (6) actions of any other tenant of the Building or of any other person or entity; (7) inability 

  
 24 

 
to furnish any service required of Landlord as specified in this Lease; or (8) leakage in any part of the Premises or the Building from rain, ice or snow, or from drains, pipes or plumbing
fixtures in the Premises or the Building. Landlord shall only be responsible for Claims arising from the items listed in the previous sentence if such items were within Landlord’s reasonable control and Landlord was negligent or acted with
willful misconduct in failing to repair or maintain the Building as required by this Lease; but in no event shall Landlord’s responsibility extend to any interruption to Tenant’s business or any indirect or consequential losses suffered by
Tenant or Tenant’s Agents or extend beyond Landlord’s responsibility as set forth in the paragraph entitled “Utilities” when that paragraph is applicable. The obligations of this paragraph shall be subject to the paragraph
captioned “Waiver of Subrogation”. 
 6.1.4 Each party to this Lease shall indemnify, defend and hold harmless the other
party from and against any and all Claims asserted against such other party by any real estate broker, finder or intermediary relating to any act of the indemnifying party in connection with this Lease. 

6.2 Tenant Insurance. 
 6.2.1
Tenant shall, throughout the Lease Term, at its own expense, keep and maintain in full force and effect the following policies, each of which shall be endorsed as needed to provide that the insurance afforded by these policies is primary and that
all insurance carried by Landlord is strictly excess and secondary and shall not contribute with Tenant’s liability insurance: 
 (a) A
policy of commercial general liability insurance, including a contractual liability endorsement covering Tenant’s obligations under the paragraph captioned “Indemnification”, insuring against claims of bodily injury and death or
property damage or loss with a combined single limit at the Commencement Date of this Lease of not less than Two Million Dollars ($2,000,000.00), which limit shall be reasonably increased during the Lease Term, at Landlord’s request, to reflect
both increases in liability exposure arising from inflation as well as from changing use of the Premises or changing legal liability standards, which policy shall be payable on an “occurrence” rather than a “claims made” basis,
and which policy names Landlord, Manager, Bentall Kennedy (U.S.) Limited Partnership, NewTower Trust Company, and each of their agents, affiliates, members, directors, officers and employees, and, at Landlord’s request, Landlord’s mortgage
lender(s) or investment advisors, as additional insureds. The commercial general liability coverage shall include “host liquor liability” and, as applicable, an endorsement covering Tenant’s dram shop/liquor liability if Tenant sells
or distributes alcoholic beverages. Dram shop/liquor liability coverage may also be purchased under a separate policy. 
 (b) “Special
Form” property insurance (which is commonly called “all risk”) covering Tenant Improvements, Tenant Alterations (including Telecommunication Facilities), and any and all furniture, fixtures, equipment, inventory, improvements and
other property in or about the Premises which is not owned by Landlord, for one hundred percent (100%) of the then current replacement cost of such property; 

(c) Business interruption insurance in an amount sufficient to cover costs, damages, lost income, expenses, Base Rent, Additional Rent and all
other sums payable under this Lease, should any or all of the Premises not be usable for a period of up to twelve (12) months; 
 (d) A
policy of worker’s compensation insurance as required by applicable law and employer’s liability insurance with limits of no less than One Million and No/100 Dollars ($1,000,000.00); and 

(e) A policy of comprehensive automobile liability insurance, including loading and unloading, and covering owned, non-owned and hired
vehicles, with limits of no less than One Million Dollars ($1,000,000.00) per occurrence. 
 (f) Excess/Umbrella Liability insurance on a
form at least as broad as the primary coverages required above with limits of not less than Five Million Dollars ($5,000,000) per occurrence and per location or project aggregate. 

6.2.2 All insurance policies required under this Section 6.2 shall be with companies with an A.M. Best Rating of A-/VII (or higher) and
that are authorized to provide insurance in California. Tenant shall be required to provide Landlord with not less than thirty (30) days’ prior written notice if any policy required to be carried by Tenant hereunder is subject to
cancellation, lapse or reduction in coverage. Tenant shall deliver to Landlord and, at Landlord’s request Landlord’s mortgage lender(s), prior to the Delivery Date and from time to time thereafter, certificates evidencing the existence and
amounts of all such policies. Deductibles above $25,000 and self-insured retentions must be declared to Landlord prior to the Delivery Date. 

  
 25 

 6.2.3 If Tenant fails to acquire or maintain any insurance or provide any certificate required by
this paragraph, which failure is not cured within ten (10) Business Days after receipt of written notice thereof (unless such insurance coverage would lapse within such ten (10) Business Day period, in which case, Landlord shall not be
required to observe the cure period hereunder), Landlord may, but shall not be required to, obtain such insurance or certificates and the costs associated with obtaining such Insurance or certificates shall be payable by Tenant to Landlord on
demand. 
 6.3 Landlord’s Insurance. Landlord shall, throughout the Lease Term, keep and maintain in full force and effect: 

(a) Commercial general liability insurance, insuring against claims of bodily injury and death or property damage or loss with a combined
single limit at the Commencement Date of not less than Three Million Dollars ($3,000,000.00) per occurrence and Five Million Dollars ($5,000,000.00) in the aggregate, which policy shall be payable on an “occurrence” rather than a
“claims made” basis; 
 (b) “Special Form” property Insurance (which is commonly called “all risk”) covering
the Building and Landlord’s personal property, if any, located on the Land in the amount of one hundred percent (100%) of the then current replacement value of such property; and 

(c) Landlord may, but shall not be required to, maintain other types of insurance as Landlord deems appropriate, including but not limited to,
property insurance coverage for earthquakes and floods in such amounts as Landlord deems appropriate. Such policies may be “blanket” policies which cover other properties owned by Landlord. Landlord shall deliver to Tenant and, at
Tenant’s request Tenant’s mortgage lender(s), prior to the Commencement Date and from time to time thereafter, certificates evidencing the existence and amounts of all such policies. 

6.4 Waiver of Subrogation. Notwithstanding anything in this Lease to the contrary, Landlord and Tenant hereby each waive and release the other
from any and all Claims or any loss or damage that may occur to the Land, Building, Premises, or personal property located therein, by reason of fire or other casualty regardless of cause or origin, including the negligence or misconduct of
Landlord, Tenant, Landlord’s Agents or Tenant’s Agents, but only to the extent of the insurance proceeds paid to such releasor under its policies of insurance or, if it fails to maintain the required policies, the insurance proceeds that
would have been paid to such releasor if it had maintained such policies. Each party to this Lease shall promptly give to its insurance company written notice of the mutual waivers contained in this subparagraph, and shall cause its insurance
policies to be properly endorsed, if necessary, to prevent the invalidation of any insurance coverages by reason of the mutual waivers contained in this subparagraph. 

SECTION 7: ASSIGNMENT AND SUBLETTING 

7.1 Assignment and Subletting by Tenant. 

7.1.1 Tenant shall not have the right to assign, transfer, mortgage or encumber this Lease in whole or in part, nor sublet the whole or any
part of the Premises, nor allow the occupancy of all or any part of the Premises by another, without first obtaining Landlord’s consent, which consent may be granted or denied in accordance with this paragraph. In no event shall the
determination of the amount of rent be expressed in whole or in part as a percentage of the income or profits derived by the subtenant from the space leased (other than an amount based on a fixed percentage or percentages of gross receipts or gross
sales). Notwithstanding any permitted assignment or subletting, Tenant shall at all times remain directly, primarily and fully responsible and liable for the payment of all sums payable under this Lease and for compliance with all of its other
obligations as tenant under this Lease. Landlord’s acceptance of Base Rent, Additional Rent or any other sum from any assignee, sublessee, transferee, mortgagee or encumbrance holder shall not be deemed to be Landlord’s approval of any
such conveyance. Upon the occurrence of an Event of Default, if the Premises or any part of the Premises are then subject to an assignment or subletting, Landlord may, at its option, collect directly from such assignee or subtenant all rents
becoming due to Tenant under such assignment or sublease and apply such rents against any sums due to Landlord from Tenant under this Lease. No such collection shall be construed to constitute a novation or release of Tenant from the further
performance of Tenant’s obligations under this Lease. Landlord’s right of direct collection shall be in addition to and not in limitation of any other rights and remedies provided for in this Lease or at law. Tenant makes an absolute
assignment to Landlord of such assignments and subleases and any rent, Lease Security Deposits and other sums payable under such assignments and subleases as collateral to secure the performance of the obligations of Tenant under this Lease. 

  
 26 

 7.1.2 In the event Tenant desires to assign this Lease or to sublet all or any portion of the
Premises, Tenant shall give written notice of such desire to Landlord prior to the proposed commencement date of such subletting or assignment, which notice shall set forth the name of the proposed subtenant or assignee, the proposed term, the
nature of the proposed subtenant’s or assignee’s business to be conducted on the Premises, the rental rate, and any other particulars of the proposed subletting or assignment that Landlord may reasonably request. Without limiting the
preceding sentence, Tenant shall also provide Landlord with: (a) such financial information as Landlord may reasonably request concerning the proposed subtenant or assignee, including recent financial statements certified as accurate and
complete by a certified public accountant, if available, or by the president, managing partner or other appropriate officer of the proposed subtenant or assignee; (b) proof satisfactory to Landlord that the proposed subtenant or assignee will
immediately occupy and thereafter use the entire Premises (or any sublet portion of the Premises) for the remainder of the Lease Term (or for the entire term of the sublease, if shorter) in compliance with the terms of this Lease; and (c) a
copy of the proposed sublease or assignment or letter of intent. Tenant shall pay to Landlord, upon Landlord’s demand therefor, Landlord’s actual attorneys’ fees incurred in the review of such documentation and in documenting
Landlord’s consent, plus an administrative fee of $2,000.00 as Landlord’s fee for processing such proposed assignment or sublease. Receipt of such fee shall not obligate Landlord to approve the proposed assignment or sublease. 

7.1.3 Without limiting what may be construed as a factor considered by Landlord, Tenant agrees that any one or more of the following will be
proper grounds for Landlord’s disapproval of a proposed assignment or sublease: 
 (a) The proposed assignee or subtenant does not, in
Landlord’s good faith judgment, have sufficient financial worth to insure full and timely performance under this Lease; or Landlord has received insufficient evidence of the financial worth or creditworthiness of the proposed assignee or
subtenant to make the determination set forth in this clause; 
 (b) Landlord has had prior negative leasing experience with the proposed
assignee or subtenant or an affiliate; or, in Landlord’s reasonable judgment, the proposed assignee or subtenant is engaged in a business, or the Premises or any part of the Premises will be used in a manner, that is not in keeping with the
then standards of the Building, or that is not compatible with the businesses of other tenants in the Building, or that is inappropriate for the Building, or that will violate any negative covenant as to use contained in any other lease of space in
the Building; 
 (c) The use of the Premises by the proposed assignee or subtenant will not be permitted under the Permitted Uses; 

(d) Tenant is in default of any obligation of Tenant under this Lease, or Tenant has defaulted under this Lease on three (3) or more
occasions during the twenty-four (24) months preceding the date that Tenant shall request such consent; 
 (e) Landlord has had written
negotiations with the proposed assignee or subtenant, in the three (3) months preceding Tenant’s request, regarding the leasing of space by such proposed assignee or subtenant in the Building or any other buildings owned by Landlord in the
metropolitan area in which the Land is located, and in each case, Landlord has comparable space available. 
 7.1.4 Within fifteen
(15) Business Days after Tenant provides Landlord with the items set forth in Section 7.1.2, Landlord shall notify Tenant of Landlord’s approval, disapproval or conditional approval of any proposed assignment or subletting or of
Landlord’s election to recapture as described below. Landlord shall have no obligation to respond unless and until all required information has been submitted. Notwithstanding the foregoing, if any items set forth in Section 7.1.2 have not
been provided by Tenant to Landlord, in Landlord’s reasonable discretion, Landlord shall provide Tenant with notice thereof, and such fifteen (15) Business Day period for Landlord’s approval, disapproval or conditional approval of any
proposed assignment or subletting shall not commence until all such items requested by Landlord pursuant to Landlord’s written notice to Tenant have been provided to Landlord for review. In the event Landlord approves of any proposed assignment
or subletting, Tenant and the proposed assignee or sublessee shall execute and deliver to Landlord an assignment (or subletting) and assumption agreement in form and content reasonably satisfactory to Landlord. Notwithstanding any contrary provision
of this Lease, if Tenant or any proposed assignee or sublessee claims that Landlord has unreasonably withheld or delayed its consent to a proposed assignment or sublease or otherwise has breached its obligations under this Section 7,
Tenant’s and such assignee’s or sublessee’s sole remedy shall be to seek a declaratory judgment and/or injunctive relief, and Tenant, on behalf of itself and, to the extent permitted 

  
 27 

 
by law, such proposed assignee or sublessee, waives all other remedies against Landlord, including without limitation, the right to seek monetary damages or to terminate this Lease (including,
without limitation, pursuant to Section 1995.310 of the California Civil Code or any successor statutes thereto). 
 7.1.5 Any
transfer, assignment or hypothecation of any of the stock or interest in Tenant, or the assets of Tenant, or any other transaction, merger, reorganization or event, however constituted which (a) results in fifty percent (50%), or more of such
stock, interest or assets going into different ownership, or (b) is a subterfuge denying Landlord the benefits of this paragraph, shall be deemed to be an assignment within the meaning and provisions of this paragraph and shall be subject to
the provisions of this paragraph. 
 7.1.6 If Landlord consents to any assignment or sublease and Tenant receives rent or any other
consideration, either initially or over the term of the assignment or sublease, in excess of the Base Rent and Additional Rent (or, in the case of a sublease of a portion of the Premises, in excess of the Base Rent paid by Tenant on a square footage
basis under this Lease), Tenant shall pay to Landlord fifty percent (50%) of such excess, less the amount of any actual, out-of-pocket and verifiable costs paid in connection with brokerage commissions, tenant improvement allowances and
alteration costs, commercially reasonable marketing expenses and reasonable attorneys’ fees, if any (“Transaction Expenses”); provided that Tenant furnishes Landlord with invoices and statements in connection with any and all
Transaction Expenses in incurred by Tenant in connection therewith. 
 7.1.7 If Tenant Intends to assign all or any portion of its interest
in this Lease or sublease all or any portion of the Premises, Landlord shall have the right to recapture the Premises or the applicable portion thereof (a “Recapture”) by giving written notice of such Recapture to Tenant within
fifteen (15) Business Days after receipt of Tenant’s written request for Landlord’s consent to such proposed assignment or subletting. Tenant shall have no right to retract its request for Landlord’s consent to assign or sublease
once such request has been made. Such Recapture shall terminate this Lease as to the applicable space effective on the prospective effective date of assignment or subletting, which shall be the last day of a calendar month and shall not be earlier
than forty-five (45) Business Days after receipt of Tenant’s request hereunder. If less than the entire Premises are recaptured, this Lease shall remain in full force and effect with respect to that remaining area not recaptured by
Landlord. Tenant shall surrender that portion of the Premises recaptured by Landlord in accordance with the terms and conditions of this Lease. 

7.2 Assignment by Landlord. Landlord shall have the right to transfer and assign, in whole or in part, its rights and
obligations under this Lease and in any and all of the Land or Building. If Landlord sells or transfers any or all of the Building, including the Premises, Landlord and Landlord’s Agents shall, upon consummation of such sale or transfer, be
released automatically from any liability relating to obligations or covenants under this Lease to be performed or observed after the date of such transfer, and in such event, Tenant agrees to look solely to Landlord’s successor-in-interest
with respect to such liability; provided that, as to the Lease Security Deposit and Prepaid Rent, Landlord shall not be released from liability therefor unless Landlord has delivered (by direct transfer or credit against the purchase price)
the Lease Security Deposit or Prepaid Rent to its successor-in-interest. 
 SECTION 8: DEFAULT AND REMEDIES 

8.1 Events of Default. 
 8.1.1 The
occurrence of any one or more of the following events shall constitute a material default and breach of this Lease by Tenant (“Event of Default”): 

(a) abandonment of all or any portion of the Premises without continued payment of Base Rent and Additional Rent; 

(b) failure by Tenant to make any payment of Base Rent or Additional Rent within five (5) Business Days’ after its due date; 

(c) failure by Tenant to pay any other sum required to be paid by Tenant under this Lease within five (5) Business Days’ after
written notice of such failure; 
 (d) failure by Tenant to observe or perform any covenant or condition of this Lease, other than the
making of payments, where such failure shall continue for a period of twenty (20) Business Days after written notice from Landlord or such additional time as is reasonably needed to cure the default provided that Tenant shall diligently and
continuously pursue the cure and complete the cure within sixty (60) Business Days; 

  
 28 

 (e) the failure of Tenant to surrender possession of the Premises at the expiration or earlier
termination of this Lease in the condition required by this Lease; 
 (f) (1) the making by Tenant of any general assignment or general
arrangement for the benefit of creditors; (2) the filing by or against Tenant of a petition in bankruptcy, including reorganization or arrangement, unless, in the case of a petition filed against Tenant, unless the same is dismissed within
twenty (20) Business Days; (3) the appointment of a trustee or receiver to take possession of substantially all Tenant’s assets located in the Premises or of Tenant’s interest in this Lease; (4) any execution, levy,
attachment or other process of law against any property of Tenant or Tenant’s interest in this Lease, unless the same is dismissed within twenty (20) Business Days; (5) adjudication that Tenant is bankrupt; (6) the making by
Tenant of a transfer in fraud of creditors; or (7) the failure of Tenant to generally pay its debts as they become due; or 
 (g) any
information furnished by or on behalf of Tenant to Landlord in connection with the entry of this Lease is determined to have been materially false, misleading or incomplete when made. 

(h) a failure of the Tenant to deliver the Letter of Credit within the time period specified in the paragraph captioned “Lease
Security Provisions”. 
 8.1.2 Notwithstanding any cure periods specified in the previous subparagraph, after the occurrence during
the Lease Term of any two events which after the giving of notice or the lapse of time would become an Event of Default, Tenant shall neither be entitled to notice nor an opportunity to cure and Landlord, at its option, may immediately declare an
Event of Default. 
 8.1.3 When this Lease requires service of a notice, that notice shall replace rather than supplement any equivalent or
similar statutory notice, including any notices required by Code of Civil Procedure section 1161 or any similar or successor statute. When a statute requires service of a notice in a particular manner, service of that notice (or a similar notice
required by this Lease) in the manner required by paragraph 6.1 shall replace and satisfy the statutory service-of-notice procedures, including those required by Code of Civil Procedure section 1162 or any similar or successor statute. 

8.1.4 If a petition in bankruptcy is filed by or against Tenant, and if this Lease is treated as an “unexpired lease” under
applicable bankruptcy law, then Tenant shall neither attempt nor cause any trustee to attempt to extend the time period specified by the Bankruptcy Act for the assumption or rejection of this Lease. 

8.2 Remedies. If any Event of Default occurs, Landlord may at any time after such occurrence, with or without notice or demand except as stated
in this paragraph, and without limiting Landlord in the exercise of any right or remedy at law which Landlord may have by reason of such Event of Default, exercise the rights and remedies, either singularly or in combination, as are specified or
described in the subparagraphs of this paragraph. 
 8.2.1 Landlord may terminate this Lease and all rights of Tenant under this Lease
either immediately or at some later date by giving Tenant written notice that this Lease is terminated. If Landlord so terminates this Lease, then Landlord may recover from Tenant the sum of: 

(a) the unpaid Base Rent, Additional Rent and all other sums payable under this Lease which have been earned at the time of termination; 

(b) interest at the Default Rate on the unpaid Base Rent, Additional Rent and all other sums payable under this Lease which have been earned
at the time of termination; plus 
 (c) the amount by which the unpaid Base Rent, Additional Rent and all other sums payable under this
Lease which would have been earned after termination until the time of award exceeds the amount of such rental loss, if any, as Tenant affirmatively proves could have been reasonably avoided and interest on such excess at the Default Rate; plus 

(d) the amount by which the aggregate of the unpaid Base Rent, Additional Rent and all other sums payable under this Lease for the balance of
the Lease Term after the time of award exceeds the amount of such rental loss, if any, as Tenant affirmatively proves could be reasonably avoided, with such difference being discounted to present value at the discount rate of the Federal Reserve
Bank of San Francisco at the time of award plus one percent (1%); plus 
 (e) any other amount necessary to compensate Landlord for the
detriment proximately caused by Tenant’s failure to perform Tenant’s obligations under this Lease or which, in the ordinary course of things, would be likely to result from such failure, including, leasing commissions, tenant improvement
costs, renovation costs and advertising costs; plus 
 (f) all such other amounts in addition to or in lieu of the foregoing as may be
permitted from time to time by applicable law. 

  
 29 

 8.2.2 Landlord shall also have the right, with or without terminating this Lease, but in
accordance with applicable law, to re-enter the Premises and remove all persons and property from the Premises. Landlord may cause property so removed from the Premises to be stored in a public warehouse or elsewhere at the expense and for the
account of Tenant. 
 8.2.3 Landlord shall also have the right, without terminating this Lease, to accelerate and recover from Tenant the
sum of all unpaid Base Rent, Additional Rent and all other sums payable under the then remaining term of the Lease, discounting such amount to present value at the Prime Rate. 

8.2.4 If Tenant abandons or surrenders the Premises without Landlord’s consent, or if Landlord re-enters the Premises as provided in
subparagraph 8.2.2 or takes possession of the Premises pursuant to legal proceedings or through any notice procedure provided by law, then, if Landlord does not elect to terminate this Lease, Landlord may, from time to time, without terminating this
Lease, either (a) recover all Base Rent, Additional Rent and all other sums payable under this Lease as they become due or (b) relet the Premises or any part of the Premises on behalf of Tenant for such term or terms, at such rent or rents
and pursuant to such other provisions as Landlord, in its sole discretion, may deem advisable, all with the right, at Tenant’s cost, to make alterations and repairs to the Premises and recover any deficiency from Tenant as set forth in
subparagraph 8.2.6. 
 8.2.5 Landlord may elect, in its absolute discretion, to maintain Tenant’s right to possession, in which case
this Lease shall continue in effect whether or not Tenant shall have abandoned the Premises. In such event, Landlord may enforce all of Landlord’s rights and remedies under this Lease, including the right to recover rent as it becomes due
hereunder, and, at Landlord’s election, to re-enter and relet the Premises on such terms and conditions as Landlord deems appropriate. Without limiting the generality of the foregoing, Landlord shall have the remedy described in California
Civil Code Section 1951.4 (lessor may continue lease in effect after lessee’s breach and abandonment and recover rent as it becomes due, if lessee has right to sublet or assign, subject only to reasonable limitations). Landlord may execute
any lease made pursuant hereto in its own name, and Tenant shall have no right to collect any such rent or other proceeds. Landlord’s re-entry and/or reletting of the Premises, or any other acts, shall not be deemed an acceptance of surrender
of the Premises or Tenant’s interest therein, a termination of this Lease or a waiver or release of Tenant’s obligations hereunder. Landlord shall have the same rights with respect to Tenant’s improvements and personal property as
under Section 8.2.2 above, even though such re-entry and/or reletting do not constitute acceptance of surrender of the Premises or termination of this Lease. 

8.2.6 None of the following remedial actions, singly or in combination, shall be construed as an election by Landlord to terminate this Lease
unless Landlord has in fact given Tenant written notice that this Lease is terminated: (a) an act by Landlord to maintain or preserve the Premises; (b) any efforts by Landlord to relet the Premises; (c) any repairs or alterations made
by Landlord to the Premises; (d) re-entry, repossession or reletting of the Premises by Landlord pursuant to this paragraph; or (e) the appointment of a receiver, upon the initiative of Landlord, to protect Landlord’s interest under
this Lease. If Landlord takes any of the foregoing remedial action without terminating this Lease, Landlord may nevertheless at any time after taking any such remedial action terminate this Lease by written notice to Tenant. 

8.2.7 If Landlord relets the Premises, Landlord shall apply the revenue from such reletting as follows: first, to the payment of
any indebtedness of Tenant to Landlord other than Base Rent, Additional Rent or any other sums payable by Tenant under this Lease; second, to the payment of any cost of reletting (including finders’ fees and leasing commissions);
third, to the payment of the cost of any alterations, improvements, maintenance and repairs to the Premises; and fourth, to the payment of Base Rent, Additional Rent and other sums due and payable and unpaid under this
Lease. Landlord shall hold and apply the residue, if any, to payment of future Base Rent, Additional Rent and other sums payable under this Lease as the same become due, and shall deliver the eventual balance, if any, to Tenant. Should revenue from
letting during any month, after application pursuant to the foregoing provisions, be less than the sum of the Base Rent, Additional Rent and other sums payable under this Lease and Landlord’s expenditures for the Premises during such month,
Tenant shall be obligated to pay such deficiency to Landlord as and when such deficiency arises. 
 8.2.8 Pursuit of any of the foregoing
remedies shall not preclude pursuit of any of the other remedies provided in this Lease or by law (all such remedies being cumulative), nor shall pursuit of any 

  
 30 

 
remedy provided in this Lease constitute a forfeiture or waiver of any Base Rent, Additional Rent or other sum payable under this Lease or of any damages accruing to Landlord by reason of the
violation of any of the covenants or conditions contained in this Lease. Tenant waives, for Tenant and for all those claiming by, through or under Tenant, Section 3275 of the California Civil Code and Sections 1174(c) and 1179 of the California
Code of Civil Procedure and any existing or future rights to redeem or reinstate, by order or judgment of any court or by any legal process or writ, this Lease or Tenant’s right of occupancy of the Premises after any termination hereof. 

8.3 Right to Perform. If Tenant shall fail to pay any sum of money, other than Base Rent or Additional Rent, required to be paid by it under
this Lease or shall fail to perform any other act on its part to be performed under this Lease, and such failure shall continue for ten (10) Business Days after written notice of such failure by Landlord, or such shorter time if reasonable
under the circumstances, Landlord may, but shall not be obligated to, and without waiving or releasing Tenant from any obligations of Tenant, make such payment or perform such other act on Tenant’s part to be made or performed as provided in
this Lease. Landlord shall have (in addition to any other right or remedy of Landlord) the same rights and remedies in the event of the nonpayment of sums due under this paragraph as in the case of default by Tenant in the payment of Base Rent. 

8.4 Landlord’s Default. Landlord shall not be in default under this Lease unless Landlord fails to perform obligations required of Landlord
within twenty (20) Business Days after written notice is delivered by Tenant to Landlord and to the holder of any mortgages or deeds of trust (collectively, “Lender”) covering the Premises whose name and address shall have
theretofore been furnished to Tenant in writing, specifying the obligation which Landlord has failed to perform; provided, however, that if the nature of Landlord’s obligation is such that more than twenty (20) Business Days are required
for performance, then Landlord shall not be in default if Landlord or Lender commences performance within such twenty (20) Business Day period and thereafter diligently prosecutes the same to completion. All obligations of Landlord hereunder
shall be construed as covenants, not conditions. In the event of any default, breach or violation of Tenant’s rights under this Lease by Landlord, Tenant’s exclusive remedy shall be either an action for specific performance or an action
for actual damages. Tenant hereby waives the benefit of any laws granting it the right to perform Landlord’s obligation, a lien upon the property of Landlord and/or upon Rent due Landlord, or the right to terminate this Lease or withhold Rent
on account of any Landlord default. 
 8.5 Limitation on Recourse. Liability with respect to the entry and performance of this Lease by or on
behalf of Landlord, however it may arise, shall be asserted and enforced only against Landlord’s estate and equity interest in the Building. Neither Landlord nor any of Landlord’s Agents shall have any personal liability in the event of
any Claim against Landlord arising out of or in connection with this Lease, the relationship of Landlord and Tenant or Tenant’s use of the Premises. Any and all personal liability, if any, beyond that which may be asserted under this paragraph,
is expressly waived and released by Tenant and by all persons claiming by, through or under Tenant. 
 SECTION 9: MISCELLANEOUS
PROVISIONS 
 9.1 Notices. All notices, demands, consents, approvals, statements and communications required or permitted under this
Lease shall be in writing and, if intended for Landlord, shall be addressed to Landlord at the addresses set forth opposite Landlord’s signature; and if intended for Tenant, shall be addressed to Tenant at the address set forth opposite
Tenant’s signature, or to such other address as either party may by written notice, given in accordance with this paragraph, advise the other party. All such communications shall be transmitted by personal delivery, reputable express or courier
service, or United States Postal Service, postage prepaid. All such communications shall be deemed delivered and effective on the earlier of (a) the date received or refused for delivery, or (b) five (5) calendar days after having
been deposited in the United States Postal Service, postage prepaid. Notwithstanding the means of transmission authorized earlier in this paragraph, those communications which contain a notice of breach or default, a notice of an event or occurrence
that with the passage of time or the giving of notice, or both, would cause a breach or default to arise, or a demand for performance shall be transmitted by one or more of the following methods: (i) United States Postal Service, certified
mail, return receipt requested; or (ii) personal delivery, accompanied by a receipt and signed by a representative of the addressee acknowledging delivery on a specified date, with delivery not effective unless the receipt is given, or
(iii) reputable express or courier service. 

  
 31 

 9.2 Attorney’s Fees and Expenses. In the event that (a) either party requires the
services of an attorney in connection with enforcing the terms of this Lease, (b) suit is brought for the enforcement of this Lease or the exercise of rights and remedies afforded by this Lease or under law, or (c) proceedings are held in
bankruptcy then the substantially prevailing party shall be entitled to a reasonable sum for attorney’s and paralegal’s fees, expenses and court costs, including those relating to any appeal. The prevailing party shall be determined under
Civil Code section 1717(b)(1) or any successor statute. 
 9.3 No Accord and Satisfaction. No payment by Tenant or receipt by Landlord of an
amount less than the Base Rent or Additional Rent or any other sum due and payable under this Lease shall be deemed to be other than a payment on account of the Base Rent, Additional Rent or other such sum, nor shall any endorsement or statement on
any check or any letter accompanying any check or payment be deemed an accord and satisfaction, nor preclude Landlord’s right to recover the balance of any amount payable or Landlord’s right to pursue any other remedy provided in this
Lease or at law. 
 9.4 Successors; Joint and Several Liability. Except as provided in the paragraph captioned “Limitation on
Recourse” and subject to the paragraph captioned “Assignment and Subletting by Landlord”, all of the covenants and conditions contained in this Lease shall apply to and be binding upon Landlord and Tenant and their
respective heirs, executors, administrators, successors and assigns. In the event that more than one person, partnership, company, corporation or other entity is included in the term “Tenant”, then each such person, partnership,
company, corporation or other entity shall be jointly and severally liable for all obligations of Tenant under this Lease. 
 9.5 Choice of
Law. This Lease shall be construed and governed by the laws of the state in which the Land is located. Venue for any actions brought by Landlord or Tenant pursuant to this Lease will be in San Francisco, California. 

9.6 No Waiver of Remedies. The waiver by Landlord of any covenant or condition contained in this Lease shall not be deemed to be a waiver of any
subsequent breach of such covenant or condition nor shall any custom or practice which may develop between the parties in the administration of this Lease be construed to waive or lessen the rights of Landlord to insist on the strict performance by
Tenant of all of the covenants and conditions of this Lease. No act or thing done by Landlord or Landlord’s Agents during the Lease Term shall be deemed an acceptance or a surrender of the Premises, and no agreement to accept a surrender of the
Premises shall be valid unless made in writing and signed by Landlord. The mention in this Lease of any particular remedy shall not preclude Landlord from any other remedy it might have, either under this Lease or at law, nor shall the waiver of or
redress for any violation of any covenant or condition in this Lease or in any of the rules or regulations attached to this Lease or later adopted by Landlord, prevent a subsequent act, which would have originally constituted a violation, from
having all the force and effect of an original violation. The receipt by Landlord of Base Rent, Additional Rent or any other sum payable under this Lease with knowledge of a breach of any covenant or condition in this Lease shall not be deemed a
waiver of such breach. The failure of Landlord to enforce any of the rules and regulations attached to this Lease or later adopted, against Tenant or any other tenant in the Building, shall not be deemed a waiver. Any waiver by Landlord must be in
writing and signed by Landlord to be effective. 
 9.7 Offer to Lease. The submission of this Lease in a draft form to Tenant or its broker or
other agent does not constitute an offer to Tenant to lease the Premises. This Lease shall have no force or effect until it is executed by both Tenant and Landlord. 

9.8 Force Majeure. In the event that either party shall be delayed, hindered in or prevented from the performance of any act or obligation
required under this Lease by reason of acts of God, strikes, lockouts, labor troubles or disputes, inability to procure or shortage of materials or labor, failure of power or utilities, delay in transportation, fire, vandalism, accident, flood,
severe weather, other casualty, Governmental Requirements (including mandated changes in the Plans and Specifications or the Tenant Improvements resulting from changes in pertinent Governmental Requirements or interpretations thereof), riot,
insurrection, civil commotion, sabotage, explosion, war, natural or local emergency, acts or omissions of others, including the other party, or other reasons of a similar or dissimilar nature not solely the fault of, or under the exclusive control
of, Landlord, then performance of such act or obligation (other than Tenant’s rental obligations under this Lease) shall be excused for the period of the delay and the period for the performance of any such act or obligation shall be extended
for the period equivalent to the period of such delay. 

  
 32 

 9.9 Severability; Captions. If any clause or provision of this Lease is determined to be illegal,
invalid, or unenforceable under present or future laws, the remainder of this Lease shall not be affected by such determination, and in lieu of each clause or provision that is determined to be illegal, invalid or unenforceable, there be added as a
part of this Lease a clause or provision as similar in terms to such illegal, invalid or unenforceable clause or provision as may be possible and be legal, valid and enforceable. Headings or captions in this Lease are added as a matter of
convenience only and in no way define, limit or otherwise affect the construction or interpretation of this Lease. 
 9.10 Interpretation.
Whenever a provision of this Lease uses the term (a) “include” or “including”, that term shall not be limiting but shall be construed as illustrative, (b) “covenant”, that term shall include any covenant,
agreement, term or provision, (c) “at law”, that term shall mean as specified in any applicable statute, ordinance or regulation having the force of law or as determined at law or in equity, or both, and (d) “day”, that
uncapitalized word shall mean a calendar day. This Lease shall be given a fair and reasonable interpretation of the words contained in it without any weight being given to whether a provision was drafted by one party or its counsel. 

9.11 Incorporation of Prior Agreement; Amendments. This Lease contains all of the agreements of the parties to this Lease with respect to any
matter covered or mentioned in this Lease, and no prior agreement or understanding pertaining to any such matter shall be effective for any purpose. No provision of this Lease may be amended or added to except by an agreement in writing signed by
the parties to this Lease or their respective successors in interest. 
 9.12 Authority. Each of Landlord and Tenant, as applicable,
represents and warrants to the other that it has been and is qualified to do business in the state in which the Premises are located, that such entity has full right and authority to enter into this Lease, and that all persons signing on behalf of
the entity were authorized to do so by appropriate actions. 
 9.13 Time of Essence. Time is of the essence with respect to the performance of
this Lease. 
 9.14 Survival of Obligations. Notwithstanding anything contained in this Lease to the contrary or the expiration or earlier
termination of this Lease, any and all obligations of either party accruing prior to the expiration or termination of this Lease shall survive the expiration or earlier termination of this Lease, and either party shall promptly perform all such
obligations whether or not this Lease has expired or terminated. Such obligations shall include any and all indemnity obligations set forth in this Lease. 

9.15 Consent to Service. Tenant irrevocably consents to the service of process of any action or proceeding at the address of the Premises.
Nothing in this paragraph shall affect the right to serve process in any other manner permitted by law. 
 9.16 Landlord’s Authorized
Agents. Notwithstanding anything contained in the Lease to the contrary, including the definition of Landlord’s Agents, the Manager of Landlord and Bentall Kennedy (U.S.) Limited Partnership (the authorized signatory of Landlord) are
the only entitles authorized to amend, renew or terminate this Lease, to compromise any of Landlord’s claims under this Lease, or to bind Landlord in any manner with respect to this Lease. Neither the Manager nor any leasing agent or broker
shall be considered an authorized agent of Landlord for such purposes. 
 9.17 Waiver of Jury Trial. Landlord and Tenant irrevocably waive the
respective rights to trial by jury in any action, proceeding or counterclaim brought by either against the other (whether in contract or tort) on any matter arising out of or relating in any way to this Lease, the relationship of Landlord and Tenant
or Tenant’s use or occupancy of the Premises. 
 9.18 Tenant Certification. Tenant certifies that it is not acting, directly or
indirectly, for or on behalf of any person, group, entity, or nation named as a terrorist, “Specially Designated National and Blocked Person”, or other banned or blocked person, group, entity, nation, or transaction pursuant to any law,
order, rule or regulation that is enforced or administered by the Office of Foreign Assets Control. Tenant is not entering this Lease, directly or indirectly on behalf of, or instigating or facilitating this Lease, directly or indirectly on behalf
of, any such person, group, entity or nation. 
 9.19 Broker. Landlord and Tenant each represents to the other that it has had no dealings,
negotiations, or consultations with any broker, representative, employee, agent or other intermediary in connection with this Lease except Broker. Landlord and Tenant agree that each will indemnify, defend and hold the other free and harmless from
the claims of any broker(s), representative(s), employee(s), agent(s) or other intermediary(ies) claiming to have represented Landlord or Tenant, respectively, or otherwise to be entitled to compensation in connection with this Lease other than
Broker. 
 [Signatures follow on next page.] 

  
 33 

 IN WITNESS WHEREOF, this Lease has been executed the day and year first above set forth. 

 

															
	Designated Address for Landlord:	 		 	LANDLORD:	 	
			
	 MEPT 600 California Street LLC
 c/o
Bentall Kennedy (U.S.) Limited Partnership
	 		 	MEPT 600 California Street LLC, a Delaware limited liability company
	Attn: Dir. of Asset Management	 		 		 		 		 		 	
	1215 Fourth Avenue, Suite 2400	 		 	By:	 	MEPT Edgemoor REIT LLC, its Manager
	Seattle, WA 98161	 		 		 	
	Facsimile: 206-682-4769	 		 		 	By:	 	Bentall Kennedy (U.S.) Limited Partnership, its Authorized Signatory
	and to:	 		 		 		 		 	
	MEPT 600 California Street LLC	 		 		 		 	By:	 	Bentall Kennedy (U.S.) G.P. LLC, its General Partner
	c/o NewTower Trust Company	 		 		 		 		 		 	
	Attn: President	 		 		 		 		 	
	3 Bethesda Metro Center, Suite 1600	 		 		 		 		 	By:	 	 /s/ Scott M. Matthews

	Bethesda, MD 20814	 		 		 		 		 	Name:	 	 Scott M. Matthews

	Facsimile: 240-235-9961	 		 		 		 		 	Its:	 	 Senior Vice President

							
	with a copy to Manager at:	 		 		 		 		 		 	
		 		 		 		 		 		 	By:	 	 /s/ David V. Policar

	Jones Lang LaSalle Americas, Inc.	 		 		 		 		 	Name:	 	 David V. Policar

	Attn: General Manager	 		 		 		 		 	Its:	 	 Assistant Vice President

	600 California Street, Suite 510	 		 		 		 		 		 	9/18/2015
	San Francisco, CA 94108	 		 		 		 		 		 	
	Facsimile:	 	415-391-2955	 		 		 		 		 		 	
							
	And to:	 		 		 		 		 		 	
							
	Jones Lang LaSalle Americas, Inc.	 		 		 		 		 		 	
	Attn: Todd Robinette, Managing Director	 		 		 		 		 		 	
	1 Front Street, Suite 1100	 		 		 		 		 		 	
	San Francisco, CA 94111	 		 		 		 		 		 	
	Facsimile:	 	  
	 		 		 		 		 		 	

  

									
	Designated Address for Tenant:	 		 	TENANT:
			
	Audentes Therapeutics, Inc.	 		 	Audentes Therapeutics, Inc., a Delaware corporation
	 600 California St.
	 		 		 	
	 San Francisco, CA 94104
	 		 	By:	 	 /s/ Matthew Patterson

	  
	 		 	Name:	 	 Matthew Patterson

	Facsimile:	 	 415-704-3095
	 		 	Its:	 	 President & CEO

  
 34 

 EXHIBIT A to Lease 

LEGAL DESCRIPTION OF LAND 
 THE LAND
REFERRED TO HEREIN BELOW IS SITUATED IN THE CITY OF SAN FRANCISCO, COUNTY OF SAN FRANCISCO, STATE OF CALIFORNIA AND IS DESCRIBED AS FOLLOWS: 
 BEGINNING AT
THE POINT OF INTERSECTION OF THE SOUTHERLY LINE OF SACRAMENTO STREET WITH THE WESTERLY LINE OF KEARNY STREET; RUNNING THENCE WESTERLY ALONG SAID LINE OF SACRAMENTO STREET 130.917 FEET; THENCE AT A RIGHT ANGLE SOUTHERLY 137.500 FEET; THENCE AT A
RIGHT ANGLE EASTERLY 30.500 FEET; THENCE AT A RIGHT ANGLE SOUTHERLY 137.500 FEET, MORE OR LESS, TO THE NORTHERLY LINE OF CALIFORNIA STREET; THENCE AT A RIGHT ANGLE EASTERLY ALONG SAID LINE OF CALIFORNIA STREET 100.417 FEET TO THE WESTERLY LINE OF
KEARNY STREET; THENCE AT A RIGHT ANGLE NORTHERLY ALONG SAID LINE OF KEARNY STREET 275.000 FEET, MORE OR LESS, TO THE POINT OF BEGINNING. 
 BEING A PORTION
OF 50 VARA BLOCK NO. 92 
 APN: LOT 27, BLOCK 241 
  

			
	COMMONLY KNOWN AS:	  	600 CALIFORNIA STREET
		  	SAN FRANCISCO, CALIFORNIA 94109

  
 Ex. A 

 EXHIBIT B to Lease 

DRAWING SHOWING LOCATION OF THE PREMISES 

17th Floor 
  

 

  
 Ex. B 

 EXHIBIT B to Lease 

DRAWING SHOWING LOCATION OF THE PREMISES 

16th Floor 
  

 

  
 Ex. B 

 EXHIBIT C to Lease 

RENT DETERMINATION IN EXTENSION PERIOD 

1. Tenant shall have the option to extend the Lease Term for the Extension Term. Base Rent for the Extension Term shall be one hundred percent (100%) of
the then-prevailing market rate for comparable space in the area (“Fair Market Value”). 
 2. In the event Landlord and Tenant are unable
to agree upon a mutually acceptable Fair Market Value by the date that is four (4) months prior to the expiration of the Initial Lease Term (the “Fair Market Deadline”), Landlord shall, within fifteen (15) days following
the Fair Market Deadline, appoint an appraiser to complete an appraisal of the Fair Market Value within fifteen (15) days after the appointment of Landlord’s appraiser and Landlord shall deliver a copy thereof to Tenant promptly upon
receipt by Landlord (“Landlord Appraisal”). For purposes of this Lease, an “appraiser” shall be an independent MAI appraiser with at least ten (10) years of experience in appraising office buildings in the San
Francisco area. 
 3. If Tenant delivers notice to Landlord of Tenant’s disapproval of the Landlord Appraisal within five (5) Business Days of
Tenant’s receipt of the Landlord Appraisal, then Tenant shall have fifteen (15) days to select an appraiser to deliver an additional appraisal of the Fair Market Value (the “Tenant Appraisal”). The Tenant Appraisal shall
be delivered within fifteen (15) days after the appointment of Tenant’s appraiser and Tenant shall deliver a copy thereof to Landlord promptly upon receipt by Tenant. 

4. If Landlord delivers notice to Tenant of Landlord’s disapproval of the Tenant Appraisal within five (5) Business Days of Landlord’s receipt
of the Tenant Appraisal, then Landlord and Tenant shall each cause their respective appraisers to jointly select a third appraiser (the “Joint Appraiser”). If the two appraisers fail to select a Joint Appraiser within thirty
(30) days following the date that Tenant received Landlord’s notice of disapproval of the Tenant Appraisal, either Landlord or Tenant may petition a court of competent jurisdiction to appoint a third appraiser. The Joint Appraiser shall,
within fifteen (15) days of appointment, select either the Landlord Appraisal or the Tenant Appraisal as the Final Appraisal. 
 5. Notwithstanding
anything to the contrary herein, the Fair Market Value for the Extension Term shall be either (i) the Fair Market Value as expressed in either the Landlord Appraisal or the Tenant Appraisal, if both Landlord and Tenant agree that one of such
appraisals properly reflects the Fair Market Value; or (ii) the Fair Market Value reflected in the Final Appraisal, as selected by the Joint Appraiser. 

6. All appraisers appointed hereunder shall be, at the time of their appointment, members of good standing of the Appraisal Institute. The party whose
appraisal the Joint Appraiser did not select shall be responsible for the cost of the Joint Appraiser’s services, otherwise, the cost of the Landlord Appraisal shall be borne by Landlord and the cost of the Tenant Appraisal shall be borne by
the Tenant. 

  
 Ex. C 

 EXHIBIT D to Lease 

FORM OF LEASE MEMORANDUM 

MEPT 600 California Street LLC, a Delaware limited liability company, as Landlord, and Audentes Therapeutics, Inc., a Delaware corporation, as
Tenant, executed that Lease dated as of                     , 201     (the “Lease”). 

The Lease contemplates that this document shall be delivered and executed as set forth in the paragraph entitled “Lease Memorandum”.
This Lease Memorandum shall become part of the Lease. 
 Landlord and Tenant agree as follows: 

1. The Commencement Date of the Lease is
                                        . 

2. The Delivery Date of the Lease is
                                        . 

3. The end of the Initial Lease Term and the date on which this Lease will expire is
                                        . 

4. The Lease is in full force and effect as of the date of this Lease Memorandum. By execution of this Lease Memorandum, Tenant confirms that
as of the date of the Lease Memorandum (a) Tenant has no claims against Landlord and (b) Landlord has fulfilled all of its obligations under the Lease required to be fulfilled by Landlord. 

5. Tenant’s Pro Rata Share is              percent
(    %). 
  

																	
	Dated:	 	  
	 		 	Dated:	 	  

															
			
	LANDLORD:	 		 	 TENANT:
			
	MEPT 600 California Street LLC, a Delaware limited liability company	 		 	 Audentes Therapeutics, Inc., a Delaware corporation
					
	By:	 	MEPT Edgemoor REIT LLC, its Manager	 		 	 By:	 	  

		 		 		 	 Name:	 	  

		 	By:	 	Bentall Kennedy (U.S.) Limited Partnership, its Authorized Signatory	 		 	 Its:	 	  

		 		 	 		 		 	
							
		 		 	By:	 	Bentall Kennedy (U.S.) G.P. LLC, its General Partner	 		 		 	
								
		 		 		 	By:	 	  
	 		 		 	
		 		 		 	Name:	 	  
	 		 		 	
		 		 		 	Its:	 	  
	 		 		 	
								
		 		 		 	By:	 	  
	 		 		 	
		 		 		 	Name:	 	  
	 		 		 	
		 		 		 	Its:	 	  
	 		 		 	

  
 Ex. D 

1 

 EXHIBIT E to Lease 

RULES AND REGULATIONS 
 1.
No sign, placard, picture, advertisement, name or notice shall be installed or displayed on any part of the outside or inside of the Building or Land without the prior written consent of the Landlord. Landlord shall have the right to remove, at
Tenant’s expense and without notice, any sign installed or displayed in violation of this rule. All approved signs or lettering on doors and walls shall be printed, painted, affixed or inscribed at the expense of Tenant by a person chosen by
Landlord. 
 2. If Landlord objects in writing to any curtains, blinds, shades, screens or hanging plants or other similar objects attached
to or used in connection with any window or door of the Premises, Tenant shall promptly discontinue such use. No awning shall be permitted on any part of the Premises. Tenant shall not place anything against or near glass partitions or doors or
windows which may appear unsightly from outside the Premises. 
 3. Tenant shall not obstruct any sidewalk, halls, passages, exits,
entrances, elevators, escalators, or stairways of the Building. The halls, passages, exits, entrances, elevators, escalators and stairways are not open to the general public. Landlord shall in all cases retain the right to control and prevent access
to such areas of all persons whose presence in the judgment of Landlord would be prejudicial to the safety, character, reputation and interest of the Land, Building and the Building’s tenants; provided that, nothing in this Lease contained
shall be construed to prevent such access to persons with whom any Tenant normally deals in the ordinary course of its business, unless such persons are engaged in illegal activities. Tenant shall not go upon the roof of the Building. 

4. The directory of the Building will be provided exclusively for the display of the name and location of tenants only, and Landlord reserves
the right to exclude any other names therefrom. 
 5. All cleaning and janitorial services for the Building and the Premises shall be
provided exclusively through Landlord, and except with the written consent of Landlord, no person or persons other than those approved by Landlord shall be employed by Tenant or permitted to enter the Building for the purpose of cleaning the same.
Cleaning and janitorial services shall be provided five (5) days per week. Tenant shall not cause any unnecessary labor by carelessness or indifference to the good order and cleanliness of the Premises. Landlord shall not in any way be
responsible to any Tenant for any loss of property on the Premises, however occurring, or for any damage to any Tenant’s property by the janitor, any of Landlord’s Agents or any other person. 

6. Landlord will furnish Tenant, free of charge, two (2) keys to each door lock in the Premises. Landlord may make a reasonable charge
for any additional keys. Tenant shall not make or have made additional keys, and Tenant shall not alter any lock or install a new additional lock or bolt on any door of its Premises (except for any secure areas of the Premises; provided however, in
such case, Tenant shall provide Manager with any keys or access codes to such secure areas). Tenant, upon the termination of its tenancy, shall deliver to Landlord the keys of all doors which have been furnished to Tenant, and in the event of loss
of any keys so furnished, shall pay Landlord therefor. 
 7. If Tenant requires Telecommunication Services, computer circuits, burglar alarm
or similar services or other utility services, it shall first obtain Landlord’s approval of the construction or installation of such services. Application for such services shall be made in accordance with the procedure prescribed by Landlord
in subsection 3.5.2 of the Lease. 
 8. No equipment, materials, furniture, packages, bulk supplies, merchandise or other property will be
received in the Building or carried in the elevators except between such hours and in such elevators as may be designated by Landlord. The persons employed to move such equipment or materials in or out of the Building must be reasonably acceptable
to Landlord. 
 9. Tenant shall not place a load upon any floor of the Premises which exceeds the load per square foot which such floor was
designed to carry and which is allowed by Governmental Requirements. Landlord shall have the right to prescribe the weight, size and position of all equipment, materials, furniture or other property brought into the Building. Heavy objects shall, if
considered necessary by Landlord, stand on such platforms as determined by Landlord to be necessary to properly distribute the weight. Business machines and mechanical equipment belonging to Tenant, which cause noise or vibration that may be
transmitted to the structure of the Building or to any space in the Building or to any other tenant in the Building, shall be placed and maintained by Tenant, at Tenant’s expense, on vibration eliminators or other devices sufficient to
eliminate noise or vibration. The persons employed to move 

  
 Ex. E 

1 

 
such equipment in or out of the Building must be reasonably acceptable to Landlord. Landlord will not be responsible for loss of, or damage to, any such equipment or other property from any
cause, and all damage done to the Building by maintaining or moving such equipment or other property shall be repaired at the expense of Tenant. 

10. Tenant shall not use or keep in the Premises any kerosene, gasoline or inflammable or combustible fluid or material other than those
limited quantities permitted by the Lease. Tenant shall not use or permit to be used in the Premises any foul or noxious gas or substance, or permit or allow the Premises to be occupied or used in a manner offensive or objectionable to Landlord or
other occupants of the Building by reason of noise, odors or vibrations nor shall Tenant bring into or keep in or about the Premises any birds or animals other than service animals. 

11. Tenant shall not use any method of heating or air-conditioning other than that supplied by Landlord or installed pursuant to the terms of
this Lease. 
 12. Tenant shall not waste any utility provided by Landlord and agrees to cooperate fully with Landlord to assure the most
effective operation of the Building’s heating and air-conditioning and to comply with any governmental energy-saving rules, laws or regulations of which Tenant has actual notice. 

13. Landlord reserves the right, exercisable without notice and without liability to Tenant, to change the name and street address of the
Building. 
 14. Landlord reserves the right to exclude from the Building between the hours of 6 p.m. and 7 a.m. the following day, or such
other hours as may be established from time to time by Landlord, and on Sundays and legal holidays, any person unless that person is known to the person or employee in charge of the Building and has a pass or is properly identified. Tenant shall be
responsible for all persons for whom it requests passes and shall be liable to Landlord for all acts of such persons. Landlord shall not be liable for damages for any error with regard to the admission to or exclusion from the Building of any
person. Landlord reserves the right to prevent access to the Building in case of invasion, mob, riot, public excitement or other commotion by closing the doors or by other appropriate action. 

15. Tenant shall close and lock the doors of its Premises and entirely shut off all water faucets or other water apparatus, and electricity,
gas or air outlets before Tenant and its employees leave the Premises. Tenant shall be responsible for any damage or injuries sustained by other tenants or occupants of the Building or by Landlord for noncompliance with this rule. 

16. Intentionally Omitted. 
 17.
The toilet rooms, toilets, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed and no foreign substance of any kind whatsoever shall be deposited in them. The expenses of any
breakage, stoppage or damage resulting from the violation of this rule shall be borne by Tenant if it or its employees or invitees shall have caused it. 

18. Tenant shall not sell, or permit the sale at retail, of newspapers, magazines, periodicals, theater tickets or any other goods or
merchandise to the general public in or on the Premises. Tenant shall not make any room-to-room solicitation of business from other tenants in the Building. Tenant shall not use the Premises for any business or activity other than that specifically
provided for in the Lease. 
 19. Tenant shall not install any radio or television antenna, loudspeaker or other device on the roof or
exterior walls of the Building. Tenant shall not interfere with radio or television broadcasting or reception from or in the Building or elsewhere. Other than the usual and customary cellular telephones, Tenant shall not install or utilize any
wireless Telecommunication Facilities, including antenna and satellite receiver dishes within the Premises or on, in, or about the Building without first obtaining Landlord’s prior written consent and Landlord at its option may require the
entry of a supplemental agreement with respect to such construction or installation. Tenant shall comply with all instructions for installation and shall pay or shall cause to be paid the entire cost of such installations. Application for such
facilities shall be made in the same manner and shall be subject to the same requirements as specified for Telecommunication Services and Telecommunication Facilities in the paragraph of the Lease entitled “Utilities”. Supplemental rules
and regulations may be promulgated by Landlord specifying the form of and information to be included with the application and establishing procedures, regulations and controls with respect to the installation and use of such wireless
Telecommunication Facilities. 
 20. Except for normal picture hanging and similar decorations, Tenant shall not mark, drive nails, screws
or drill into the partitions, woodwork or plaster or in any way deface the Premises. Landlord reserves the right to direct electricians as to where and how telephone and telegraph wires are to be 

  
 Ex. E 

 
introduced to the Premises. Tenant shall not cut or bore holes for wires. Tenant shall not affix any floor covering to the floor of the Premises in any manner except as approved by Landlord.
Tenant shall repair any damage resulting from noncompliance with this rule. 
 21. Tenant shall not install, maintain or operate upon the
Premises any vending machine without the written consent of Landlord. 
 22. Canvassing, soliciting and distribution of handbills or any
other written material, and peddling in the Building or Land are prohibited, and Tenant shall cooperate to prevent the same. 
 23. Landlord
reserves the right to exclude or expel from the Building and Land any person who, in Landlord’s judgment, is intoxicated, under the influence of liquor or drugs or in violation of any of these Rules and Regulations. 

24. Tenant shall store all of its trash and garbage within the Premises. Tenant shall not place in any trash box or receptacle any material
which cannot be disposed of in the ordinary and customary manner of trash and garbage disposal. All garbage and refuse disposal shall be made in accordance with directions issued from time to time by Landlord. 

25. The Premises shall not be used for lodging or any improper or immoral or objectionable purpose. No cooking shall be done or permitted by
Tenant, except that use by Tenant of Underwriters’ Laboratory approved equipment for brewing coffee, tea, hot chocolate and similar beverages shall be permitted; provided that, such equipment and its use is in accordance with all Governmental
Requirements. 
 26. Tenant shall not use in the Premises or in the public halls of the Building any hand truck except those equipped with
rubber tires and side guards or such other material-handling equipment as Landlord may approve. Tenant shall not bring any other vehicles of any kind into the Building. 

27. Tenant may transport bicycles only through the Parking Facility of the Building to the Premises using only the freight elevator. In no
event shall Tenant use the passenger elevators of the Building to transport any bicycles or take any bicycles through the main lobby of the Building. If the freight elevator of the Building is unavailable, Landlord will designate a passenger
elevator to be used for such transportation. Tenant may regulate its employees’ use and storage of bicycles within the Premises but, in all events, Tenant shall maintain the Building and Premises in good condition and repair and in compliance
with all applicable Regulations, pursuant to the terms of the Lease. At its sole cost and expense, Tenant shall promptly repair any damage caused to the Building as a result of bicycle transportation to and from the Premises and shall be responsible
for any janitorial expenses incurred by Landlord as a result of such usage. Landlord shall have no liability for any damage to any bicycles or contents thereof and the transportation and storage of any bicycles throughout the Building shall be at
the sole risk of Tenant. Tenant’s indemnity obligations under the Lease shall fully apply with respect to any bicycles brought onto the property or into the Building by Tenant and/or any Tenant Entities. 

28. Without the prior written consent of Landlord, Tenant shall not use the name of the Building in connection with or in promoting or
advertising the business of Tenant except as Tenant’s address. 
 29. Tenant shall comply with all safety, fire protection and
evacuation procedures and regulations established by Landlord or any governmental agency. 
 30. Tenant assumes any and all responsibility
for protecting the Premises from theft, robbery and pilferage, which includes keeping doors locked and other means of entry to the Premises closed. 

31. Tenant requests for services must be submitted to the Building office by an authorized individual. Employees of Landlord shall not perform
any work or do anything outside of their regular duties unless under special instruction from Landlord, and no employee of Landlord will admit any person (Tenant or otherwise) to any office without specific instructions from Landlord. 

32. Tenant shall not park its vehicles in any parking areas designated by Landlord as areas for parking by visitors to the Building or Land.
Tenant shall not leave vehicles in the parking areas overnight nor park any vehicles in the Building parking areas other than automobiles, motorcycles, motor driven or nonmotor driven bicycles or four-wheeled trucks. 

33. Tenant shall not permit any animals other than service animals, e.g., seeing-eye dogs, to be brought or kept in or about the Premises or
any common area of the Building. 
 34. Landlord may waive any one or more of these Rules and Regulations for the benefit of Tenant or any
other tenant, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other person, nor prevent Landlord from thereafter revoking such waiver and enforcing any such Rules and Regulations against
any or all of the tenants of the Building. 

  
 Ex. E 

 35. These Rules and Regulations are in addition to, and shall not be construed to in any way
modify or amend, in whole or in part, the covenants and conditions of any lease of premises in the Building. If any provision of these Rules and Regulations conflicts with any provision of the Lease, the terms of the Lease shall prevail. 

36. Landlord reserves the right to make such other and reasonable, nondiscriminatory Rules and Regulations as, in its judgment, may from time
to time be needed for safety and security, the care and cleanliness of the Building and Land, the preservation of good order in the Building and the maintenance or enhancement of the value of the Building as a rental property. Tenant agrees to abide
by all the Rules and Regulations stated in this exhibit and any additional reasonable, nondiscriminatory rules and regulations which are so made by Landlord and provided to Tenant. 

37. Tenant shall be responsible for the observance of all of the foregoing rules by Tenant and Tenant’s Agents. 

  
 Ex. E 

 EXHIBIT F to Lease 

SCHEDULE OF CLEANING SERVICES 

Introductory Note: All services set forth in this Exhibit shall only be performed if and to the extent the applicable surface to be vacuumed, buffed,
polished, swept, moped, dusted, wiped, washed or otherwise cleaned is exposed and readily accessible. 
 Daily Cleaning Services 

 

	1.	Empty waste baskets and remove refuse to designated area. Reline and wipe clean receptacles as needed. 

  

	2.	Break down all boxes or any items marked trash and remove to designated areas. 

  

	3.	Vacuum upholstered chairs and sofas where necessary. 

  

	4.	Sweep all hard floors (tile, wood, etc.). 

  

	5.	Sweep and damp mop all vinyl, marble and quarry tile floors. Spot buff as needed. 

  

	6.	Spot clean all tenant and common area carpets as needed. Shampoo all common area high traffic lanes as needed. 

  

	7.	Dust and/or wipe clean the following surfaces: 

  

	 	•	 	desks 

  

	 	•	 	chairs 

  

	 	•	 	file cabinets 

  

	 	•	 	tables 

  

	 	•	 	telephones 

  

	 	•	 	pictures and frames 

  

	 	•	 	doors 

  

	 	•	 	lamps 

  

	 	•	 	ledges and shelves 

  

	 	•	 	desk/furniture partitions 

  

	 	•	 	any other horizontal surface of a fixture or furniture subject to collecting dust 

  

	8.	Wipe clean the following surfaces: 

  

	 	•	 	window sills and ledges 

  

	 	•	 	counter tops and kitchen cabinets 

  

	 	•	 	switch plates 

  

	 	•	 	private entrance doors 

  

	 	•	 	glass, mirrored and wood doors, panels, windows and walls 

  

	 	•	 	walls in kitchen and disposal area 

  

	 	•	 	conference tables 

  

	9.	Wash, clean and disinfect water fountains and/or coolers. Give special attention to adjacent floor areas. 

  

	10.	Establish regular cleaning maintenance program for floor in public lobby area in conjunction with Property Manager; standard necessary to maintain is high quality shine with no water marks, stains, scuffing or other
signs of wear. 

  
 Ex. F 

	11.	Wipe and polish all glass, chrome and metal surfaces such as windows (interior and up to standard ceiling height), partitions, banisters, door knobs, light switch plates, kick plates, directional signs and door saddles.

  

	12.	Polish directory. 

  

	13.	Vacuum and spot shampoo all carpet entrance mats. 

  

	14.	Spot clean all wall surfaces. 

  

	15.	Clean all entrance doors. 

 Daily Elevators 

 

	1.	Wash and polish wood and stainless walls, doors and hall plate. Keep tracks clean of dust, dirt and debris. Vacuum carpet. Spot clean carpet as needed. 

Daily Lavatories 
  

	1.	Sweep and wet mop all tile floors using disinfectant. 

  

	2.	Thoroughly clean all mirrors, top to bottom. 

  

	3.	Scour, wash and disinfect all sink basins, counter tops, bowls, urinals, including undersides. 

  

	4.	Wash toilet seats, both sides. 

  

	5.	Wipe clean all partitions. 

  

	6.	Wipe clean all wall tile as needed. 

  

	7.	Remove all trash and sanitary waste, wash receptacles as necessary. Remove rubbish to designated area. 

  

	8.	Restock hand soap and paper products. 

  

	9.	Polish all stainless dispensers. 

 Weekly Cleaning Services 

 

	1.	Wash and sanitize metal partitions. Dust horizontal surfaces exceeding 70” height. Damp clean ceiling and exhaust fans. 

  

	2.	Wash all interior glass, including hallways, widows (excluding second story atrium windows), lobby doors, partitions and glass door panels. 

 

	3.	Dust all blinds in common areas. 

  

	4.	Sweep fire tower stairwells. Wet mop as needed. Wipe hand rails and dust metalwork. 

  

	5.	Wipe clean all desk tops and credenzas. 

  

	6.	Remove all finger prints and dirt from door frames, kick and push plates, handles and railings. 

  
 Ex. F 

	7.	Wet wipe all horizontal surfaces to 70” including moldings, shelves, etc. 

  

	8.	Polish all fine wood furniture including desks, chairs and cabinets. 

  

	9.	Spray buff all vinyl tiles floors as necessary. 

  

	10.	Buff other hard surfaces, floors to include ceramic, quarry and marble title as necessary. 

  

	11.	Wipe clean all plant containers in common areas. 

  

	12.	Thorough vacuuming of all carpeted area, including corner and crevice vacuuming in all tenant spaces and common areas. 

Monthly / Quarterly Cleaning Services 
  

	1.	Thoroughly wipe clean all ceiling vents and exhaust fans and area immediately adjacent: monthly to quarterly, as needed. 

  

	2.	Strip and refinish all tile floors including restroom floors on a quarterly basis. 

  

	3.	Wipe clean and remove all fingerprints from full height doors. 

  

	4.	Thoroughly clean all pipes, ventilating and air conditioning louvers, ducts and high molding: monthly to quarterly, as needed. 

  

	5.	Wipe clean as needed all vinyl base. Vacuum as needed all carpet cove base: monthly to quarterly, as needed. 

  

	6.	Thoroughly wash all trash receptacles, inside and outside. 

  

	7.	Spot clean all vertical surfaces. 

  

	8.	Spray buff all vinyl floors (both tenant and common areas) quarterly. 

  
 Ex. F 

 Rider 1 

LETTER OF CREDIT CRITERIA 
 1. The letter
of credit shall be clean, irrevocable and unconditional. 
 2. The letter of credit shall be in the amount specified in the Lease paragraph captioned
“Lease Security Provisions”. 
 3. The letter of credit shall be issued in favor of: 

MEPT 600 California Street LLC 

c/o NewTower Trust Company 
 Attn:
President 
 3 Bethesda Metro Center, Suite 1600 

Bethesda, MD 20814 
 The letter
of credit shall be effective immediately on its issuance. 
 4. The letter of credit will be issued by Silicon Valley Bank or any other bank proposed by
Tenant and reasonably acceptable to Landlord. 
 5. The letter of credit shall have an expiration date no earlier than the first anniversary of the date of
its issuance and shall provide for its automatic renewal from year to year unless terminated by the issuing bank by notice to Landlord given not less than thirty (30) days prior to its expiration date. Notice to Landlord shall be in writing,
made by (i) United States Postal Service, certified mail, return receipt requested; or (ii) reputable express or courier service. Notice to Landlord shall be addressed to Landlord at its address in paragraph 2 above and to the
following parties: 
 Bentall Kennedy (U.S.) Limited Partnership 

Attn: Dir. of Asset Management 

1215 Fourth Avenue, Suite 2400 

Seattle, WA 98161 
 and to: 

Jones Lang LaSalle Americas, Inc. 

Attn: Reina L. Hugh, General Manager 

600 California Street, Suite 510 

San Francisco, CA 94108 

Facsimile: 415-391-2955 
 The final expiration
date of the letter of credit and all renewals of it shall be no earlier than thirty (30) days following the end of the Lease Term. 
 6. The letter of
credit may be drawn at the designated banking office of either the issuer of the letter of credit described in clause (a) of paragraph 4 or, if clause (b) of paragraph 4 is applicable, the confirming bank described in clause (b) of
such paragraph 4. The letter of credit shall allow for draws to be made at sight on a draft drawn by NewTower Trust Company. The draft shall be approved as to form by Landlord. The letter of credit must allow for one draw in the whole amount or
multiple partial draws. Landlord shall not be required to deliver any certificate, affidavit or other writing to the issuer expressing the basis for the draw as a condition to any draw. 

7. The letter of credit shall be transferable and any applicable transfer fees shall by paid for by Tenant. 

  
 Rider 1 

 8. The letter of credit shall be governed by the International Standby Practices (ISP 98 published by the
International Chamber of Commerce. Alternatively, if approved by the lender and if required by either the issuing bank or the confirming bank, the Uniform Customs and Practices for Documentary Credits published by the International Chamber of
Commerce may be substituted for the International Standby Practices to the extent such Customs and Practices are not inconsistent with the criteria in this Rider 1. 

9. Issuer shall waive all waiting periods whether under Uniform Commercial Code Section 5.112 or otherwise. 

10. The letter of credit shall otherwise be in such form and shall be subject to such requirements as Landlord may reasonably require. 

  
 Rider 1 

 Rider 2 

Description of Landlord’s Work 

Landlord work will include: 
  

	 	•	 	Construction of the Multi-Tenant Common Area Corridor 

  

	 	•	 	ADA upgrades in the 16th Floor Common Area Restrooms 

  

	 	•	 	Construction of a Full Height Demising Wall 

  

	 	•	 	Tenant is responsible for all MEP costs associated with their improvement work 

  
 Rider 2 

 Rider 4 

Asbestos Notification 
 Month
    , Year 
 Tenant 
  

					
	Re:	 	
Asbestos Notification - California Health & Safety 
Code Sec. 25914 et seq. for 600 California Street, San Francisco, CA 94109
	 	

 Dear: 

California Health and Safety Code Sections 25915 et seq. requires commercial landlords to notify their tenants at the start of their leases
and annually thereafter regarding known asbestos-containing construction materials (“ACM”) present in buildings constructed prior to 1979, and CalOSHA regulations require building owners to determine and inform tenants and others regarding
hazards associated with disturbing presumed ACMs (“PACM”) in buildings constructed prior to 1981. PACM consists of thermal system insulation and surfacing material, both of which prior to that date commonly contained asbestos. This notice
provides you with the required ACM and PACM notifications under California law with respect to your tenancy in the above-referenced building (the “Building”). 

In addition, you should be aware that there are certain potential health risks that may result from exposure to asbestos. Because we are not
physicians, scientists or industrial hygienists, we have no special knowledge of the health impact of exposure to asbestos. However, we retained an environmental consulting firm to survey and sample the Building. The consulting firm identified ACM
and suspect ACM in constructions materials and other components located in portions of the Building identified on the attached list. 
 The
survey only involved testing and sampling of selected building materials, and the Building may contain additional areas of ACM other than those specifically identified. 

In addition, we have had an Asbestos Management Program (“O&M Plan”) prepared to identify and address asbestos matters at the
Building. The O&M Plan is designed to minimize the potential for a release of asbestos fibers and outlines a schedule of actions to be undertaken with respect to asbestos. The asbestos survey and the O&M Plan are available for your review at
our Building Management Office during regular business hours, and a copy of the O&M Plan will be provided to you upon request. 
 In
general, the written O&M Plan describes the risks associated with asbestos exposure and how to prevent such exposure. The O&M Plan is also designed to manage the ACM and PACM in the Building and to avoid the inadvertent disturbance of these
materials. To that end, the O&M Plan provides for the training of building housekeeping and maintenance personnel so that they can conduct their work without causing a release of asbestos fibers. As part of the O&M Plan, we maintain records
of all asbestos-related activities and the results of any asbestos survey, sampling or monitoring conducted in the Building. 

  
 Rider 4 

 Tenant 
 Month
    , Year 
 Page 2 
  

The written O&M Plan describes a number of activities which should be avoided in order to prevent a release of asbestos fibers in the
Building. In particular, you should be aware that activities which may present a health risk by causing an airborne release of asbestos fibers include moving, drilling, boring or otherwise disturbing ACM or PACM. Consequently, such activities should
not be attempted by any person not qualified to handle ACM or PACM. In other words, you must obtain the approval of Building Management prior to engaging in or having others engage in any such activities on your behalf. 

You must contact the Property Manager prior to any activity conducted by you or any contractor or service personnel which might disturb ACM.
Specifically, this means any construction activity or activity requiring opening up the drop-ceiling such as running telephone or electrical cables or working on air ducts or piping above the drop-ceiling. Moving, drilling, boring or otherwise
disturbing ACM may present a health risk and should not be attempted by any employee who has not been trained and qualified to handle ACM. Should you observe any of the materials described in this letter in a damaged condition or notice individuals
working above the suspended ceiling, please contact the building management office immediately. 
 Finally, please be aware that you may
have certain obligations under California and federal laws with regard to the ACM and PACM in the Building, including obligations to notify your own employees, contractors, subtenants, agents and others of the presence of ACM and PACM particularly
if their work will involve disturbing ACM or PACM. You are solely responsible for complying with all such applicable laws. 
 Please contact
the Building Management if you have any questions regarding the contents of this Notice. 
 Sincerely, 

Building Owner/Property Manager 

  
 Rider 4 

 List 

of 
 600 California Street

 ACM, Assumed ACM and PACM Locations 
  

	 	•	 	Mirror mastic in the floors of the Building 

  
 Rider 4Collaborative Development Agreement (Genethon)

 EXHIBIT 10.12 
  

					
		  		  	 *  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 COLLABORATIVE DEVELOPMENT AGREEMENT 

No. 013135-1MTUB-00 

This COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the
“Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon,
a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”). 

BACKGROUND 
 A. Audentes
is a biotechnology company focused on the research, development and commercialization of treatments for rare diseases. 
 B. Genethon is a
French not-for-profit organization focused on the research, development and commercialization of treatments for rare diseases, and has notably developed an expertise in (i) the preclinical and clinical development of gene therapy products,
especially gene therapy vectors based on AAV vectors, (ii) the development of bioprocesses, (iii) the manufacture and supply of gene therapy products for preclinical studies and clinical trials, and (iv) regulatory affairs related to
such activities. 
 C. Audentes and Genethon share a mutual interest in researching, developing, and commercializing pharmaceutical products
for the treatment of XLMTM and desire to enter a collaboration wherein Genethon will perform certain pre-clinical and clinical manufacturing and development activities, on the terms set forth below. 

NOW THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, it is agreed by and between the
Parties as follows: 
 1. DEFINITIONS 

As used herein, the following terms will have the meanings set forth below: 

*Confidential Treatment Requested. 

 1.1 “Affiliate” shall mean any corporation or other entity, which is directly or
indirectly controlling, controlled by or under common control of a Party hereto for so long as such control exists, where “control” shall mean the direct or indirect ownership of at least fifty percent (50%) of the outstanding shares
or other voting rights of the subject entity having the power to vote on or direct the affairs of the entity, or if not meeting the preceding, the maximum voting right that may be held by the particular Party under the laws of the country where such
entity exists. 
 1.2 “Background Intellectual Property” shall mean, collectively, any and all Background
Know-How and Background Patent Rights. 
 1.3 “Background Know-How” shall mean any and all Know-How
Controlled by a Party on the Effective Date that is used by the Party to conduct the Research Program and/or provided to the other Party for such purpose. 

1.4 “Background Patent Rights” shall mean any and all Patent Rights Controlled by a Party on the Effective Date
that relate to the Product or to the materials or methods used to conduct the Research Program. The Genethon Background Patent Rights include notably the Patent Rights listed in Exhibit D. 

1.5 “Confidential Information” shall have the meaning set forth in Section 9.1. 

1.6 “Control” or “Controlled” shall mean ownership or possession of the ability to grant
the licenses or sublicenses as provided herein without violating the terms of any agreement or other arrangements with any Third Party. 

1.7 “Development Plan” shall mean the reasonably detailed description of the specific activities to he conducted
by the Parties with respect to the research, development and manufacturing of Product (including the Genethon Research Program Activities), and corresponding timeline estimates and budget of Genethon’s costs, as further described in
Section 2.2 and as such may from time to time be updated, completed or otherwise modified in accordance with Section 3.6. 

1.8 “Genethon Additional Internal IP” shall have the meaning set forth in Section 4.3. 

1.9 “Genethon Additional In-Licensed IP” and “Genethon Additional IP” shall have the
meanings set forth in Section 4.4. 
 1.10 “Genethon Research Program Activities” are the activities to
be conducted by Genethon as part of the. Research Program, as generally described in Exhibit A hereto (as such may be modified from time to time by amendment to this Agreement) and as set forth in more detail in the Development Plan. 

1.11 “JDC” or “Joint Development Committee” shall have the meaning set forth in
Section 3.1. 
  

  
 2 

 1.12 “Know-How” means any and all ideas, inventions (whether or
not patentable), data, instructions, processes, formulas, expert opinions and information, including without limitation biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing
and quality control data and information, and biological and chemical materials, including without limitation viruses and plasmids. 

1.13 “Patent Rights” means any and all (i) patent applications, (ii) divisions, continuations, and
continuations-in-part, including U.S. and foreign thereof, (iii) patents that issue as a result of any of the foregoing, and (iv) reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of
the patents in (iii) above, and any substitutions, confirmations, registrations or revalidations of any of the foregoing. 

1.14 “Party” or “Parties” shall mean, respectively, Genethon or Audentes individually,
or Genethon and Audentes collectively. 
 1.15 “Product” shall mean any pharmaceutical product for the
treatment of X-linked myotubular myopathy (XLMTM) which is based on MTM1 gene replacement. 

1.16 “Program Intellectual Property” shall mean, collectively, Program Know-How and Program Patent
Rights. 
 1.17 “Program Know-How” shall mean any and all Know-How developed solely or jointly by or on
behalf of Genethon and/or Audentes in the course of performing the Research Program. 
 1.18 “Program Patent
Rights” shall mean all Patent Rights covering inventions conceived, reduced to practice or otherwise made solely or jointly by or on behalf of Genethon and/or Audentes in the course of performing the Research Program. 

1.19 “Research Program” shall mean the research, development and manufacturing program to be undertaken by the
Parties under the Development Plan. 
 1.20 “Term” is defined in Section 14.1. 

1.21 “Third Party” shall mean any person or entity other than Genethon and Audentes, and their respective
Affiliates. 
 2. RESEARCH COLLABORATION 

2.1 Conduct of the Research Program. 

(a) Subject to the terms and conditions set forth herein, the Parties agree to conduct research in accordance with the Research Program, which
shall be funded as set forth in Section 5.2. Genethon and Audentes shall collaborate and conduct the Research Program in accordance with the Development Plan within the time schedules contemplated therein and shall keep each other informed as
to the progress and results of the Research Program hereunder. 
 (b) Given the experimental nature of the activities to be conducted under
the Research Program, it is expected that the Parties shall conduct the activities for which they are responsible in conformance with that level of care and skill ordinarily exercised by other 

  
 3 

 
professionals in similar circumstances and in compliance with applicable laws and regulations but it is acknowledged that neither Party represents and warrants that the activities for which they
are responsible will be successful. The Parties shall use commercially reasonable efforts to achieve the objectives set out in the timelines attached to the Development Plan, but neither Party represents or warrants that it will successfully achieve
these objectives. Each Party shall notify the other promptly in the event it becomes aware of any fact or circumstance which is likely to delay the performance of the Development Plan activities. 

2.2 Development Plan. The initial Development Plan for the Genethon Research Program Activities, including a reasonably detailed
description of the activities to be conducted during at least the first [*] of the Research Program and the corresponding timelines and budget for Genethon’s costs, shall be agreed upon in good faith by the Parties within [*] of the Effective
Date. The Development Plan shall thereafter be updated and completed on at least a yearly basis to include a reasonably detailed description, and the corresponding timelines and budget for Genethon’s costs, of additional Development Program
activities the JDC agrees to include in the Development Plan, subject to Section 3.6. Either Party may prepare any such updates and submit them to the JDC for approval in accordance with Section 3.6. The Parties acknowledge and agree that
including additional Genethon activities in the Development Plan may require agreeing on additional legal or regulatory terms and conditions applicable thereto, as required by applicable laws or otherwise reasonably necessary. For example, any
addition of GMP manufacturing activities to the Development Plan will require the Parties to enter into a Quality Agreement relating thereto. 

2.3 Records; Inspection. 

(a) Records. Genethon shall maintain records of the Genethon Research Program Activities in sufficient detail and in good scientific
manner as will properly reflect all work done and results achieved in the performance of the Genethon Research Program Activities (including all data in the form required under any applicable governmental regulations and as directed by the JDC).
Genethon shall maintain such records for a period of [*] following termination or expiration of the Agreement, and shall provide Audentes access to such records, at Genethon’s place of business upon reasonable advance notice of Audentes. 

(b) Reports and Information Exchange. Each of Genethon and Audentes shall use commercially reasonable efforts to report to the other
Party through the JDC all material information relating to the Research Program, including any material item of Program Know-How, promptly after it is learned or its materiality is appreciated. Each Party shall also keep the other Party, through the
JDC, informed as to its progress under the Development Plan. 
 2.4 Genethon Manufacture of Product and Technology
Transfer. 
 (a) Genethon shall, subject to Genethon’s capability to supply required quantities of Product in a timely
manner in accordance with the timelines set forth in the applicable Development Plan, have the exclusive right to manufacture and supply, and shall manufacture and supply in accordance with the Development Plan and the terms and conditions of this
Agreement, the Product required by Audentes and/or its Affiliates or sublicensees for preclinical and clinical purposes pursuant to this Agreement. 

  

					
		  	4	  	*Confidential Treatment Requested.

 (b) The manufacture and supply by Genethon of batches of Product for commercial purposes shall be
the subject of further discussions in good faith between the Parties and shall in any case depend on Genethon demonstrating its capability to conduct such manufacturing, it being understood that in no event shall either Party be liable to the other
in case of failure to agree on the terms of such manufacturing. In the event the Parties are unable to agree on such terms, at Audentes’s request, Genethon shall promptly perform the activities set forth in Section 2.4(d). 

(c) At any time during the Term, should Genethon be unable to manufacture Product required by Audentes for the performance of clinical
development in a timely manner consistent with the agreed timelines, the JDC shall meet promptly to discuss the situation and possible actions to remedy the situation, including if appropriate the related work plan timelines and budget. Should the
JDC be unable to agree on remedial actions for a period of [*] after their first meeting, the matter will be submitted to, the Parties’ respective CEOs for resolution. Should the CEOs be unable to agree on remedial actions to implement for a
period of [*] after the matter has been submitted to them, then, if the transfer of such manufacturing to Audentes or a Third Party subcontractor or CMG would [*] as compared with [*] or would [*], Genethon will [*] in accordance with
Section 2.4(d) below, subject to the principles set out in Sections 2.4(e) and 5.3 below. 
 (d) In any case of technology transfer
under Sections 2.4(b) and/or 2.4(c), Genethon shall provide to Audentes or its designee, such assistance and materials, including but, not limited to drawings, procedures and other documents and materials (including any relevant item of Background
Know-How and/or Program Know-How) as Audentes may request, to enable Audentes or its designee (including a manufacturer) to manufacture the Products and, if requested by Audentes, Genethon shall reasonably assist Audentes in locating other Third
Parties to continue the manufacture of the Products. 
 (e) In any case of technology transfer under Sections 2.4(b) and/or 2.4(c), Audentes
shall provide to Genethon in advance the identity and address of any proposed Third Party manufacturer. The transfer shall also be subject to the Third Party manufacturer entering into a customary agreement to protect the confidentiality of
Background Intellectual Property and Program Intellectual Property provided by Genethon and undertaking to use such Intellectual Property only for the purpose of manufacturing Product for the benefit of Audentes, its Affiliates and/or licensees or
sublicensees. Genethon may object to the proposed Third Party manufacturer but only on the basis of reasonable concerns (based on documentation reasonably acceptable to Audentes) as to the security of any confidential Know-How of Genethon to be
provided to the Third Party manufacturer as part of such technology transfer. 
 3. GOVERNANCE 

3.1 Joint Development Committee. Within ninety (90) days following the Effective Date, Audentes and Genethon will establish
a Joint Development Committee (the “JDC”). The responsibilities of the JDC shall include, among other things: (i) ensuring open and frequent exchange between the Parties regarding Research Program activities and
(ii) overseeing and reviewing the status and findings of the Research Program activities. 

  

					
		  	5	  	*Confidential Treatment Requested.

 3.2 Membership. The JDC shall include [*] representatives of each of Audentes and
Genethon, each Party’s members selected by that Party. The JDC shall initially include [*]. Genethon and Audentes may each replace its JDC representatives at any time, upon written notice to the other Party. From time to time, the JDC may
establish subcommittees, to oversee particular projects or activities, and such subcommittees will be constituted as the JDC agrees. 

3.3 Meetings. During the Research Program, the JDC shall meet at least quarterly, or as agreed by the Parties, at such locations
as the Parties agree, and will otherwise communicate regularly by telephone, electronic mail, facsimile and/or video conference. With the consent of the Parties, other representatives of Genethon or Audentes may attend JDC meetings as nonvoting
observers, including relevant outside experts subject to their first entering into a confidentiality agreement. To the extent Audentes requires the JDC to meet at a location other than Paris, [*] shall be responsible for the [*] associated with
attendance of such meetings. 
 3.4 Minutes. The JDC shall keep accurate minutes of its deliberations which shall record all
proposed decisions and all actions recommended or taken. The Secretary of the JDC (as appointed by the members of the JDC) shall be responsible for the preparation of draft minutes. Draft minutes shall be sent to all members of the JDC within [*]
after each meeting and shall be approved, if appropriate, at the next meeting. All records of the JDC,’ shall at all times be available to both Genethon and Audentes. 

3.5 Decision Making. All decisions of the JDC shall be made by consensus. In the event that the votes required to approve a
decision cannot be reached within the JDC, then such matter shall first be referred to Audentes’s CEO and Genethon’s CEO, who shall attempt in good faith to resolve such disagreement within [*] of such matter being referred to them. If
such matter is not resolved within such [*] period, then Audentes may exercise its deciding vote with respect to such matter, subject to Section 3.6. In any case, the JDC may not modify the Parties’ rights and obligations set out in the
body of this Agreement or make any decision that is identified in this Agreement as requiring an amendment to the Agreement. 

3.6 Modifications of the Development Plan. The JDC may from time to time as required modify the Development Plan. In the event
the JDC is unable to agree on a modification of the Development Plan, subject to the escalation process set forth in Section 3.5, Audentes may exercise the casting vote; provided, however, that Audentes may not do so with respect to
modifications involving (a) modifying the nature of the activities to be conducted by Genethon as set forth in Exhibit A, or (b) adding additional Genethon activities that Genethon does not typically conduct or that Genethon does not
reasonably have the available capacity to perform (taking into account committed current obligations and anticipated future obligations for both internal and Third Party programs) or that would, in Genethon’s reasonable opinion, give rise to
material safety or regulatory issues. Any modification of the Development Plan decided by the JDC must be formally recorded in the JDC minutes. 
  

  

					
		  	6	  	*Confidential Treatment Requested.

 4. LICENSES 

4.1 Background Intellectual Property. 

(a) Genethon hereby grants to Audentes a royalty-free, fully paid-up, worldwide, sublicenseable (through multiple tiers), exclusive (including
as to Genethon) license under its Background Intellectual Property, for the sole purpose of making, using, importing, selling, offering for sale and otherwise discovering, researching, developing or commercializing Products. Notwithstanding the
above, the license granted in this Section 4.1(a) shall be subject to the following: 
 (i) With respect to [*], the licenses granted
to Audentes under this Section 4.1(a) shall be limited to Genethon’s co-ownership share and subject to the rights of the co-owners identified in Exhibit D-1. The Parties agree that (a) Genethon shall [*], and (b) any co-ownership
agreement Genethon may enter into with such co-owners shall [*] and (c) subject to the foregoing sub-clause (h), Audentes shall [*]. 

(ii) With respect to [*], the licenses granted to Audentes under this Section 4.1(a) shall be subject to the rights of the co-owner
identified in Exhibit D-2, provided that Genethon shall use [*] efforts to [*]. 
 (iii) With respect to [*], Genethon hereby grants to
Audentes an option to obtain a sublicense under the terms set forth in Exhibit E under that certain Patent License Agreement entered into by Genethon with the United States Department of Health and Human Services (the “HHS”) on
June 22, 2012 (such agreement, a copy of which has been provided to Audentes subject to confidentiality obligations, the “HHS Patent License Agreement”) for the sole purpose of making, using, importing, selling, offering for
sale and otherwise discovering, researching, developing or commercializing Products following a technology transfer under Section 2.4(b) or 2.4(c); it being understood that such option to obtain a sublicense is subject to HHS’s reasonable
prior written approval in, accordance with Section 4.1 of the HHS Patent License Agreement. Audentes may exercise such option at any time following the Effective Date upon delivery of written notice to Genethon, subject to the following
conditions: (a) Audentes shall make a sublicense payment to Genethon of [*]; and (b) Audentes hereby agrees that, following the exercise of such option, Audentes shall pay directly to HHS (unless HHS does not accept the direct payment
thereof, in which case Audentes shall make such payments to Genethon) all earned and benchmark royalty payments due to HHS pursuant to Appendix C —HI and IV of the HHS Patent License Agreement in consideration for such sublicense in connection
with Audentes’s or its sublicensees’ manufacture, development and commercialization of Product. 
 (iv) Genethon agrees, not to,
without Audentes’s prior written consent, terminate any agreement (including any co-ownership agreement) under which Genethon has in-licensed Genethon Background Intellectual Property rights granted to Audentes under this Section 4.1(a),
or amend any such agreement such that it would adversely affect such rights or impose any payment or other obligations on Audentes or its sublicensees (or in the case of the HHS Patent License Agreement, that would increase or accelerate the payment
obligations provided for in such agreement as of the Effective Date). 
  

  

					
		  	7	  	*Confidential Treatment Requested.

 (b) Audentes hereby grants to Genethon a non-exclusive, royalty-free, fully-paid up,
non-sublicenseable license under its Background Intellectual Property to the extent necessary or useful to conduct the Genethon Research Program Activities under the Agreement, including without limitation the manufacturing activities contemplated
as part of the Research Program. 
 4.2 Program Intellectual Property. Genethon hereby grants to Audentes an exclusive
(including as to Genethon), royalty-free, fully paid-up, worldwide, sublicenseable license under Genethon’s interest in any Program Intellectual Property for the purpose of making, using, importing, selling, offering for sale and otherwise
discovering, researching, developing or commercializing Products. 
 4.3 Genethon Additional Internal Intellectual
Property. 
 (a) Genethon shall propose to Audentes additional Patent Rights or material Know-How that may be necessary or
useful to conduct the activities to be conducted by Genethon pursuant to the Research Program, including without limitation the manufacture of Product, that are developed by or on behalf of Genethon independently from the Research Program (i.e.
excluding in-licensed Patent Rights or Know-How) and in respect of which Genethon has the right to grant the licenses as provided herein without violating the terms of any agreement or other arrangements with any Third Party (any of such being
“Genethon Additional Internal IP”). In such a case, Genethon shall describe such Patent Rights and/or Know-How to Audentes and discuss with Audentes in the context of the JDC whether to include one or more elements of such
Genethon Additional Internal IP in the performance of the Research Program and the licenses to be granted to Audentes pursuant to this Agreement, it being understood that no royalties or other consideration shall be payable to Genethon for the
exploitation of such Genethon Additional Internal IP in connection with the activities contemplated under this Agreement where Genethon is manufacturing Products (whether clinical or commercial) hereunder. 

(b) Notwithstanding the above, Genethon hereby grants to Audentes a royalty-free, fully paid-up, worldwide, sublicenseable (through multiple
tiers, but in any case only if sublicensed along with the Product), non-exclusive license to access and use for regulatory purposes in connection with the development and commercialization of Products the data generated pursuant to a [*] that it is
expected will be conducted pursuant to that certain Collaborative Research Agreement [*] among Genethon, the [*], which have been agreed by the parties but not signed on the Effective Date, and which follows a first [*] signed by the same parties on
[*]. 
 4.4 Genethon Additional In-Licensed Intellectual Property. 

(a) Genethon shall propose to Audentes additional Patent Rights or Know-How in-licensed by Genethon from Third Parties during the term of the
Agreement that may be useful to conduct the Genethon Research Program Activities, including without limitation the manufacture of Product (any of such, together with any rights to Third Party Patent Rights or Know-How in-licensed by Genethon
pursuant to Section 4.4(b) below, being “Genethon Additional In-Licensed IP” and together with the Genethon Additional Internal IP, 
  

  

					
		  	8	  	*Confidential Treatment Requested.

 
“Genethon Additional IP”). In such a case, Genethon shall describe such Patent Rights and/or Know-How to Audentes and discuss with Audentes in the context of the JDC whether
to include one or more elements of such Genethon Additional In-Licensed IP in the performance of the Research Program and the licenses to be granted to Audentes pursuant to this Agreement. Notwithstanding the above, it is agreed that Genethon shall
not in-license any Third Party Know-How and/or Patent Rights that may be necessary or useful to conduct the Genethon Research Program Activities, including without limitation the manufacture of Product, and that are specific to Product (i.e. cannot
reasonably be used by Genethon in the context of other current or planned programs at the time of the negotiation of the applicable in-license) and that are not in-licensed as of the Effective Date, without the prior written consent of Audentes; the
Parties agree that in any such case Audentes shall be the lead Party with respect to the negotiation of the terms of the license with the applicable Third Party. 

(b) Genethon shall inform Audentes of any additional Third Party Patent Rights or Know-How of which it becomes aware (including those of which
Genethon has informed Audentes prior to the Effective Date) that may be necessary to conduct the Genethon Research Program Activities under the terms of the Agreement. In such a case, Genethon shall describe such Patent Rights and/or Know-How to
Audentes. Genethon shall have the lead for negotiating any such Third Party licenses with respect to Patent Rights or Know-How that are not specific to Product (i.e. that can be used by Genethon in the context of other programs), provided that
Genethon shall (i) keep Audentes reasonably informed about the status of such negotiations and (ii) reasonably consider any comments provided by Audentes on the terms and conditions of the applicable license. If Audentes is not in
agreement with the terms and conditions negotiated by Genethon, Genethon shall, upon Audentes’ s written notification of its disagreement, exclude Product from the scope of the license negotiated by Genethon and Audentes shall negotiate with
the Third Party independently for required license rights in respect of Product Audentes shall have the lead for negotiating any such Third Party licenses with respect to Patent Rights or Know-How that are specific to Product (i.e. that cannot
reasonably be used by Genethon in the context of other current or planned programs at the time of the negotiation of the applicable in-license). 

(c) In all cases where Genethon Additional In-Licensed IP may be included pursuant to either paragraphs (a) or (b) above, Audentes
shall be responsible for either, as the case may be, reimbursing to Genethon or paying directly to the Third Party licensor all amounts due to the Third Party licensor for the applicable Genethon Additional In-Licensed IP, without any mark-up, and
subject to a reasonable pro rata allocation if such Genethon Additional In-Licensed Know-How and/or Patent Rights are in-licensed by Genethon for multiple products or programs. 

(d) Genethon shall not knowingly, without Audentes’ prior written consent, include any Know-How or Patent Rights in the performance of
the Genethon Research Program Activities in respect of which a license is required from a Third Party for the purposes of conducting the Research Program and/or making, using, importing, selling, offering for sale and otherwise discovering,
researching, developing or commercializing Products. 

  
 9 

 4.5 Right of First Negotiation. Genethon shall from time to time in the context of
the JDC inform Audentes of any internal research programs (i.e. excluding programs conducted in collaboration with and/or funded by Third Parties) conducted by Genethon to research, develop, manufacture or commercialize product(s) for the treatment
of XLMTM other than Products. Before commencing discussions with respect to any such program with a Third Party, or before transitioning early research to a proof-of-concept study in animal models of the disease (“POC Study”),
Genethon shall provide written notice thereof to Audentes. Audentes will have [*] following receipt of such notice to inform Genethon as to whether Audentes is interested in collaborating with Genethon with respect to such product(s). If Audentes
elects to provide such notice, Audentes and Genethon shall negotiate in good faith the terms of such collaboration for not less than [*] from the date of Genethon’s receipt of Audentes’s notice (the “Term Sheet Negotiation
Period”). If (a) Audentes does not provide its notice within such [*] period, or (b) the Parties fail to agree a final reasonably detailed non-binding term sheet within the Term Sheet Negotiation Period, or (c) having agreed
such a term sheet prior to the end of the Term Sheet Negotiation Period, the Parties fail to enter into a definitive agreement within [*] following the end of the Term Sheet Negotiation Period, Genethon will be free to collaborate with Third Parties
on such a program or to transition to the POC Study on its own, in each case without any further obligations to Audentes. 
 4.6 No
Implied Licenses. Only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force or effect. No other license or rights shall be created by implication, estoppel or otherwise. 

5. FINANCIAL TERMS 

5.1 Equity. Immediately upon the effectiveness of this Agreement, Audentes shall issue to Genethon
shares of Audentes Common Stock (the “Common Shares”), which Common Shares (i) represent [*]% of the Company’s issued and outstanding common stock on a fully-diluted basis (including the [*]% issued to Genethon)
after completion of Audentes’s Series A financing, and (ii) shall be issued pursuant to the terms of the Common Stock Purchase Agreement (SPA), attached hereto as Exhibit C. 

5.2 Research Program Funding. Audentes shall fund Genethon’s activities in performance of the Research Program based on the
agreed-upon budget included in the Development Plan, it being understood that Genethon’s activities shall be performed [*]. 

(a) internal research and development activities will be invoiced on an FTE basis for Genethon personnel at an agreed average full-time
equivalent annual rate of [*] for scientists and [*] for technicians (value added taxes excluded), with such FTE rates to be adjusted, on an annual basis beginning January 1, 2014 based on the Indices du cout horaire du travail
revise—Tous salariés (ICHTrev-TS)—Indices mensuels—S’alaires et charges—Activités spécialisées, scientifiques et techniques index available on the INSEE (French national statistic agency)
website: http ://www. indices.insee.fr/),  
 (b) manufacturing (preclinical and clinical) and process development activities will be
invoiced [*] determined in accordance with a cost accounting method consistent with industry practice and French GAAP, and external costs incurred by Genethon for the purposes of the Research Program shall be invoiced at cost without any mark-up.

  

  

					
		  	10	  	*Confidential Treatment Requested.

 5.3 Terms Applicable to Transfer of Genethon Intellectual Property. Without
prejudice to the foregoing Sections 5.1 and 5.2, in the event Genethon shall pursuant to Section 2.4 not be responsible for manufacturing commercial Product (following written notice thereof provided by Audentes) or otherwise transfers
manufacturing of Product to a Third Party, the Parties agree to negotiate in good faith, and under terms consistent with market practice, the compensation to be paid to Genethon in consideration for the technology transfer activities to be conducted
to transfer the manufacturing process to Audentes or its designee for that purpose, such compensation to be based on the principles set out above in this Article 5. The Parties also acknowledge that such transfer of manufacturing to Audentes or its
designee shall be subject to the payment by Audentes of certain amounts due to Third Party licensors: (a) to the extent applicable in accordance with Section 4.1(a), Audentes shall pay costs for which Audentes is responsible under the
applicable sublicense from Genethon to the Genethon Background Intellectual Property in-licensed from Third Parties, and (b) to the extent applicable in accordance with Section 4.3, Audentes shall pay the amounts due under the applicable
license to the Genethon Additional Internal IP, and (c) to the extent applicable in accordance with Section 4.4, Audentes shall pay the amounts due under the applicable sublicense to the Genethon Additional In-Licensed IP. 

6. PAYMENTS; RECORDS 

6.1 Payment Method. All payments due under this Agreement shall be made by bank wire transfer [*] following the receipt of an
invoice to a bank account designated by Genethon. 
 6.2 Taxes. Payments sent to Genethon shall be net of any taxes required to
be withheld by Audentes from payment made to Genethon and exclusive of any applicable sales, use or value-added taxes. Audentes shall bear all such taxes, and especially US sales, use or withholding taxes, related to the payment made to Genethon in
accordance with this Agreement. In event that any taxes are required to be withheld from a payment made to Genethon, Audentes will: increase the amounts payable to Genethon so that it receives the same net payment it would have received absent such
taxes, timely pay the taxes to the proper taxing authority, and notify Genethon and promptly furnish Genethon with copies of any documentation evidencing such withholding. Genethon will provide Audentes with all documentation and assistance
reasonably requested by Audentes in connection with the collection of any taxes covered by this Section 6.2, including but not limited to providing Audentes with any applicable certificates or forms necessary to obtain a reduction in
such taxes. 
 6.3 Books and Records; Accounting and Audits. Genethon shall maintain complete and accurate books
and records with respect to all costs or expenses to be reimbursed by Audentes under this Agreement during the term of the Agreement, which books and records shall be sufficient in detail to verify all reimbursed amounts hereunder and shall be
maintained for a period of [*] following the year to which they pertain. Audentes shall have the right, at its own expense and not more than once in any calendar year during, the Term of this Agreement, to have an independent, certified public
accountant under an obligation of confidence, audit the books and records of Genethon at the location(s) where such books and records are maintained upon reasonable notice (which shall be no less than [*] prior written notice) and during regular
business hours, and for the sole purpose of verifying the basis and accuracy of the payments  
  

  

					
		  	11	  	*Confidential Treatment Requested.

 
required and made under this Agreement and amounts to be reimbursed, as applicable. The report and communication of such accountant with respect to such an audit shall be limited to a certificate
stating whether any, as applicable, report made or reimbursement or other payment submitted during such period is accurate or inaccurate and, if a discrepancy is identified, shall also indicate the amount and if applicable, with respect to any
report, the nature, of any discrepancy, and the correct information (with respect to the applicable period). Such accountant shall provide Audentes with a copy of each such report simultaneously. In the event that the audit reveals an overpayment by
Audentes, Genethon shall promptly reimburse such difference to Audentes. In addition, if such overpayment is greater than [*] of the amount due for such audited period, then Genethon shall promptly pay or reimburse the reasonable cost charged by
such accountant for such audit. 
 7. PRIX JUSTE 

Audentes shall use reasonable efforts so as to make available the Product in Europe at a price (“Prix Juste”) such that it does not
constitute a material obstacle to the ability of patients to have access to the Product, taking into account the global pricing strategy of Audentes, any existing and applicable regulatory and reimbursement systems and any other applicable legal and
regulatory regimes on a relevant national, international, or regional level at the date of such price decisions. 
 8. INTELLECTUAL
PROPERTY 
 8.1 Ownership; Disclosure. 

(a) Background Intellectual Property. Each Party will retain all right, title and interest to its respective Background Intellectual
Property. As between the Parties, Genethon shall retain all right, title and interest to the Genethon Additional IP. 
 (b) Program
Intellectual Property. Any and all Program Intellectual Property shall be owned jointly by the Parties, and, subject to the license granted to Audentes under Section 4.2, each Party shall be free to exploit any such Program Intellectual
Property. Subject to the license granted to Audentes under Section 4.2, neither Party shall have any obligation to account to the other for profits, or to obtain any approval of the other Party to license out or exploit patented jointly-owned
subject matter, by reason of joint ownership thereof, and each Party hereby waives any right it may have under the laws of any jurisdiction to require any such consent or accounting, and further agrees to execute any documents and instruments as may
be required under such laws in order to permit the other Party to exploit its rights in any Program Intellectual Property in accordance with this Section 8.1(b). 

(c) Disclosure of Inventions. Each Party shall promptly disclose to the other any inventions made by or on behalf of such Party in
performance of the Research Program. 
  

  

					
		  	12	  	*Confidential Treatment Requested.

 8.2 Patent Prosecution. 

8.2.1 Program Patent Rights. Unless the Parties otherwise agree, Audentes shall be responsible (the “Patent
Prosecutor”) for managing Program Patent Rights that are specific to the Product, and Genethon shall be the Patent Prosecutor for Program Patent Rights that are not specific to the Product, including for example Program Patent Rights
related to manufacturing methods or materials that may be used for products other than the Product. The Patent Prosecutor shall be solely responsible, at its expense, for (i) preparing, filing, prosecuting and maintaining Program Patent Rights,
and (ii) for conducting any interferences, re-examinations, reissues and oppositions relating thereto. The Patent Prosecutor may elect, at its sole discretion, to discontinue prosecution of any such patent applications and/or not to file or
conduct any further activities with respect to such patent applications or patents; provided, in each case, that it provide timely notice of such decision to the other Party such that such other Party has the opportunity to replace the discontinuing
Party as Patent Prosecutor and pursue at its cost and in the name of both Parties the prosecution and maintenance of the relevant patent applications or patents. The Patent Prosecutor shall keep the other Party reasonably informed with respect to
the prosecution status and issuance of patents filed by the Patent Prosecutor pursuant to this Section 8.2.1, and shall provide the other Party with all material filings and correspondences with the patent authorities prior to the submission
and shall reasonably consider any comments provided by the other Party on such filings and correspondences. 
 8.2.2
Cooperation. The non-prosecuting Party shall reasonably cooperate with and assist the Patent Prosecutor in connection with the activities of the Patent Prosecutor under Section 8.2.1 upon the reasonable request of the Patent
Prosecutor, including without limitation by making scientists and scientific records reasonably available to the Patent Prosecutor and the execution of all such documents and instruments and the performance of such acts as may be reasonably
necessary in order to permit the Patent Prosecutor to continue any filing, prosecution, maintenance or extension of such patents and patent applications. The Patent Prosecutor shall reimburse the non-prosecuting Party for any out-of-pocket expenses
incurred in connection with cooperation provided pursuant to this Section 8.2.2. 
 8.3 Enforcement and Defense.

 8.3.1 Notice. Each Party shall promptly notify the other of any knowledge it acquires of any potential infringement of the
Program Intellectual Property. 
 8.3.2 Enforcement. 

(a) If either (a) any Program Patent Right or (b) any Genethon Background Patent Right that is specific to Product (i.e. that does
not apply to any products other than Product) is infringed by a Third Party in any country in connection with the manufacture, use, sale, offer for sale or importation of a Product in such country, Audentes shall have the first right, but not the
obligation, to institute, prosecute, and control any action or proceeding with respect to such infringement, by counsel of its own choice, and Genethon shall have the right, at its own expense, to be represented in that action by counsel of its own
choice. If Audentes fails to bring an action or proceeding within a period of [*] after a request by Genethon to do so, Genethon shall have the right to bring and control any such action by counsel of its own choice, at its own expense, and Audentes
shall have the right to be represented in any such action by counsel of its own choice at its own expense. 
  

  

					
		  	13	  	*Confidential Treatment Requested.

 (b) If any Genethon Background Patent Right that is not specific to the Product is infringed by
a Third Party in any country in connection with the manufacture, use, sale, offer for sale or importation of a Product in such country, Genethon shall have the first right, but not the obligation, to institute, prosecute, and control any action or
proceeding with respect to such infringement, by counsel of its own choice, and Audentes shall have the right, at its own expense, to be represented in that action by counsel of its own choice. If Genethon fails to bring an action or proceeding
within a period of [*] after a request by Audentes to do so, Audentes shall have the right to bring and control any such action by counsel of its own choice, at its own expense, and Genethon shall have the right to be represented in any such action
by counsel of its own choice at its own expense. 
 8.3.3 Assistance. If one Party brings an action or proceeding in
accordance with Section 8.3.2, the second Party agrees to be joined as a party plaintiff if necessary and to give the first Party reasonable assistance and authority to file and prosecute the suit. The costs and expenses of the Party bringing
suit under this Section 8.3.3 shall be borne by such Party, and any damages or other monetary awards recovered shall be retained by such Party. A settlement or consent judgment or other voluntary final disposition of a suit under this
Section 8.3.3 may be entered into without the consent of the Party not bringing the suit. Neither Party shall, however, have the right to enter into any settlement or consent to any claim to the effect that the patent protection offered under
the applicable patent(s) would be materially negatively affected, without the consent of the other Party, such consent not to be unreasonably withheld. 

8.3.4 Other Instances. Any infringement or declaratory judgment actions relating to Program Patent Rights falling outside of the
application of Section 8.3.2 shall be discussed and coordinated in good faith by the Parties. For the avoidance of doubt, Audentes shall have no right to bring any actions in connection with any infringement of Genethon Background Patent Rights
other than in connection with the manufacture, use, sale, offer for sale or importation of a Product. 
 8.3.5 In-Licensed
Patents. Notwithstanding anything in this Section 8.3 to the contrary, the Parties acknowledge that certain Genethon Background Patent Rights are in-licensed from Third Parties and consequently that the rights and obligations of the Parties
set out in this Section 8.3 remain in any case subject to the terms of the license agreement with such Third Parties and to the legal rights of such Third Parties. As a consequence, neither Party shall be in breach of any of its obligations
under this Section 8.3 to the extent it is unable to comply with such obligation as a consequence of the legal rights of the Third Party licensor under the applicable license agreement. 

9. CONFIDENTIALITY 

9.1 Confidential Information. Except as otherwise expressly provided herein, the Parties agree that, for the term of this
Agreement and for [*] thereafter, the receiving Party shall not, except as expressly provided in this Article 9, disclose to any Third Party any Confidential Information furnished to it by the disclosing Party hereto pursuant to this Agreement. For
purposes of this Article 9, “Confidential Information” shall mean any information, samples or other materials, which if disclosed in tangible form is marked 
  

  

					
		  	14	  	*Confidential Treatment Requested.

 
“confidential” or with other similar designation to indicate its confidential or proprietary nature, or, if disclosed orally, is indicated orally to be confidential or proprietary at
the time of such disclosure and is confirmed in writing as confidential or proprietary within [*] after such disclosure. Notwithstanding the foregoing, Confidential Information shall not include any information that can be established by the
receiving Party by competent proof that such information: 
 (a) was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure; 
 (b) was generally available to the public or otherwise part of the public
domain at the time of its disclosure to the receiving Party; 
 (c) became generally available to the public or otherwise part of the public
domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was
independently developed by the receiving Party as demonstrated by documented evidence prepared contemporaneously with such independent development; or 

(e) was disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the
disclosing Party not to disclose such information to others. 
 Notwithstanding anything to the contrary in this Section 9.1,
and for the purposes of clarity, the results of the Research Program (“Results”) shall be deemed Confidential Information of both Parties in respect of which both Parties have confidentiality and restricted use obligations under
this Section 9.1, subject to Sections 9.2 and 9.5. All Genethon Background Know-How and any information concerning as yet unpublished Genethon Background Patent Rights and all information concerning and Genethon Additional IP, in each case that
may have been or be disclosed to Audentes, shall be deemed to be Confidential Information of Genethon. All Audentes Background Know-How and any information concerning as yet unpublished Audentes Background Patent Rights that may have been or be
disclosed by Audentes to Genethon in connection with this Agreement shall be deemed to be Audentes Confidential Information. 

9.2 Permitted Use and Disclosures. Each Party hereto may use or disclose Confidential Information of the other Party to the
extent such use or disclosure is reasonably necessary and permitted in the exercise of the rights granted hereunder (including, in the case of Audentes, for the purpose of developing and commercializing Products) and in filing or prosecuting patent
applications, prosecuting or defending litigation (in each case in accordance with the Agreement), complying with applicable governmental laws, regulations or court order or otherwise submitting information to tax or other governmental authorities,
conducting clinical trials, or otherwise exercising license rights expressly granted by the other Party to it pursuant to the terms of this Agreement, provided that if a Party is required by governmental authority to make any such disclosure, other
than pursuant to a confidentiality agreement, it will give 
  

  

					
		  	15	  	*Confidential Treatment Requested.

 
reasonable advance notice to the other Party of such disclosure and, save to the extent inappropriate in the case of patent applications, will use its reasonable efforts to secure confidential
treatment of such information in consultation with the other Party prior to its disclosure (whether through protective orders or otherwise) and disclose only the minimum necessary to comply with such requirements. In addition, each Party may
communicate Results to such Party’s attorneys, advisors, investors and potential investors and acquirers, in each case to the extent such are subject either to a prior written confidentiality agreement or to a statutory or ethical obligation of
confidentiality. 
 9.3 Termination of Prior Agreement. This Agreement supersedes the
Mutual Non-Disclosure Agreement No. 013002-1MTUB-00 entered into between the Parties, dated January 13, 2013 (the “Prior NDA”). Information exchanged between the Parties under
the Prior NDA shall be deemed Confidential Information under this Agreement and shall as of the Effective Date be subject to the Willis of this Article 9 and not those of the Prior NDA. 

9.4 Nondisclosure of Terms. Subject to Article 10, each of the Parties hereto agrees not to disclose the terms of this Agreement
to any Third Party without the prior written consent of the other Party hereto, which consent shall not be unreasonably withheld, except to such Party’s attorneys, advisors, investors and potential investors and acquirers, in each case to the
extent such are subject either to a prior written confidentiality agreement or to a statutory or ethical obligation of confidentiality, or to the extent required to comply with applicable laws (including securities laws, regulations and guidances)
or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded, in any such case subject to Section 10.3.6. In addition, in the
context of pursuing the development and commercialization of the Product Audentes may disclose terms of this Agreement to actual or prospective collaborators or licensees, in each case on a need to know basis and subject to a prior written
confidentiality obligation. Either Party may also disclose terms of this Agreement to the extent required by applicable laws subject to the applicable conditions set out in Section 9.2 above. 

9.5 Publications. Except as set forth in Section 10.3, prior to publishing or making any other public disclosure of any
Results, the Party (the “Publishing Party”) wishing to make such publication will provide the other Party (the “Reviewing Party”) with a draft of such publication or other disclosure, so that the Reviewing Party may
review, the same, over a period of at least [*], and if it wishes, provide comments and require reasonable changes to ensure that no Confidential Information regarding the Reviewing Party’s business or technology will be disclosed, and that no
public disclosures are made that could jeopardize or impair any right of the Reviewing Party to obtain patents with respect to any inventions disclosed in such draft. If during such [*] period, the Reviewing Party determines that one or more patent
filings should be made prior to such public disclosures, and if it so notifies the Publishing Party, then the Reviewing Party will be afforded a further period of [*] more [*] in which to prepare and file such application(s). In either case, any
publication of the Results shall, unless a Party does not so wish, describe the contribution of each Party to the generation of the Results in accordance with standard practices in the industry. 

 

  

					
		  	16	  	*Confidential Treatment Requested.

 10. COMMUNICATIONS 

10.1 Support by Audentes. Audentes will provide reasonable support to Genethon’s communication needs, and will collaborate
with Genethon on mutually beneficial activities and publications as follows: 
 10.1.1 Unless it is prohibited
by law or if Genethon requests the contrary, Audentes shall include the logo of Genethon and the words “discovered, and developed with Genethon” in any press release, public presentation, investor or potential investor presentation
or scientific publication related to Research Program, Research Program results and Products. The obligation to include Genethon’s logo shall not apply in cases where such would be inconsistent with customary practice in such circumstances, for
example in scientific publications. 
 10.1.2 Following approval of Product, Genethon and/or the AFM-Telethon may make
paid advertising relative to Product which highlights the contribution of Genethon and/or the AFM-Telethon in the discovery and development of Product. Such advertising shall be at the sole expense of Genethon and/or AFM-Telethon and shall conform
to all applicable laws and regulations. Such advertising further shall be consistent with the marketing, sales and promotion strategy of Audentes and/or Audentes’s sublicensee and shall require advance approval by, and coordination with,
Audentes and/or Audentes’s sublicensee. 
 10.1.3 Audentes shall ensure that all its agreements with sublicensees of
Product shall contain provisions consistent with those set out in this Section 10.1 and Section 10.2, requiring such sublicensees to comply with Audentes’s obligations set forth in Sections 10.1.1 and in Section 10.1.2. 

10.2 Disclosure for Purposes of the Telethon. The Parties acknowledge that AFM-Telethon, in view of accomplishment of its
recognized role of working in the public interest (that is, by curing rare diseases and reducing the disabilities to which they give rise), has an obligation to provide the general public with information on the research programs and work to which
it provides, or has provided, a financial contribution, directly or indirectly, in order to facilitate an understanding of these diseases, the development of treatments, and the prevention of disabilities. The Parties expressly authorize
AFM-Telethon to make use of their name and to report on the Research Program and its progress, orally and/or in writing, to the general public, notably during fundraising campaigns, during the Telethon and Annual General Meeting of AFM-Telethon,
without releasing: (a) any details of the Research Program which may be detrimental to intellectual property rights or their protection, or (b) any of Audentes’s Confidential Information (other than, subject to (a), information about
the Research Program and its progress), and subject in all cases to any guidelines the Parties may agree upon to comply with regulatory, disclosure, and intellectual property requirements and all other applicable laws. 

10.3 Press Releases. 

10.3.1 Audentes may issue any press release or other public communication concerning this Agreement or the Research Program or the
Results (each a “Press Release”), provided that Audentes shall (a) provide a copy of any proposed Press Release to Genethon in advance of publication, and (b) use good faith efforts to consider any reasonable comment
timely provided by Genethon. 

  
 17 

 10.3.2 Genethon may issue a Press Release upon the prior written consent of Audentes
(except to the extent permitted under Section 10.2 above), such consent not to be unreasonably withheld or delayed. 
 10.3.3
Notwithstanding Sections 10.3.1 and 10.3.2, the Parties shall collaborate on a mutually agreeable first Press Release, to be issued on or after February 1, 2014 (timing to be mutually agreed upon). 

10.3.4 Notwithstanding the above, once certain information has been disclosed in a Press Release in accordance with Sections 10.3.1,
10.3.2 and/or 10.3.3, either Party may thereafter refer to such information publicly so long as it remains relevant and accurate. 

10.3.5 Audentes shall use good faith efforts to coordinate with Genethon any Press Release to be issued during the annual three- month
periods between November 1 and January 31 to avoid any such Press Release having a negative impact on the Telethon fundraising. 

10.3.6 Nothing in this Section 10.3 or otherwise in this Agreement shall be construed to restrict a Party’s ability to issue
Press Releases to the extent required to comply with applicable laws (including securities laws, regulations and guidances) or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which
such Party has its securities listed or traded. In the event either Party is required to make a press release or filing pursuant to any such laws or requirements, such Party shall (a) except to the extent such Party in consultation with legal
counsel determines that a more rapid disclosure is legally required, notify the other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing not less than five (5) days prior to such
filing, and no less than [*] prior to any filing of a copy of this Agreement, including any exhibits thereto relating to the Agreement, and (b) use reasonable efforts to obtain confidential treatment of any information concerning the Agreement
that such other Party reasonably requests be kept confidential, and shall only disclose Confidential Information which it is advised by counsel is legally required to be disclosed. 

11. ABANDONMENT 

In the event of Abandonment of the Product, Genethon shall have the right to continue the development of the Product itself, in which case
Audentes shall grant to Genethon a license to any Background Intellectual Property Controlled by Audentes to the extent necessary for Genethon to continue such development and commercialize the Product, subject to terms to be negotiated by the
Parties in a separate agreement. Audentes shall assure that all its agreements with sublicensees of Product shall contain provisions consistent with this Article 11. For purposes of this Article 11, “Abandonment” means either
(1) a resolution adopted by the Board of Audentes or its successor or assignee to abandon the development of the Product everywhere in the world or (2) the absence of any material development activities with respect to the Product 

 

  

					
		  	18	  	*Confidential Treatment Requested.

 
anywhere in the world (e.g., clinical trials, certification attempts), whether by Audentes or any of its successors or sublicensees in any tier for a full, uninterrupted [*], unless Audentes
provides Genethon reasonable justification for the situation. For the purposes hereof, the “absence of any material development activities” shall mean that less than [*] has been expended in external costs on development activities with
respect to the Product during the [*] period. For the sake of clarity, it is understood by the Parties that such “external costs on development activities” include amounts paid by Audentes to Genethon in respect of Genethon’s
activities under the Development Plan. 
 12. REPRESENTATIONS AND WARRANTIES 

12.1 Audentes. Audentes represents and warrants as of the Effective Date that: (i) it has the legal power, authority and
right to enter into this Agreement and to fully perform all of its obligations hereunder; (ii) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; (iii) the performance of its
obligations hereunder do not conflict with, violate or breach or constitute a default or require any consent under, any contractual obligations, of Audentes; and (iv) to the knowledge of Audentes, the use by Genethon of the Audentes Background
Intellectual Property provided by or for Audentes for the purposes of conducting the Genethon Research Program Activities will not infringe or misappropriate any Third Party intellectual property rights. 

12.2 Genethon. Genethon represents and warrants as of the Effective Date that: (i) it has the legal power, authority and
right to enter into this Agreement and to fully perform all of its obligations hereunder; (ii) this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms; (in) the performance of its obligations
and the grant of rights hereunder do not conflict with, violate or breach or constitute a default or require any consent under, any contractual obligations of Genethon, (iv) to the [*], except as communicated to Audentes prior to the Effective
Date including the intellectual property rights listed in Exhibit B hereto, [*]. 
 12.3 Disclaimer. EXCEPT AS OTHERWISE
EXPRESSLY SET FORTH IN THIS AGREEMENT, GENETHON AND AUDENTES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE PRODUCT, ANY BACKGROUND OR PROGRAM INTELLECTUAL PROPERTY OR OTHER
INFORMATION DISCLOSED HEREUNDER OR PRODUCTS INCLUDING, BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF ANY PROGRAM INTELLECTUAL PROPERTY PATENTED OR UNPATENTED, OR NONINFRINGEMENT OF THE INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES. 
 12.4 EXCEPT IN THE EVENT OF A PARTY’S BREACH OF ARTICLE 9, NEITHER PARTY NOR ANY
OF ITS AFFILIATES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT
ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY IS REQUIRED TO PROVIDE INDEMNIFICATION UNDER ARTICLE 13. 
  

  

					
		  	19	  	*Confidential Treatment Requested.

 13. INDEMNIFICATION 

13.1 Audentes. Audentes agrees to indemnify, defend and hold Genethon and its Affiliates and their respective directors,
officers, employees, agents and their respective successors, heirs and assigns (the “Genethon Indemnitees”) harmless from and against any losses, costs, claims, damages, liabilities or expense (including reasonable attorneys’
and professional fees and other expenses of litigation) (collectively, “Liabilities”) arising out of Third Party claims, suits, actions, demands or judgments, relating to (i) the conduct of the Research Program by Audentes
and/or Genethon, including, without limitation, any claim for personal injury or death resulting from the administration of any Products, or any claim for infringement of Third Party intellectual property, (ii) the use or sale of any Products
or Results by Audentes, its Affiliates and/or sublicensees, including without limitation, any product liability claims by or on behalf of persons to whom Product is administered, or any claim for infringement of Third Party intellectual property,
and (iii) any breach by Audentes of its obligations under this Agreement, including its representations and warranties made in this Agreement; except, in each case, to the extent such Liabilities result from the gross negligence or intentional
misconduct or breach of contract of Genethon. 
 13.2 Genethon. Genethon agrees to indemnify, defend and hold Audentes
and its Affiliates and their respective directors, officers, employees, agents and their respective successors, heirs and assigns (the “Audentes Indemnitees”) harmless from and against any Liabilities arising out of Third Party
claims, suits, actions, demands or judgments, relating to any breach by Genethon of its obligations under this Agreement, including its representations and warranties made in this Agreement, except to the extent such Liabilities result from the
gross negligence or intentional misconduct or breach of contract of Audentes. 
 13.3 Indemnification Procedure. A Party
that intends to claim indemnification (the “Indemnitee”) under this Article 13 shall promptly notify the other Party (the “Indemnitor”) in writing of any claim, complaint, suit, proceeding or cause of
action with respect to which the Indemnitee intends to claim such indemnification (for purposes of this Section 13.3, each a “Claim”), and the Indemnitor shall have sole control of the defense and/or settlement thereof; provided that
the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim; provided that, if the Indemnitor is also involved in defending against such Claim in its own
name and if defense of the Indemnitor and Indemnitee by the same counsel would place such counsel in a position of conflict of interest, the Indemnitor shall pay the reasonable cost of the Indemnitee’s separate counsel. The indemnification
obligations of the Parties under this Article 13 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the consent of the Indemnitor, which consent shall, not be withheld or delayed unreasonably. The
failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such Claim, if prejudicial to its ability to defend such action, shall to the extent it is prejudicial relieve such Indemnitor of any
liability to the Indemnitee under this Article 13, but the omission so to deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability to any Indemnitee otherwise than under this Article 13. The Indemnitee under this
Article 13, and its employees, at the Indemnitor’s request and expense, shall provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to such Claims covered by this indemnification. 

  
 20 

 14. TERM AND TERMINATION 

14.1 Term. The Agreement will be effective on the Effective Date and will continue in full force and effect until completion of
the Research Program unless and until terminated early as set forth in the remainder of this Article 14 (the “Term”). 

14.2 Termination Rights for either Party. 

(a) For Breach. Either Party may terminate this Agreement in the event the other Party has materially breached or defaulted in the
performance of any of its material obligations hereunder, and such default shall have continued for [*] following receipt of written notice thereof; provided, however, that where the Party alleged to be in breach disputes in good faith that the
claimed breach exists, such cure period will not start to run until such dispute either can no longer be maintained in good faith or has been resolved by agreement of the Parties or pursuant to Section 15.2; and (ii) if a breach is not
reasonably capable of being cured within the [*] cure period described above and the breaching Party is making continuing good faith efforts to cure such breach, the cure period applicable to such breach shall be extended to [*]. 

(b) For Bankruptcy. Either Party may terminate this Agreement at any time upon the other Party’s filing or institution of
bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy
proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within sixty (60) days after the filing thereof 

14.3 Specific Termination Rights. 

(a) Termination By Audentes for Convenience. Audentes may terminate the Agreement for convenience upon [*] prior written notice
to Genethon. 
 (b) Termination by Genethon for Disagreement as to Continuation of the Program. Genethon may terminate the
Agreement upon [*] notice in the event (a) Genethon raises an objection with respect to the continued development of the Product on the grounds of a safety or efficacy issue, and (b) Audentes disagrees and wishes to pursue with the
development of the Product as planned. In such a case, if the JDC is unable to agree pursuant to Section 3.5 then. Audentes shall not have a deciding vote at the JDC level as contemplated by Section 3.5 but the disagreement shall be
submitted for resolution to the CEOs. If the Parties are still unable to agree within [*] after the matter is submitted to the CEOs, Audentes shall have the final say and the Research Program shall proceed until the next meeting that is held with
any regulatory authority to discuss the Product. Following such meeting, and regardless of the outcome of such meeting, if the Parties are still in disagreement, Genethon shall be free to terminate the Agreement pursuant to the Section 14.3(b)
upon written notice to Audentes. For the avoidance of doubt, during any such period of disagreement, Audentes shall indemnify Genethon against Third Party claims in accordance with Section 13.1. 

  

					
		  	21	  	*Confidential Treatment Requested.

 14.4 Consequences of Termination. 

(a) Accrued Rights and Obligations. Termination of this Agreement for any reason shall not release either Party hereto from any
liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement. 
 (b) General Consequences. Upon any termination of this Agreement: 

(i) Each Party shall promptly return to the other all Confidential Information received from such other Party, except one copy of which may be
retained for archival purposes. 
 (ii) The license granted to Genethon under Section 4.1(b) shall automatically terminate. 

(iii) Genethon will use commercially reasonable efforts to promptly cancel all cancellable obligations incurred under the Development Plan.
Subject to the preceding sentence, Audentes shall remain responsible in accordance with Article 5 for paying all costs related to Genethon Research Program Activities conducted by Genethon until the effective termination date and reimbursing
Genethon for all noncancellable costs and expenses reasonably incurred by Genethon for the purposes of the Genethon Research Program Activities prior to delivery of the termination notice, whether such costs and expenses are actually payable by
Genethon before or after the effective termination date, provided that Genethon shall use commercially reasonable efforts to cancel all cancellable obligations promptly upon receipt of Audentes’s termination notice or delivery of
Genethon’s termination notice, as applicable. 
 (c) Effect of Termination by Audentes for Convenience or by Genethon for
Cause. Upon termination of this Agreement by Audentes pursuant to Section 14.3(a) or by Genethon for cause pursuant to Section 14.2(a) or (b), the licenses granted to Audentes under Sections 4.1(a), 4.2, 4.3 and 4.4 shall automatically
terminate. For the avoidance of doubt, terminations contemplated under this Section 14.4(c) shall not affect Genethon’s rights under Article 11 should there be an Abandonment by Audentes prior to, contemporaneously with or during the [*]
following the termination. 
 (d) Effect of Termination by Genethon for Disagreement as to Continuation of the Program. Upon
termination of this Agreement by Genethon pursuant to Section 14.3(b), the licenses granted to Audentes under Sections 4.1(a) and 4.2 shall convert to non-exclusive, and the licenses granted to Audentes under Sections 4.3 and 4.4 shall
automatically terminate. 
 14.5 Survival Clause. In the case of expiry of this Agreement as a result of the completion of the
Research Program or termination by Audentes pursuant to Section 14.2(a) or (b) (but not in any case of any other termination pursuant to Sections 14.3 or 14.4 which shall be  

 

  

					
		  	22	  	*Confidential Treatment Requested.

 
governed by Section 14.4 above), the licenses granted to Audentes pursuant to Sections 4.1(a), 4,2, 4.3 and 4.4 shall survive and remain in effect in accordance with the relevant terms
and conditions set out therein and elsewhere in this Agreement, including if applicable Section 5.3. In addition, Sections 2.3(a), 2.4(b), (d) and (e), 4.6, 6.2, 6.3, Articles 7, 8 9, 10, 12 and 13, Sections 14.4 and 14.5 and Article 15
shall survive the expiry or any early termination of this Agreement for any reason. 
 15. MISCELLANEOUS 

15.1 Governing Laws. This Agreement and any dispute arising from the construction, performance or breach hereof shall be governed
by and construed, and enforced in accordance with, the laws of England and Wales, without reference to conflicts of laws principles. 

15.2 Arbitration. 

(a) The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related
to this Agreement or the breach thereof If the Parties do, not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not an Excluded Claim (as defined below) shall be finally resolved by binding
arbitration conducted under the commercial arbitration rules of the International Chamber of Commerce (the “ICC Rules”), and judgment on the arbitration award may be entered in any court having jurisdiction thereof Evidentiary
questions shall be governed by the International Bar Association (“IBA”) Rules on the Taking of Evidence in International Arbitration then in effect. 

(b) The arbitration shall be conducted by a panel of three persons experienced in the pharmaceutical business: within thirty (30) days
after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within thirty (30) days of their appointment. If the arbitrators selected by the
Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed in accordance with the ICC Rules. The place of arbitration shall be London, England, and all proceedings and communications shall be in English.

 (c) Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is
otherwise resolved. Either Party also may,. without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the
arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages. Unless the arbitral tribunal decides otherwise based on the merits of the case, each Party
shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any administrative fees of arbitration. 

(d) Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose the
existence, content, or results of an arbitration without the prior written consent of both Parties. 

  
 23 

 (e) The Parties agree that any payments made pursuant to this Agreement pending resolution of
the dispute shall be refunded if the arbitral tribunal determines that such payments are not due. 
 (f) As used in this Section, the term
“Excluded Claim” means a dispute, controversy or claim that concerns (i) the scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or copyright; or (ii) any antitrust,
anti-monopoly or competition law or regulation, whether or not statutory. 
 15.3 Waiver. It is agreed that no waiver by either
Party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default. 

15.4 Assignment. This Agreement shall not be assignable by either Party to any Third Party hereto without the written consent of
the other Party hereto, and any attempted assignment shall be null and void. Notwithstanding the foregoing, each Party may assign this Agreement without consent in the event of an assignment to an entity that acquires all or substantially all of the
business or assets of such Party to which this Agreement pertains, whether by merger, reorganization, acquisition, sale, or otherwise. This Agreement shall be binding upon and accrue to the benefit of any permitted assignee, and any such assignee
shall agree to perform the obligations of the assignor. 
 15.5 Independent Contractors. The relationship of the Parties
hereto is that of independent contractors. The Parties hereto are not deemed to be agents, partners or joint venturers of the other for any purpose as a result of this Agreement or the transactions contemplated thereby. 

15.6 Compliance with Laws. In exercising their rights under this Agreement, the Parties shall fully comply in all material
respects with the requirements of any and all applicable laws, regulations applicable to each Party’s performance of this Agreement. 

15.7 Notices. All notices, requests and other communications hereunder shall he in writing and shall be delivered personally or
by registered or certified mail, return receipt requested, postage prepaid, or by internationally recognized express courier service, in each case to the respective address specified below, or such other address as may be specified in writing to the
other Party hereto and shall be deemed to have been given upon receipt: 
  

					
		 	If to Audentes:	  	 AUDENTES
 101 Montgomery Street Suite 2650

San Francisco
 CA 94104

USA
 Attn: CEO

			
		 	If to Genethon:	  	 GENETHON
 1bis rue de l’Internationale

91002 Evry
 France

Attn: Directeur Général

  
 24 

 15.8 Severability. Each Party hereby agrees that it does not intend to violate any
public policy, statutory or common laws, rules, regulations, treaty or decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become
invalid, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid provisions which valid provisions in their economic effect are sufficiently similar to the invalid provisions that it can be reasonably assumed that
the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalidity of one or several provisions of its Agreement shall not affect the validity of this Agreement as a
whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provisions. 

15.9 Advice of Counsel. Genethon and Audentes have each consulted counsel of their choice regarding this Agreement, and each
acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly. 

15.10 Complete Agreement. This Agreement, together with its Exhibits (including the Common Stock Purchase Agreement (SPA)
attached hereto as Exhibit C) and the Development Plan as such is to be finalized and updated in accordance with Section 2.2, constitutes the entire agreement, both written and oral, between the Parties with respect to the subject matter
hereof, and all prior agreements respecting the subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are null and void and of no effect. No amendment or change hereof or addition hereto shall be
effective or binding on either of the Parties hereto unless reduced to writing and executed by the respective duly authorized representatives of Genethon and Audentes. 

15.11 Headings. The captions to the several Sections hereof are not a part of this Agreement, but are included merely for
convenience of reference and shall not affect its meaning or interpretation. 
 15.12 Counterparts. This Agreement may
be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. 

[SIGNATURE PAGE FOLLOWS] 

  
 25 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their
authorized representatives and delivered in duplicate originals as of the Effective Date. 
  

									
	AUDENTES THERAPEUTICS, INC.	 		 	GENETHON
					
	By:	 	/s/ Matthew Patterson	 		 	By:	 	/s/ Frederic Revah
	Name:	 	Matthew Patterson	 		 	Name:	 	FREDERIC REVAH
	Title:	 	Chief Executive Officer	 		 	Title:	 	CEO

 EXHIBIT A 

Genethon Research Program Activities 

1. Scientific collaboration related to pre-clinical and clinical development of the Product (Principal Investigator: [*], Ph.D.). This may
include laboratory work according to the Development Plan and agreed to by the JDC. 
 2. Manufacturing of the Product. This is anticipated
to be performed with Genethon’s existing manufacturing process producing AAV8/MTM1 and will be performed according to the Development Plan and agreed to by the JDC: 

3. Management of interactions with and submissions to regulatory authorities in France with the goal of establishing clinical investigational
site in France. This work will be performed according to the Development Plan and agreed to by the JDC. 
  

  

					
		  		  	*Confidential Treatment Requested.

 EXHIBIT B 

[*] 
  

  

					
		  		  	*Confidential Treatment Requested.

 EXHIBIT C 

Common Stock Purchase Agreement 

 AUDENTES THERAPEUTICS, INC. 

COMMON STOCK PURCHASE AGREEMENT 

This Agreement is made and entered into as of January 24, 2014 (the “Effective Date”) by and between Audentes
Therapeutics, Inc. (the “Company”), a Delaware corporation, and Genethon, a French non-profit organization organized under the French law of July 1, 1901 (the “Purchaser”). 

1. PURCHASE OF SHARES. On the Effective Date and subject to the terms and conditions of this Agreement and that certain
Collaborative Development Agreement, dated as of January 24, 2014 by and between the Company and Purchaser (the “Development Agreement”), Purchaser hereby purchases from the Company, and Company hereby sells to Purchaser, an aggregate
of 585,084 shares of the Company’s Common Stock, $0.00001 par value per share (the “Shares”). Purchaser and the Company each hereby acknowledge and agree that the Shares are being sold and issued to Purchaser pursuant to the
terms of Section 5.1 of the Development Agreement in exchange for Purchaser’s agreements and obligations set forth in the Development Agreement. As used in this Agreement, the term “Shares” refers to the Shares purchased under
this Agreement and includes all securities received (a) in substitution of the Shares, (b) as a result of stock dividends or stock splits with respect to the Shares, or as a result of the issuance of additional Common Stock to Purchaser
pursuant to Section 3.3 below, and (c) in replacement of the Shares in a merger, recapitalization, reorganization or similar corporate transaction. 

2. CLOSING. Purchaser hereby delivers to the Company a duly executed copy of this Agreement. Upon its receipt of a duly executed
copy of this Agreement and the Development Agreement from Purchaser, the Company will issue a duly executed stock certificate evidencing the Shares in the name of Purchaser, registered in Purchaser’s name. 

3. REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF COMPANY. 

3.1 Capitalization. The Company represents and warrants that the capitalization table attached at
Exhibit A is true, accurate and fairly summarizes the current capitalization of the Company, as of the Effective Date and after giving effect to the purchase of the Shares by Purchaser. The Second Closing, as defined in Section 1.2.3 of certain
Series A Preferred Stock Purchase Agreement dated July 16, 2013 (the “Series A Agreement”), was consummated on December 20, 2013. Apart from the foregoing, there have not been any other. material changes to the
Company’s capitalization as set forth in Section 2.3 of the Series A Agreement. 
 3.2 No Material
Adverse Change. The Company represents and warrants to Purchaser that there has not been any material adverse change in the Company’s business, assets (tangible and intangible), liabilities or financial condition, in comparison to the
representations, warranties and disclosures made by the Company to certain investors on July 16, 2013 pursuant to the Series A Agreement. 

 3.3 Delivery of Financial Statements; Registration Rights. 

(a) The Company shall deliver to Purchaser such financial information as the Company delivers to Major Investors pursuant to
Section 2.1.1 of that certain Amended and Restated Investors’ Rights Agreement dated as of July 16, 2013, by and among the Company and certain stockholders, as may be amended (the “Rights Agreement”), subject
to compliance by Purchaser with the provisions of Section 2.3 of the Rights Agreement. 
 (b) In addition, the Company agrees that
Shares shall be considered “Registrable Securities” under the Rights Agreement for purposes of the registration rights described in Section 3 of the Rights Agreement, and the Company shall, as the next practicable interval, cause the
Rights Agreement to be amended to the extent necessary to reflect the agreement described in this sentence. 
 3.4 Anti-Dilution
Right. If prior to the earlier of (a) the date the Company has sold additional shares of Preferred Stock (other than the Series A Preferred Stock that may be issued at additional closings under the Series A Agreement) with an aggregate
purchase price of at least [*] and (b) [*] after the Effective Date, the Company issues “Additional Shares of Common Stock” (as such term is defined in the Company’s currently-effective Amended and Restated Certificate of
Incorporation, as may be amended (the “Restated Charter”)) and such issuance results in an adjustment to the “Conversion Price” (as defined in the Restated Charter) of the Company’s Series A Preferred Stock
pursuant to Section 5.1.3 of the Restated Charter, then promptly following such issuance, the Company shall issue to the Purchaser, without additional consideration, a number of additional shares of Common Stock of the Company equal to the
number of shares of Common Stock by which the Purchaser’s holdings would have increased, on an as-converted basis, pursuant to Section 5.1.3 of the Restated Charter if, in lieu of the Shares, the Purchaser held an 585,084 shares of Series
A Preferred Stock of the Company (as adjusted for any stock dividends or stock splits following the Effective Date). 
 4.
REPRESENTATIONS AND WARRANTIES OF PURCHASER. Purchaser hereby represents and warrants to the Company as follows. 
 4.1
Purchase for Own Account for Investment. Purchaser is purchasing the Shares for Purchaser’s own account for investment purposes only and not with a view to or for sale in connection with, a distribution of the Shares within the
meaning of the Securities Act of 1933, as amended (the “1933 Act”). Purchaser has no present intention of selling or otherwise disposing of all or any portion of the Shares and no one other than Purchaser has
any beneficial ownership of any of the Shares. 
 4.2 Access to Information. Purchaser has had access to all information
regarding the Company and its present and prospective business, assets, liabilities and financial condition that Purchaser reasonably considers important in making the decision to purchase the Shares, and Purchaser has had ample opportunity to ask
questions of the Company’s representatives concerning such matters and this investment. 

  

					
		  	2	  	*Confidential Treatment Requested.

 4.3 Understanding of Risks. Purchaser is fully aware of: (a) the highly
speculative nature of the investment in the Shares; (b) the financial hazards involved; (c) the lack of liquidity of the Shares and the restrictions on transferability of the Shares (e.g., that Purchaser may not be able to sell or dispose
of the Shares or use them as collateral for loans); (d) the qualifications and backgrounds of the management of the Company; and (e) the tax consequences of investment in the Shares. 

4.4 Purchaser’s Qualifications. Purchaser has a preexisting personal or business relationship with the Company and/or
certain of its officers and/or directors of a nature and duration sufficient to make Purchaser aware of the character, business acumen and general business and financial circumstances of the Company and/or such officers and directors. By reason of
Purchaser’s business or financial experience, Purchaser is capable of evaluating the merits and risks of this investment, has the ability to protect Purchaser’s own interests in this transaction and is financially capable of bearing a
total loss of this investment. 
 4.5 No General Solicitation. At no time was Purchaser presented with or solicited by
any publicly issued or circulated newspaper, mail, radio, television or other form of general advertising or solicitation in connection with the offer, sale and purchase of the Shares. 

4.6 Compliance with Securities Laws. Purchaser understands and acknowledges that, in reliance upon the representations and
warranties made by Purchaser herein, the Shares are not being registered with the Securities and Exchange Commission (“SEC”) under the 1933 Act. but instead are being issued under an exemption or exemptions from
the registration and qualification requirements of the 1933 Act and applicable state securities laws which impose certain restrictions on Purchaser’s ability to transfer the Shares. 

4.7 Restrictions on Transfer. Purchaser understands that Purchaser may not transfer any Shares unless such Shares are registered
under the 1933 Act and registered or qualified under applicable state securities laws or unless, in the opinion of counsel to the Company, exemptions from such registration and qualification requirements are available. Purchaser understands that
only the Company may file a registration statement with the SEC or applicable state securities commissioners and that the Company is under no obligation to do so with respect to the Shares. Purchaser has also been advised that exemptions from
registration and qualification may not be available or may not permit Purchaser to transfer all or any of the Shares in the amounts or at the times proposed by Purchaser. 

4.8 Regulation S. 

(a) Purchaser is not a U.S. Person as defined in Rule 902(k) of Regulation S under the 1933 Act. The offer and sale of the Shares to such
Purchaser was made in an offshore transaction (as defined in Rule 902(h) of Regulation S), no directed selling efforts (as defined in Rule 902(c) of Regulation S) were made in the United States, and the Purchaser is not acquiring the Shares for the
account or benefit of any U.S. Person. 
 (b) Purchaser will not, during the Restricted Period applicable to the Shares set
forth in the legend set forth in Section 9.1 below (the “Restricted Period”) and to any certificate representing the Shares, offer or sell any of the foregoing securities (or create or maintain any derivative position
equivalent thereto) in the United States, to or for the account or benefit of a U.S. Person or other than in accordance with Regulation S. 

  
 3 

 (c) Purchaser will after the expiration of the applicable Restricted Period, offer, sell, pledge
or otherwise transfer the Shares (or create or maintain any derivative position equivalent thereto) only pursuant to registration under the 1933 Act or any available exemption therefrom and, in any case, in accordance with applicable state
securities laws. 
 (d) Purchaser acknowledges and agrees that the Company shall not register the transfer of the Shares in violation of
these restrictions. Purchaser acknowledges and agrees that the certificates evidencing the Shares will bear the legend concerning these restrictions set forth in Section 9.1 below (in addition to any other legend required by applicable federal,
state or foreign securities laws or provided in any other agreement with the Company). 
 5. MARKET STANDOFF AGREEMENT.
Purchaser agrees in connection with any registration of the Company’s securities under the 1933 Act that, upon the request of the Company or the underwriters managing any registered public offering of the Company’s securities, Purchaser
will not sell or otherwise dispose of any Shares without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days) after the effective date of such
registration requested by such managing underwriters and subject to all restrictions as the Company or the managing underwriters may specify for employee-shareholders generally. Purchaser further agrees to enter into any agreement reasonably
required by the underwriters to implement the foregoing and that such underwriters are express third party beneficiaries of this Section 4. 

6. RIGHT OF FIRST REFUSAL. Before any Shares held by Purchaser or any transferee of such Shares (either sometimes referred to
herein as the “Holder”) may be sold or otherwise transferred (including without limitation a transfer by gift or operation of law), the Company and/or its assignee(s) will have a right of first refusal to purchase the Shares to be sold or
transferred (the “Offered Shares”) on the terms and conditions set forth in this Section (the “Right of First Refusal”). 

6.1 Notice of Proposed Transfer. The Holder of the Offered Shares will deliver to the Company a written notice (the
“Notice”) stating: (a) the Holder’s bona fide intention to sell or otherwise transfer the Offered Shares; (b) the name and address of each proposed purchaser or other transferee (the
“Proposed Transferee”); (c) the number of Offered Shares to be transferred to each Proposed Transferee; (d) the bona fide cash price or other consideration for which the Holder proposes to transfer the
Offered Shares (the “Offered Price”); and (e) that the Holder acknowledges this Notice is an offer to sell the Offered Shares to the Company and/or its assignee(s) pursuant to the Company’s
Right of First Refusal at the Offered Price as provided for in this Agreement. 
 6.2 Exercise of Right of First
Refusal. At any time within thirty (30) days after the date of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all (or, with the consent of the Holder, less than all) the
Offered Shares proposed to be transferred to any one or more of the Proposed Transferees named in the Notice, at the purchase price determined in accordance with Section 5.3 below. 

  
 4 

 6.3 Purchase Price. The purchase price for the Offered Shares purchased under this
Section will be the Offered Price, provided that if the Offered Price consists of no legal consideration (as, for example, in the case of a transfer by gift), the purchase price will be the fair market value of the Offered Shares as determined in
good faith by the Company’s Board of Directors. If the Offered Price includes consideration other than cash, then the value of the non-cash consideration, as determined, in good faith by the Company’s Board of Directors, will conclusively
be deemed to be the cash equivalent value of such non-cash consideration. 
 6.4 Payment. Payment of the purchase price
for the Offered Shares will be payable, at the option of the Company and/or its assignee(s) (as applicable), by check or by cancellation of all or a portion of any outstanding indebtedness owed by the Holder to the Company (or to such assignee, in
the case of a purchase of Offered Shares by such assignee) or by any combination thereof The purchase price will be paid without interest within sixty (60) days after the Company’s receipt of the Notice, or, at the option of the Company
and/or its assignee(s), in the manner and at the time(s) set forth in the Notice. 
 6.5 Holder’s Right to
Transfer. If all of the Offered Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section, then the Holder may sell or otherwise
transfer such Offered Shares to each Proposed Transferee at the Offered Price or at a higher price, provided that (a) such sale or other transfer is consummated within [*] after the date of the Notice, (b) any such, sale or other transfer
is effected in compliance with all applicable securities laws, and (c) each Proposed Transferee agrees in writing that the provisions of this Section will continue to apply to the Offered Shares in the hands of such Proposed Transferee. If the
Offered Shares described in the Notice are not transferred to each Proposed Transferee within such [*] period, then a new Notice must be given to the Company, pursuant to which the Company will again be offered the Right of First Refusal before any
Shares held by the Holder may be sold or otherwise transferred. 
 6.6 Exempt Transfers. Notwithstanding anything to the
contrary in this Section, the following transfers of Shares will be exempt from the Right of First Refusal: (a) in the case of a Holder that is an entity, the transfer of any or all of the Shares to its stockholders, members, partners or other
equity holders; (b) in the case of a Holder who is a natural person, the transfer of any or all of the Shares during Holder’s lifetime by gift or on Holder’s death by will or intestacy to Holder’s “Immediate Family” (as
defined below) or to a trust for the benefit of Holder or Holder’s Immediate Family, provided, that in the case of clauses (a) and (b), each transferee or other recipient agrees in a writing satisfactory to the Company that the provisions
of this Section will continue to apply to the transferred Shares in the hands of such transferee or other recipient); (c) except as provided in Section 6.7 clause (b) below, any transfer or conversion of Shares made pursuant to a
statutory merger or statutory consolidation of the Company with or into another corporation or corporations; or (d) any transfer of Shares pursuant to the winding up and dissolution of the Company. As used herein, the term
“Immediate Family” will mean Holder’s spouse or Spousal Equivalent, the lineal descendant or antecedent, brother or sister, of Holder or Holder’s spouse or Spousal Equivalent, or the spouse or
Spousal Equivalent, of any lineal descendant or antecedent, brother or sister of Holder, or Holder’s spouse or Spousal Equivalent, whether or not any of the above are adopted. As used herein, a person is deemed to be a “Spousal
Equivalent” if the relevant person and the related party are registered as “domestic partners” under any law having such effect or provided the following circumstances are true: (a) irrespective of whether or not the relevant
person and the  
  

  

					
		  	5	  	*Confidential Treatment Requested.

 
Spousal Equivalent are the same sex, they are the sole spousal equivalent of the other for the last twelve (12) months, (b) they intend to remain so indefinitely, (c) neither are
married to anyone else, (d) both arc at least eighteen (18) years of age and mentally competent to consent to contract, (e) they are not related by blood to a degree of closeness that which would prohibit legal marriage in the state
in which they legally reside, (f) they are jointly responsible for each other’s common welfare and financial obligations, and (g) they reside together in the same residence for the last twelve (12) months and intend to do so
indefinitely. 
 6.7 Termination of Right of First Refusal. The Right of First Refusal will terminate as to all Shares
(a) on the effective date of the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the SEC under the 1933 Act (other than a registration statement relating
solely to the issuance of Common Stock pursuant to a business combination or an employee incentive or benefit plan) or (b) on any transfer or conversion of Shares made pursuant to a statutory merger or statutory consolidation of the Company
with or into another corporation or corporations if the common stock of the surviving corporation or any direct or indirect parent corporation thereof is registered under the Securities Exchange Act of 1934, as amended. 

7. COMPANY’S REPURCHASE OPTION. 

7.1 Repurchase Option; Termination Date. The Company or its assignees shall have the option to repurchase all or a portion of the
Unvested Shares (defined in Section 6.2 below) on the terms and conditions set forth in this Section (the “Repurchase Option”) if (i) the Development Agreement is no longer in effect in
accordance with its terms or (ii) if Genethon ceases to perform its obligations thereunder ((i) or (ii), the “Termination Date”). 

7.2 Unvested and Vested Shares. 

7.2.1 Vesting Schedule. Shares that are vested pursuant to the schedule set forth herein are “Vested
Shares”. Shares that are not vested pursuant to the schedule set forth herein are “Unvested Shares.” Unvested Shares may not be sold or otherwise transferred by Purchaser without the Company’s prior written
consent. On the Effective Date one-third (1/3rd) of the Shares will be Vested Shares and the remaining two-third (2/3rds) of the Shares will be Unvested Shares. If the Development Agreement remains in effect in accordance with its terms
and Genethon continues to perform its obligations thereunder, at all times since the Effective Date, then on each of the first and second annual anniversary dates of the effective date of the Development Agreement, an additional one-third
(1/3rd) of the Shares will become Vested Shares. No Unvested Shares will become Vested Shares after the Termination Date. 
 7.2.2
Acceleration of Vesting. In addition to any Shares that have become Vested Shares pursuant to Section 6.2.1 hereof, if there is a Change of Control or an IPO then, effective as of such Change of Control or IPO, 100% of the Shares
will become Vested Shares at such time. 

  
 6 

 As used in this Section 7.2.2: 

“Change of Control” means (a) any transaction or series of related transactions resulting in a
liquidation, dissolution or winding up of the Company, (b) a sale of all or substantially all of the assets of the Company, (c) any sale or exchange of the capital stock of the Company by the stockholders of the Company in one transaction
or a series of related transactions where more than fifty percent (50%) of the outstanding voting power of the Company is acquired by a person or entity or group of related persons or entities (other than pursuant to a recapitalization of the
Company solely with its equity holders) or (d) any merger or consolidation (each, a “combination transaction”), in which the Company is a constituent entity or is a party with another entity if, as a result of such
combination transaction, in one transaction or series of related transactions, the voting securities of the Company that are outstanding immediately prior to the consummation of such combination transaction (other than any such securities that are
held by an “Acquiring Stockholder,” as defined below) do not represent, or are not converted into, securities of the surviving entity in such combination transaction (or such surviving entity’s parent entity if the surviving entity is
owned by the parent) that, immediately after the consummation of such combination transaction, together possess at least a majority of the total voting power of all voting securities of such surviving entity (or its parent, if applicable) that are
outstanding immediately after the consummation of such combination transaction, including securities of such surviving entity (or its parent, if applicable) that are held by the Acquiring Stockholder. For purposes of this paragraph, an
“Acquiring Stockholder” means a stockholder or stockholders of the Company that (i) merges or combines with the Company in such combination transaction or (ii) directly or indirectly owns or controls a majority
of the voting power of another entity that merges or combines with the Company in such combination transaction. 

“IPO” means the sale of shares of Common Stock to the public in a firm-commitment underwritten public
offering pursuant to an effective registration statement under the Securities Act. 
 7.3 Adjustments. The
number of Shares that are Vested Shares or Unvested Shares will be proportionally adjusted to reflect any stock dividend, stock split, reverse stock split or recapitalization of the common stock of the Company occurring after the
Effective Date. 
 7.4 Exercise of Repurchase Option. At any time within [*] after the Termination Date, the
Company may elect to repurchase any or all of the Unvested Shares by giving Purchaser written notice of exercise of the Repurchase Option. The Company and/or its assignee(s) will then have the option to repurchase from Purchaser (or from
Purchaser’s personal representative as the case may be) any or all of the Unvested Shares at a purchase price of $0.00001 per share, as adjusted to reflect any stock dividend, stock split, reverse stock split or recapitalization of the common
stock of the Company occurring after the Effective Date (the “Repurchase Price”). 
 7.5 Payment of Repurchase Price.
The Repurchase Price will be payable, at the option of the Company or its assignee(s), by check or by cancellation of all or a portion of any outstanding indebtedness owed by Purchaser to the Company (or to such assignee) or by any combination
thereof, The Repurchase Price will be paid without interest within [*] after the Company gives the Purchaser written notice of the exercise of its Repurchase Option. 

7.6 Right of Termination Unaffected. Nothing in this Agreement will be construed to limit or otherwise affect in any manner
whatsoever the right or power of the Company to terminate the Development Agreement in accordance with its terms. 
  

  

					
		  	7	  	*Confidential Treatment Requested.

 8. RIGHTS AS OWNER OF SHARES. 

8.1 Encumbrances on Shares. Purchaser may grant a lien or security interest in, or pledge, hypothecate or encumber Shares only if
each party to whom such lien or security interest is granted, or to whom such pledge, hypothecation or other encumbrance is made, agrees in a writing satisfactory to the Company that (a) such lien, security interest, pledge, hypothecation or
encumbrance will not apply to such Shares after they are acquired by the Company and/or its assignees under this Section; and (b) the provisions of this Section will continue to apply to such Shares in the hands of such party and any transferee
of such party. 
 8.2 Encumbrance on Shares. Subject to the terms and conditions of this Agreement, Purchaser will have
all of the rights to the Shares from and after the date that Purchaser delivers payment of the Purchase Price until such time as Purchaser disposes of the Shares or the Company and/or its assignee(s) exercise(s) the Right of First Refusal or
Repurchase Option. Upon an exercise of the Right of First Refusal or Repurchase Option, Purchaser will have no further rights as a holder of the Shares so purchased upon such exercise, except the right to receive payment for the Shares so purchased
in accordance with the provisions of this Agreement, and Purchaser will promptly surrender the stock certificate(s) evidencing the Shares so purchased to the Company for transfer or cancellation. 

9. TAX CONSEQUENCES. PURCHASER UNDERSTANDS THAT PURCHASER MAY SUFFER ADVERSE TAX CONSEQUENCES AS A RESULT OF PURCHASER’S
PURCHASE OR DISPOSITION OF THE SHARES. PURCHASER REPRESENTS` (a) THAT PURCHASER HAS CONSULTED WITH A TAX ADVISER THAT PURCHASER DEEMS ADVISABLE IN CONNECTION WITH THE PURCHASE OR DISPOSITION OF THE SHARES AND (b) THAT PURCHASER IS NOT
RELYING ON THE COMPANY FOR ANY TAX ADVICE. Purchaser hereby acknowledges that Purchaser has been informed that in addition to receiving taxable income upon the receipt of any Shares paid for by the cancellation of compensation for services rendered,
unless an election is filed by the Purchaser with the Internal Revenue Service (and, if necessary, the proper state taxing authorities) within 30 days after the purchase of the Shares to be effective, electing pursuant to Section 83(b)
of the Internal Revenue Code (and similar state tax provisions, if applicable) to be taxed currently on any difference between the purchase price of the Shares and their fair market value on the date of purchase, there will be a recognition of
taxable income to the Purchaser, measured by the excess, if any, of the fair market value of the Shares, at the time they cease to be Unvested Shares, over the purchase price for such Shares. Purchaser represents that Purchaser has consulted any tax
advisors Purchaser deems advisable in connection with Purchaser’s purchase of the Shares and the filing of the election under Section 83(b) and similar tax provisions. PURCHASER HEREBY ASSUMES ALL RESPONSIBILITY FOR FILING SUCH ELECTION
AND PAYING ANY TAXES RESULTING FROM SUCH ELECTION OR FROM FAILURE 70 PILE THE ELECTION AND PAYING TAXES RESULTING FROM THE LAPSE OF THE REPURCHASE RESTRICTIONS ON THE UNVESTED SHARES. 

  
 8 

 10. RESTRICTIVE LEGENDS AND STOP-TRANSFER ORDERS. 

10.1 Legends. Purchaser understands and agrees that the Company will place the legends set forth below or similar legends on any
stock certificate(s) evidencing the Shares, together with any other legends that may be required by state or federal securities laws, the Company’s Certificate of Incorporation or Bylaws, any other agreement between Purchaser and the Company or
any third party: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER 7’HE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT’) WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION, AND THE COMPANY DOES NOT INTEND TO REGISTER THEM. PRIOR TO JANUARY 31, 2015, THE SHARES MAY NOT BE OFFERED OR SOLD (INCLUDING OPENING A SHORT POSITION IN SUCH
SECURITIES) IN THE UNITED STATES OR TO U.S. PERSONS AS DEFINED BY RULE 902(k) ADOPTED UNDER THE ACT, OTHER THAN TO DISTRIBUTORS UNLESS THE SHARES ARE REGISTERED UNDER THE ACT OR AN EXEMPTION FROM TILE REGISTRATION REQUIREMENTS OF THE ACT IS
AVAILABLE. PURCHASERS OF SHARES PRIOR TO JANUARY 31, 2015, MAY RESELL SUCH SECURITIES ONLY PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT OR OTHERWISE IN ACCORDANCE WITH THE PROVISIONS OF REGULATIONS OF THE ACT OR IN TRANSACTIONS EFFECTED
OUTSIDE OF THE UNITED STATES PROVIDED THEY DO NOT SOLICIT (AND NO ONE ACTING ON THEIR BEHALF SOLICITS) PURCHASERS IN THE UNITED STATES OR OTHERWISE ENGAGE(S) IN SELLING EFFORTS IN THE UNITED STATES AND PROVIDED THAT HEDGING TRANSACTIONS IN
7’HESE SECURITIES ,WAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT. A HOLDER OF THE SECURITIES WHO IS A DISTRIBUTOR, DEALER, SUB-UNDERWRITER OR OTHER SECURITIES PROFESSIONAL IN ADDITION CANNOT PRIOR TO JANUARY 31, 2015 RESELL THE
SECURITIES TO A US PERSON AS DEFINED BY RULE 902(k) OF REGULATION S UNLESS THE SECURITIES ARE REGISTERED UNDER THE ACT OR AN EXEMPTION FROM REGISTRATION UNDER THE ACT IS AVAILABLE THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF
THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND
ANY APPLICABLE STATE SECURITIES LAWS. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON PUBLIC RESALE AND
TRANSFER, INCLUDING THE RIGHTS OF REPURCHASE AND FIRST REFUSAL HELD BY THE ISSUER AND/OR ITS ASSIGNEE(S), AND A MARKET STANDOFF RESTRICTION, AS SET FORTH IN A COMMON STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE
SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF 77IE ISSUER. SUCH PUBLIC SALE AND TRANSFER RESTRICTIONS INCLUDING THE RIGHTS OF REPURCHASE AND FIRST REFUS.4L AND THE MARKET STANDOFF RESTRICTION, ARE BINDING ON TRANSFEREES OF THESE
SHARES. 

  
 9 

 10.2 Stop-Transfer Instructions. Purchaser agrees that, to ensure compliance with
the restrictions imposed by this Agreement, the Company may issue appropriate “stop-transfer” instructions to its transfer agent, if any, and if the Company transfers its own securities, it may make appropriate notations to the same effect
in its own records. The Company will not be required (a) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (b) to treat as owner of such Shares, or
to accord the right to vote or pay dividends, to any purchaser or other transferee to whom such Shares have been so transferred. 

11. COMPLIANCE WITH LAWS AND REGULATIONS. The issuance and transfer of the Shares will be subject to and conditioned upon,
compliance by the Company and Purchaser with all applicable state and federal laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company’s Common Stock may be listed or
quoted at the time of such issuance or transfer. 
 12. GENERAL PROVISIONS. 

12.1 Notices. Any and all notices required or permitted to be given to a party pursuant to the provisions of this Agreement will
be in writing and will be effective and deemed to provide such party sufficient notice under this Agreement on the earliest of the following: (a) at the time of personal delivery, if delivery is in person; (b) one (1) business
day after deposit with an express overnight courier for United States deliveries, or two (2) business days after such deposit for deliveries outside of the United States; or (c) three (3) business days after deposit in the United
States mail by certified mail (return receipt requested) for United States deliveries. All notices for delivery outside the United States will be sent by express courier. All notices not delivered personally will be sent with postage and/or other
charges prepaid and properly addressed to the party to be notified at the address set forth below the signature lines of this Agreement or at such other address as such other party may designate by one of the indicated -means of notice herein to the
other party hereto. A “business day” shall be a day, other than Saturday or Sunday, when the banks in the city of San Francisco are open for business. 

12.2 Further Assurances. The parties agree to execute such further documents and instruments and to take such further actions as
may be reasonably necessary to carry out the purposes and intent of this Agreement. 
 12.3 Titles and Headings. The
titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references herein to “sections” and
“exhibits” will mean “sections” and “exhibits” to this Agreement. 
 12.4 Governing Law.
This Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to that body of laws pertaining to conflict of, laws. 

  
 10 

 12.5 Assignments; Successors and Assigns. The Company may assign any of its rights
and obligations under this Agreement, including but not limited to its rights to repurchase Shares under the Right of First Refusal and the Repurchase Option. Any assignment of rights and obligations by any other party to this Agreement requires the
Company’s prior written consent. This Agreement, and the rights and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal
representatives. 
 12.6 Entire Agreement. This Agreement and the documents referred to herein constitute the entire
agreement and understanding of the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements, whether oral or written, between or among the parties hereto with respect to the specific subject
matter hereof. 
 12.7 Amendment and Waivers. This Agreement may be amended only by a written agreement executed by
each of the parties hereto. No amendment of or waiver of, or modification of any obligation under this Agreement will be enforceable unless set forth in a writing signed by the party against which enforcement is sought. Any amendment effected in
accordance with this section will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of this Agreement shall constitute a waiver of that provision as to
that or any other instance. No waiver granted under this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the waiver of any performance other
than the actual performance specifically waived. 
 12.8 Severability. If any provision of this Agreement is determined
by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be
so enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been contained in this
Agreement Notwithstanding the forgoing, if the value of this Agreement, based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by the presiding court or arbitrator of competent
jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations. 
 12.9
Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same
agreement. This Agreement may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 

[SIGNATURE PAGE FOLLOWS] 

  
 11 

 IN WITNESS WHEREOF, the Company has caused this Common Stock Purchase Agreement to be executed by
its duly authorized representative and Purchaser has executed this Agreement, each as of the Effective Date. 
  

									
	 “COMPANY”
  

AUDENTES THERAPEUTICS, INC.
	 		 	 “PURCHASER”
  

GENETHON

					
	By:	 	/s/ Matthew Patterson	 		 	By:	 	/s/ Frederic Revah
	Name:	 	Matthew Patterson	 		 	Name:	 	FREDERIC REVAH
	Title:	 	Chief Executive Officer	 		 	Title:	 	CEO
					
	Address:	 	 101 Montgomery St., Suite 2650
 San Francisco,
CA 94104
	 		 	Address:	 	 1bis, rue de l’Internationale – 91000 EVRY

Tél. 33 (0)1 69 47 25 71 – Fax 33 (0)1 60 77 86 98

 Exhibit A 

Capitalization 
 AUDENTES THERAPEUTICS,
INC.—PRO FORMA CAPITALIZATION 
  

															
	 Name
	  	Common	 	Series Seed	 	Series A
(Current).	 	Series A
(Final
Milestone)	 	Total	 	$ Total
Post-
Genethon	 
	 Investor Group
	  	[*]	 	[*]	 	[*]	 	[*]	 	[*]	 	 	[	*]% 
	 Management Team and Other Common Holders
	  	[*]	 	—  	 	—  	 		 	[*]	 	 	[	*]% 
	 Genethon
	  	[*]	 	—  	 	—  	 		 	[*]	 	 	[	*]% 
	 Subtotals
	  	[*]	 	[*]	 	[*]	 	[*]	 	[*]	 			
	 2012 Plan Options Outstanding
	  	[*]	 	—  	 	.—  	 	—  	 	[*]	 	 	[	*]% 
	 2012 Plan Options Available
	  	[*]	 	—  	 	—  	 		 	[*]	 	 	[	*]% 
	 Totals
	  	[*]	 	[*]	 	[*]	 	[*]	 	[*]	 	 	[	*]% 

  

					
		  		  	*Confidential Treatment Requested.

 EXHIBIT D 

Genethon Background Patent Rights 

As of the Effective date of this Agreement the Genethon Background Patent Rights comprise: 

 

	 	1.	Background Patent 1: [*] 

  

	 	2.	Background Patent 2: [*] 

  

	 	3.	Background Patent 3: [*] 

  

  

					
		  		  	*Confidential Treatment Requested.

 EXHIBIT E 

HHS — Form of Sublicense Agreement 

 SUBLICENSE AGREEMENT 

This SUBLICENSE AGREEMENT (this “Agreement”), effective as of [•], 201[•] (the “Sublicense Effective
Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104 (“Audentes”) and Genethon, a French non-profit
organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”). 

Audentes and Genethon are each individually referred to herein as a “Party” and collectively as the
“Parties”. 
 BACKGROUND 

A. Genethon and the United States Department of Health and Human Services (“HHS” or “PHS”) entered
into that certain Patent License Agreement dated effective June 22, 2012 (the “HHS Patent License Agreement”), a copy of which has been provided to Audentes subject to confidentiality obligations. 

B. The Parties entered into that certain Collaborative Development Agreement dated January 24, 2014 (the “Collaborative
Development Agreement”), whereby, among other things, Genethon granted to Audentes licenses under its Background Intellectual Property, including an option (set out in section 4.1(a)(iii) thereof) to obtain, subject to certain conditions
including the approval by PHS of the sublicense agreement, a sublicense under the HHS Patent License Agreement to make, develop and commercialize a certain Product (as defined in the Collaborative Development Agreement). 

C. Audentes has exercised its option to obtain said sublicense, and Genethon is willing to grant the sublicense on the terms and conditions
hereof 
 D. PHS has approved this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, the Parties covenant and agree as follows: 

1. DEFINITIONS 
 As
used herein, the following terms will have the meanings set forth below: 
 “Affiliate” shall have the meaning attributed
thereto in the HHS Patent License Agreement, for this purpose treating Audentes as if it were the “Licensee” referred to in such definition in the HHS Patent License Agreement. 

“Licensed Patent Rights” shall have the meaning attributed thereto in the HHS Patent License Agreement. 

 “Licensed Processes” shall mean processes, which in the course of being
practiced, would be within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction 

“Licensed Products” shall mean any Product which in the course of manufacture, use sale; or importation, would be
within the scope of one or more claims of the Licensed Patent Rights that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. For the avoidance of doubt, a Product
whose manufacture involves the practice of a Licensed Process shall be a Licensed Product. 
 “Licensed
Territory” shall mean worldwide. 
 “Net Sales” shall mean the total gross receipts for sales of
Licensed Products or practice of Licensed Processes by or on behalf of Audentes or its sublicensees, and from leasing, renting, or otherwise making Licensed Products available to others without sale or other dispositions, whether invoiced or not,
less returns or allowances, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in amounts customary in the trade to the extent actually granted.
For avoidance of doubt, transfers of Licensed Products by Audentes to an academic institution only in the context of a collaborative research or development agreement solely between Audentes and the academic institution will be excluded from the
calculation of Net Sales. No deductions shall be made for commissions paid to individuals, whether they are with independent sales agencies or regularly employed by Audentes, or sublicensees and on its payroll, or for the cost of collections.

 “Party” or “Parties” has the meaning set forth on the first page hereof. 

“Product” has the meaning attributed thereto in section 1.15 of the Collaborative Development Agreement. 

“Sublicense Effective Date” shall mean the date first above written as the effective date of this Agreement.

 All other capitalized terms not otherwise defined in this Article I or herein shall have the meanings assigned to them in the Collaborative
Development Agreement. 
 2. GRANT 

2.1 Sublicense Grant. Genethon hereby grants to Audentes a non-exclusive sublicense under the this Patent License Agreement to
the Licensed Patent Rights in the Licensed Territory, for the sole purpose of making, having made, using, importing, selling, offering for sale and otherwise discovering, researching, developing or commercializing Licensed Products following a
technology transfer under Section 2.4(b) or 2.4(c) of the Collaborative Development Agreement. 
 2.2 Sublicense
Conditions. Audentes acknowledges and agrees that Audentes’s rights in this Agreement are subject to the terms and conditions of the HHS Patent License Agreement. 

  
 2 

 In particular, and without limitation, in accordance with paragraph 4.2 thereof, Genethon’s
obligations to PHS set out in paragraphs 5.1, 7.1, 9.1, 9.2, 11, 12.4 and 13.6-13.7 of the HHS Patent License Agreement shall be binding upon Audentes as if Audentes were a party thereto (i.e., for the purposes hereof, Audentes shall be deemed to be
the “Licensee” referred to in these paragraphs). Copies of such paragraphs are set out in Exhibit A hereto. 
 2.3
Further Sublicenses. Audentes shall have the right to further sublicense the rights granted to Audentes hereunder subject to all the relevant terms and conditions of the HHS Patent License Agreement applicable to sublicensing, including
without limitation article 4 thereof. 
 2.4 No Implied Licenses. Only the license granted pursuant to the express terms
of this Agreement shall be of any legal force or effect. No other license or rights shall be created by implication, estoppel or otherwise. No license is granted to Audentes hereunder to manufacture, develop or commercialize any products other than
Product. 
 3. DEVELOPMENT 

3.1 Development Responsibility. As of the Sublicense Effective Date, Audentes shall assume responsibility for the development and
reporting obligations set out in paragraphs 9.1 through 9.3 and article 10 of the HHS Patent License Agreement, as such apply to the development and commercialization of Licensed Product. Audentes shall provide to Genethon a copy of all documents
provided to PHS pursuant to its obligations under paragraphs 9.1 through 9.3 of the HHS Patent License Agreement, and the same shall be Confidential Information to be protected as provided in article 9 of the Collaborative Development Agreement and
as described in paragraph 9.9 of the HHS Patent License Agreement. Genethon’s rights of termination under Section 5.3 hereof shall be the sole remedy for any breach by Audentes of the obligations set out in article 10 of the HHS Patent
License Agreement. 
 3.2 Audentes Compliance. Audentes represents and warrants that it shall comply with all applicable
laws, rules and regulations regarding the research, development, commercialization, marketing, manufacture, import, export and sale of Licensed Products in the Licensed Territory. Audentes shall not take any action or make any omission that it knows
will result in Genethon being in breach of its obligations under the HITS Patent License Agreement. 
 3.3 Affiliates,
Subcontractors and Sublicensees. To the extent Audentes performs certain of its obligations or exercises certain of its rights under this Agreement through Affiliates, subcontractors and/or sublicensees, Audentes shall remain directly
responsible to Genethon and if applicable HHS for the performance and compliance by all such Affiliates, subcontractors and/or sublicensees in accordance with the terms and conditions hereof, as is such obligations were performed or rights exercised
by Audentes. In the event of any dispute arising from the act or omission of an Affiliate, subcontractor and/or sublicensee under this Agreement, Genethon may proceed directly against Audentes, without any obligation to first proceed against the
Affiliate, subcontractor and/or sublicensee. 

  
 3 

 4. FINANCIAL TERMS 

In consideration for the sublicense rights granted under Section 2.1 hereof, Audentes shall make the following payments: 

4.1 Sublicense Fee. Audentes shall pay to Genethon a sublicense fee of [*] within [*] of the Sublicense Effective Date. 

4.2 Royalty Payments. Audentes shall pay directly to PHS all earned and benchmark royalty payments due to PHS pursuant to
Appendix C—III and IV that relate to or result from Audentes’s exercise of its sublicense rights hereunder and/or its or its sublicensees’ manufacture, development and/or commercialization of Licensed Product. In addition, in the case
of any further sublicense being granted by Audentes in accordance with Section 2.3 hereof, Audentes shall pay directly to NISI any sublicensing royalties due to PHS any sublicensing royalties due to PHS pursuant to Appendix C — V of the
HHS Patent License Agreement and that relate to or result from such further sublicensing by Audentes. 
 4.3 Accounting;
Payments. 
 4.3.1 Audentes shall in accordance with paragraph 8.1 of the HHS Patent License Agreement keep and maintain complete
hooks and records containing an accurate accounting of all data in sufficient detail to enable verification of earned royalties and other payments due hereunder. 

4.3.2 Audentes shall provide to PHS the royalty reports required pursuant to paragraph 9.4 of the HHS Patent License Agreement in
respect of the manufacture, development and commercialization of Licensed Product and concurrently provide copies thereof to Genethon, and the same shall be Confidential Information to be protected as provided in Article 9 of the Collaborative
Development Agreement and as described in paragraph 9.9 of the HHS Patent License Agreement. Audentes acknowledges that Genethon may provide such reports to, or, as necessary, receive them from, PHS. 

4.3.3 Audentes acknowledges and agrees that the inspection rights provided in paragraph 8.1 of the HHS Patent License Agreement may be
exercised by PITS or Genethon; provided, however, that in no event will Audentes be liable (whether to PHS or to Genethon, or in the aggregate to both) for the costs of. more than one inspection of records covering any period, even if more than one
inspection shows an underreporting or an underpayment in excess of five percent for such period. 
 4.3.4 All payments due by
Audentes hereunder shall, for the avoidance of doubt, be subject to paragraphs 9.6, 9.7 and 9.8 of the HHS Patent License Agreement, it being agreed, however, that no late fees imposed under such paragraph 9.8 or under this Section 4.3.4 shall
(whether to PHS or to Genethon, or in the aggregate to both) exceed the rate of one percent per month. 
  

  

					
		  	4	  	*Confidential Treatment Requested.

 5. TERM AND TERMINATION 

5.1 Term. The term of this Agreement shall begin on the Sublicense Effective Date and continue until the earlier of
(a) payment of the last royalty due hereunder after the expiration of the last to expire Licensed Patent Right or (b) early termination of this Agreement as provided in this Article 5. 

5.2 Termination by Audentes for Convenience. Audentes may terminate the Agreement for convenience in any country of the Licensed
Territory upon [*] prior written notice to Genethon. 
 5.3 Termination for Default. In the event that Audentes is in default
in the performance of any material obligations under this Agreement or of the obligations applicable to it under the HHS Patent License Agreement, and if Audentes fails to remedy any such default within [*] after written notice thereof by Genethon,
Genethon may at its option, terminate this Agreement by giving written notice of termination to Audentes; provided, however, that (i) where Audentes disputes in good faith that the claimed breach exists, such cure period will not start to run
until such dispute either can no longer be maintained in good faith or has been resolved by agreement of the Parties or pursuant to Section 15.2 of the Collaborative Development Agreement as incorporated herein; and (ii) if a breach is not
reasonably capable of being cured within the [*] cure period described above and Audentes is making continuing good faith efforts to cure such breach, the cure period applicable to such breach shall be extended to [*]. Notwithstanding the above,
should a default by Audentes under this Agreement give rise to a termination of the IBIS Patent License Agreement by HHS under paragraph 13.2 thereof, this Agreement shall terminate immediately upon termination of the HHS Patent License Agreement,
and in such case PHS may pursue outstanding royalties owed by Audentes through procedures provided by the Federal Debt Collection Act. 

5.4 Bankruptcy. Either Party may terminate this Agreement at any time upon the other Party s filing or institution of bankruptcy,
reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy proceeding such
right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within [*] after the filing thereof. 

5.5 Termination of the Collaborative Development Agreement. This Agreement shall automatically terminate upon any termination of
the Collaborative Development Agreement contemplated in section 14.4(c) thereof. 
 5.6 Termination of the HHS Patent License
Agreement. Subject to Section 5.5 hereof, in the event that the HHS Patent License Agreement is terminated for any reason in accordance with its terms and through no fault of Audentes, this Agreement shall either terminate or, at the option
of Audentes, be converted to a license directly between Audentes and PUS in accordance with paragraph 4.3 of the HHS Patent License Agreement. Audentes acknowledges and agrees that the conversion of this Agreement shall be subject to PHS approval
and contingent upon acceptance by Audentes of all provisions of the HHS Patent License Agreement. 
  

  

					
		  	5	  	*Confidential Treatment Requested.

 5.7 Consequences of Termination. Upon termination of this Agreement for any reason,
Audentes shall remain obligated to provide an accounting for and to pay royalties earned up to the effective date of the termination. 

5.8 Survival. The terms of Articles 1 and 6 through 9 inclusive and of Sections 2.2, 3.3, 5.6, 5.7 and 5.8 shall survive the
termination or expiration of this Agreement. 
 6. CONFIDENTIALITY 

6.1 Confidentiality Obligation. As between the Parties, the confidentiality obligations set out in sections 9.1 to 9.3
(inclusive) of the Collaborative Development Agreement shall apply; provided, however, that Genethon shall be permitted to provide PHS with a complete fully executed copy of this Agreement and of any information provided by Audentes in connection
with this Agreement without Audentes’s prior consent. 
 7. INTELLECTUAL PROPERTY RIGHTS 

7.1 Notice. Each Party shall promptly notify the other of any knowledge it acquires of any potential infringement of the Licensed
Patent Rights, as well as any facts which may affect the validity, scope or enforceability of the Licensed Patent Rights, of which such Party becomes aware. Notwithstanding any provision to the contrary herein contained, Audentes acknowledges that
Genethon may communicate any information provided to it by Audentes in accordance with this Section 7.1 to PHS. 
 7.2 Filing,
Prosecution and Maintenance. Audentes acknowledges and agrees that all preparation, filing, prosecution and maintenance of the Licensed Patent Rights shall be the responsibility of PBS. 

7.3 Negation of Representations and Warranties. Genethon makes no representations or warranties regarding the validity, scope or
merchantability or fitness for a particular purpose of the Licensed Patent Rights. 
 8. INDEMNIFICATION — INSURANCE 

8.1 Indemnification. As between the Parties, the indemnification provisions set out in sections 13.1 through 13.3 inclusive of
the Collaborative Development Agreement shall apply and are hereby incorporated herein by reference. In particular, each Party shall in accordance with such sections defend and indemnify the other in respect of any claims and all resulting
Liabilities (as defined in the Collaborative Development Agreement ) brought by PHS against the other Party arising out of such Party’s breach of its obligations hereunder. 

In addition, Audentes shall be directly liable to PHS and its employees, students, fellows, agents and consultants for the indemnification
obligations set out in paragraph 12.5 of the BIBS Patent License Agreement as they related to Audentes’s or its sublicensees’ exercise of its rights under this Agreement and/or the manufacture, development or commercialization of Licensed
Product by or for Audentes or its sublicensees. 

  
 6 

 8.2 Insurance. Beginning on the Effective Date, Audentes shall, at its sole cost
and expense, procure and maintain product and general liability insurance (contractual liability included) consistent with sound business practice. 

9. MISCELLANEOUS 

9.1 EXCEPT IN THE EVENT OF A PARTY’S BREACH OF ARTICLE 6 HEREOF, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE IN
CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE
PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY IS REQUIRED TO PROVIDE INDEMNIFICATION UNDER SECTION 8.1 HEREOF. For the avoidance of doubt, the above shall not limit any amounts due to HHS in connection with Licensed Product. 

9.2 As between the Parties, the miscellaneous provisions set forth in sections 15.1 through 15.3 and 15.5 through 15.7 inclusive of
the Collaborative Development Agreement shall apply and are hereby incorporated by reference herein. 
 9.3 Without prejudice to
Section 9.2 above, all notices by Audentes to PHS hereunder shall be given in accordance with paragraph 14.6 of the HHS Patent License Agreement and sent to: 

Office of Technology Transfer 

National Institute of Health 

6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 

Attn: Chief,’ Monitoring & Enforcement Branch 

E-mail: LicensesNotices_Report@mail.nih.gov 

9.4 In exercising its rights under this Agreement, and in particular in connection with the manufacture, development, use and
commercialization of Licensed Product, Audentes shall be subject to and abide by the obligations applicable to the Licensee set out in paragraphs 14.8 through 14.11 of the HHS Patent License Agreement. 

9.5 The assignment by Audentes of this Agreement shall be subject to section 15.4 of the Collaborative Development Agreement and
not paragraph 14.7 of the HHS Patent License Agreement. 

  
 7 

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the Sublicense
Effective Date. 
  

									
	GENETHON	 		 	AUDENTES THERAPEUTICS, INC.
					
	By:	 	 	 		 	By:	 	 
					
	Title:	 	 	 		 	Title:	 	 

 EXHIBIT A 

PROVISIONS OF THE HHS PATENT LICENSE AGREEMENT 
  

	 	•	 	Paragraph 5.1: 

 “Licensee agrees that product used or sold in the United States
embodying Licensed Products or produced through use of Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from PHS.” 

 

	 	•	 	Paragraph 7.1: 

 “PHS agrees to take responsibility for the preparation, filing,
prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights.” 
  

	 	•	 	Paragraph 9.1: 

 “Prior to signing this Agreement, Licensee has provided PHS with the
Commercial Development Plan in Appendix E, under which Licensee intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this
Agreement. Based on this plan, performance Benchmarks are determined as specified In Appendix D.” 
  

	 	•	 	Paragraph 9.2: 

 “Licensee shall provide written annual reports on its product
development progress or efforts to commercialize under the Commercial Development Plan for each of the Licensed Fields of Use within sixty (60) days alter December 31 of each calendar year. These progress reports shall include, but not he
limited to: progress on research and development„ status of applications for regulatory approvals, manufacturing, marketing, importing, and sales during the preceding calendar year, as well as, plans for the present calendar year. PHS also
encourages these reports to include information on any Licensee’s public service activities that relate to the licensed Patent Rights. If reported progress differs from that projected in the Commercial Development Plan and Benchmarks, Licensee
shall explain the reasons for such differences. In any annual report, Licensee may propose amendments to the Commercial Development Plan, acceptance of which by PHS may not be denied unreasonably. Licensee agrees to provide any additional
information reasonably required by PHS to evaluate Licensee’s performance under this Agreement. Licensee may amend the Benchmarks at any time upon written approval by PHS. PHS shall not unreasonably withhold approval of any request of Licensee
to extend the time periods of this schedule if the request is supported by a reasonable showing by Licensee of diligence in its performance under the Commercial Development Plan and toward bringing the Licensed Products to the point of
Practical Application.” 

	 	•	 	Article 11: 

 “INFRINGEMENT AND PATENT ENFORCEMENT 

 

	11.1	PHS and Licensee agree to notify each other promptly of each infringement or possible infringement of the Licensed Patent Rights, as well as any facts which may affect the validity, .scope, or enforceability of the
Licensed Patent Rights of which either Party may become aware. 

  

	11.2	In the event that a declaratory judgment action alleging invalidity of any of the Licensed Patent Rights shall he brought against PI IS, PHS agrees to notify Licensee that an action alleging invalidity has been
brought. PHS does not represent that it shall commence legal action to defend a declaratory action alleging invalidity. Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action of
Licensee, Licensee shall reimburse the Government for any costs, expenses, or fees, which the Government incurs as a result of the motion or other action. Upon Licensee’s payment of all costs incurred by the Government as a result of
Licensee’s joinder motion or other action, these actions by Licensee shall not be considered a default in the performance of any material obligation under this Agreement.” 

 

	 	•	 	Paragraph 12.4: 

 “PUS does not represent that it shall commence legal actions against
third parties infringing the Licensed Patent Rights. Should PHS not commence any legal actions against said third parties after notification sent by Licensee, Licensee will have the choice to commence legal action(s) against such third parties at
its own costs.” 
  

	 	•	 	Paragraph 13.6: 

 “In making the determination referenced in Paragraph 13.5, PHS shall
take into account the normal course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by Licensee under Paragraph 9.2. Prior to invoking termination or
modification of this Agreement under Paragraph 13.5, PHS shall give written notice to Licensee providing Licensee specific notice of and ninety (90) day opportunity to respond to 111S. concerns as to the items referenced in 135(a) 135(g) If
Licensee fails to alleviate PHS’ concerns as to the items referenced in 13.5(a)-13.5(g) or fails to initiate corrective actions to PHS” satisfaction, PHS may terminate this Agreement.” 

 

	 	•	 	Paragraph 13.7: 

 “PHS reserves the right according to 35 U.S.C. §209(d)(3) to
terminate or modify this Agreement if it is determined that the action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by
Licensee. 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]